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Abstract:
Development of CXCR4-Inhibiting Nanoparticles for the Treatment of Metastatic
Cancer
Yan Wang, Ph.D.
University of Nebraska Medical Center, 2016
Supervisor: David Oupický, Ph.D.
Metastasis is the main cause of cancer mortality and morbidity, leading to several
million deaths every year. Less than 20% of pancreatic cancer (PC) patients are
candidates for surgery due to spread beyond the pancreas. Desmoplasia presents
substantial barriers to perfusion, diffusion, and convection of antitumor therapeutics into
the PC tissues. We focus on developing novel therapies that regulates tumor
microenvironment, chemosensitizing tumor to therapeutics and preventing metastasis.
Gene therapy is emerging as a promising new therapeutic agents for cancer
treatment. A targeted, systemic, effective and safe gene delivery system should be
developed. CXCR4/SDF-1 axis plays a crucial role in the crosstalk between cancer cells
and their microenvironment, and is involved in tumor progression, angiogenesis,
metastasis and survival. We successfully designed dual-function polymeric CXCR4
inhibitors (PCX) as gene delivery vectors.
To enhance the CXCR4 antagonism, we reported synthesis of novel monocyclam
monomers and their polymerization to PCX. In order to improve the physical properties
and safety of PCX, it was modified by PEGylation. The negative effect of PEG on
transfection activity of PEG-PCX polyplexes could be overcome by using polyplexes
formulated with a mixture of PCX and PEG-PCX. Moreover, modification of PCX with
cholesterol, the enzymatic stability against RNase and siRNA delivery efficiency were
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enhanced dramatically. NCOA3 silencing can downregulate mucin expression and
regulate tumor microenvironment. Using a series of PCX, we optimized formulation of
PCX/siNCOA3 polyplexes to simultaneously target CXCR4 and NCOA3 in PC.
Cholesterol-modified PCX showed maximum CXCR4 antagonism, NCOA3 silencing and
inhibition of PC cell migration in vitro. The optimized PCX/siNCOA3 polyplexes were used
in evaluating antitumor and antimetastatic activity in orthotopic mouse model of metastatic
PC. The polyplexes displayed significant inhibition of primary tumor growth, which was
accompanied by a decrease in tumor necrosis and increased tumor perfusion. These dualfunction polyplexes also showed significant antimetastatic effect and effective suppression
of metastasis to distant organs. Overall, dual-function PCX/siNCOA3 polyplexes can
effectively regulate the tumor microenvironment to decrease progression and
dissemination of PC.
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Chapter 1. Introduction
Please note that part of this chapter was taken from a review titled“Potential of
CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery” published in Drug Delivery [1].
The authors of the book chapter include Ying Xie, Prof. David Oupický and me. I wrote
the draft of manuscript, Ying gave me suggestions, Dr. David Oupickýrevised it and made
it published. All the authors agreed with including their contributions in this dissertation.

1.1 Cancer metastasis
Metastasis is the major reason for the failure of cancer therapy and accounts for
approximately 90% mortality of cancer patients [2]. It requires several successive steps
for cancer cells spreading from the primary site and continuous growth into secondary
tumors in distant organs. Metastasis is a complex process that begins with invasion into
local stroma, followed by intravasation of cancer cells into blood and lymphatic vessels,
movement of cancer cells through the lymphatic system or blood circulation, extravasation
into the parenchyma of distant tissues, adaption to a new environment at secondary site,
formation of micrometastases, and finally the growth into macroscopic tumors [3, 4].
During the process of intravasation, cancer cells should be survival without adhesion and
escape from recognition by the host immune system [5]. The complex molecular
mechanism of metastasis includes the alteration of multistep, multistage and multigene.
However, cancer cells tightly interact with their surrounding microenvironment during each
step, which plays a critical part in the cancer metastasis [6].
Tumor microenvironment consists of the extracellular matrix (ECM) and stromal
cells, involving endothelial cells, fibroblasts, immune cells, bone marrow-derived cells,
progenitor cells and stem cells. Clarification of the relationship between the tumor
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microenvironment and metastasis will suggest a key point to prevent cancer metastasis
and improve the life quality of patients [7]. Stromal cells interact with cancer cells directly
and indirectly to influence the progress of tumorigenesis and development. There are two
complementary strategies facilitate cancer cells take advantage of the primary tumor
microenvironment to initiate metastasis [2]. First, cancer cells alter their gene expression
pattern to utilize the signals from tumor stroma and migrate to a different site. Second,
stromal cells will be vigorously recruited to primary tumor site to promote metastasis. In
another words, cancer cells gain metastatic potential at the primary tumor site, which is
supported by the comparability in the investigations that gene expressions of metastases
and the corresponding primary tumor are similar in various cancers, such as breast,
colorectal, prostate and pancreatic cancer [8-10].
1.1.1 Epithelial to mesenchymal transition (EMT)
EMT is a key developmental program and often activated in the initiating steps of
primary tumor invasion. Tumor cells lose epithelial markers, acquire mesenchymal traits,
express stem cell markers and obtain a migratory phenotype [11]. In a normal tissue,
epithelial cells connect tightly with each other by epithelial adherens junctions with the aid
of protein E-cadherin and their migratory capacity is prohibited. However, in the first step
of cancer metastasis, cancer cells have to break the ECM. Epithelial cells are separated
from multiple layers of stroma by ECM [2]. In EMT, the expression of E-cadherin is
suppressed, resulting in the detachment of cancer cells from epithelial sheets [12].
Moreover, the mesenchymal state is related with the ability of cancer cells to subsequently
differentiate into multiple cell types during the initiation and development of metastasis.
Researchers reported that the stroma plays an critical role in the phenotypic
transitions in cancer by the expression of transforming growth factor β (TGF-β) [12].
Labelle et al. investigated that platelet-tumor cell interactions were sufficient to prime
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tumor cells for subsequent metastasis. The TGF-β/Smad and NF-ĸB pathways were
synergistically activated in cancer cells by the interaction of platelet-derived TGF-β and
direct platelet-tumor cell, leading to the transition to an invasive mesenchymal-like
phenotype and increased metastasis in vivo. However, inhibition of NF-ĸB signaling
pathway or the expression of TGF-β1 alone in platelets prevents lung metastasis in vivo
[13]. Bonde et al. found that tumor associated macrophages regulated EMT intratumorally
through TGF-β signaling and activation of the β-catenin pathway [14]. Long term exposure
of teratocarcinoma cells to macrophage-conditioned medium resulted in reduced
expression of E-cadherin, activation of the EMT-mediating β-catenin signaling pathway,
enhanced mesenchymal marker and an invasive phenotype [14]. Moreover, it was proved
that intratumor macrophage densities, EMT markers and TGF-β levels have a positive
correlation by an immunohistochemical study of a series of non-small cell lung cancer
patients’ samples.
1.1.2 Recruitment of immune and stromal cells
In order to alter tumor microenvironment to a metastasis-promoting position,
stromal cells will be transformed to support cancer cells invasion or metastasis-promoting
stromal cells will be recruited to remodel the microenvironment [2]. Researchers revealed
that direct communication between macrophages and tumor cells in the microenvironment
resulted in invasion and intravasation of tumor cells into the blood or lymphatic vessels.
Macrophages promote the angiogenesis, facilitate ECM breakdown/remodeling and
enhance the motility of cancer cells, suggesting a potential target for anticancer drugs [15].
Recruited immature myeloid cells can facilitate cancer cells evade the host immune
response through inhibiting the differentiation of antigen-presenting DCs after
accumulation in cancer microenvironment. In the normal conditions, myeloid cells are the
most abundant nucleated hematopoietic cells and terminally differentiated into three
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groups, including macrophages, dendritic cells and granulocytes, which are necessary for
the innate and adaptive immune systems. However, in the tumor microenvironment,
myeloid cells would be changed into effect immunosuppressive cells and support tumor
immune evasion [16]. Van Zijl et al. found that myofibroblasts or cancer-associated
fibroblasts (CAFs) induced invasion of hepatocellular carcinoma was through TGF-β and
platelet-derived growth factor (PDGF) signaling pathway using a collagen gel-based three
dimensional hepatocellular carcinoma model in vitro. Thus, TGF-β/PDGF axis is very
important during hepatic tumor-stroma crosstalk to regulate tumor growth and progression
[17]. Moreover, CAFs keeps continuously activated in tumors. The long-term activation of
fibroblasts contributes to the perpetual secretion of activating cytokines, such as SDF-1,
VEGF, PDGF and HGF [18, 19]. Orimo et al. demonstrated that CAFs within invasive
breast carcinomas secreted SDF-1, which promoted the recruitment of endothelial cells
and contributed to tumor promotion by acting the cognate receptor CXCR4 expressed by
carcinoma cells [20].
1.1.3 ECM remodeling
Proteolysis

and

breakdown

of

ECM

is

an

essential

component

of

microenvironment remodeling and important in the early step of local invasion of cancer
cells

into

adjacent

tissue.

During

the

process

of

ECM

remodeling,

matrix

metalloproteinases (MMPs) are crucial effectors [21]. For instance, tumor-associated
fibroblasts differentiate into myofibroblasts and promote tumor progression by proteasecatalysed remodeling of the stroma using MMP9 [22]. MMP9 is recruited to the cell surface
of fibroblasts by lysyl hydroxylase via fibronectin-like domain and facilitate the
differentiation of tumor-associated fibroblasts.
1.1.4 Hypoxia
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Due to the rapid proliferation of primary cancer cells, the concentration of oxygen
is much lower in the region of tumor cells than in the normal tissues. Hypoxia-inducible
factors (HIFs) are the most critical transcription factors, which response to hypoxia, induce
the formation of angiogenesis and promote the survival of cancer cells. Cancer cells alter
their intrinsic gene expression and adapt to the hypoxic environment by the HIF signaling
pathway [23]. Moreover, hypoxia is also a main driving force for recruiting stromal cells to
tumors. Chouaid et al. reported that hypoxia contributed to the tumor tolerance to immune
surveillance through the recruitment of regulatory T cells and myeloid derived suppressor
cells by activating HIF-1 and vascular endothelial growth factor (VEGF) pathways [24].
After stromal cell recruitment medicated by hypoxia, cancer invasion is promoted at the
edge of tumor periphery. Simultaneously, hypoxia provides an aggressive selection
pressure for cancer stem cells migrate to the tumor periphery to facilitate cancer cell
escape. Therefore, hypoxia and stromal cells work together to promote cancer metastasis
[6].
1.1.5 Intravasation and selection at distant site
The possibility of cancer metastasis to a specific organ is determined by various
reasons, including routes of blood circulation, the ability of cancer cell intravasation into
vasculature and modulating tumorigenesis at secondary organs. During this process,
cancer cells also need to deal with the microenvironments. Macrophages localizing to
blood vessels facilitate cancer cells intravasate into the circulation [25]. Platelets play an
important role in the enemy microenvironment of the vasculature and support tumor
metastasis by directly interacting with cancer cells. In circulation, platelets can form
protective clusters with cancer cells, impacting NK cell-mediated cytotoxicity, preventing
the recognition by immune cells, promoting the arrest at the endothelium and supporting
the establishment of secondary lesions [26]. However, most disseminated cancer cells die
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at the secondary site and only 0.01% of cancer cells intravasating into circulation are able
to form detectable metastasis [27]. The metastatic outgrowth is affected by the
microenvironment factors in the secondary organs [28]. After cancer cells initially reach
distant organs, the microenvironment may suppress metastatic cancer growth by inhibitory
stromal factors. For instance, immune cells (cytotoxic T cells or natural killer cells) of
adaptive and innate immune system form a critical barrier for the survival and proliferation
of cancer cells. Stroma cells from the secondary sites release apoptotic signals (Fas-L
and Trail), which inhibit the cancer cell proliferation and cause elimination. However,
cancer cells can induce alternation of stroma and regulation of microenvironment to
support cancer growth and metastasis. For example, cancer-associated fibroblasts
secrete various cytokines and growth factors, such as SDF-1, PDGF, VEGF and HGF.
Modified ECM and secreted growth factors can reactivate metastatic cancer cells from
dormancy, inducing angiogenesis and enhance the survival as well as multi-functionality
of metastatic cancer cells. Furthermore, the recruitment of macrophages, myeloid
progenitors and mesenchymal cells establish an inflammatory environment and secrete
various signals to enhance the metastatic cancer growth.
1.2 Pancreatic Cancer
In 2016, it is expected to have 53,070 new cases and 41,780 deaths of pancreatic
cancer (PC) in the US. From 2000 to 2012, the incidence rate enhanced by 1.2% per year
and since 2000, the death rate increased slightly by 0.4% per year. PC is predicted to
become the second leading cause of cancer-related mortalities by 2030 [29]. The patients
usually do not feel the symptoms until the disease has progressed, including weight loss,
abdominal discomfort and occasionally the development of diabetes. Diagnosis at an early
stage is difficult for PC, except that tumor develops near the common bile duct and cause
jaundice. Until now, there is no reliable method for the early detection of PC. PC patients
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at advanced stage may have nausea, vomiting and severe abdominal pain. Smoking
cigarette is one of the significant risk factors of PC (~2 fold vs. nonsmokers). About onefifth of PC patients are because of smoking. Also, family history of PC, history of chronic
pancreatitis, obesity, diabetes and genetic syndromes (BRCA1&2 mutation) can cause
high risk of PC.
The main treatment options for PC are surgery, radiation therapy, and
chemotherapy to extend survival or relieve symptoms, however, seldom produce a cure.
The one-year and five-year survival rates remain consistently low (~29% and ~7%
respectively), which are due to late diagnosis, early metastasis, and complex
microenvironment in PC. PC microenvironment contributes to inherent resistance to
available therapies and severely limits drug delivery [30-32]. More than half (53%) of
patients are diagnosed at a distant stage, for which the 1- and 5-year survival is 15% and
2%, respectively. Less than 20% of patients are candidates for surgery because PC is
usually detected after it has spread beyond the pancreas. Thus, there is a urgent need to
develop better therapeutic strategies for the treatment of PC [33].
1.3 Desmoplasia and Treatment Strategies
PC is unique among solid tumors due to the extremely dense desmoplastic
reaction which wraps the cancer cells. The emergence of desmoplasia in PC is becoming
a problem which presents substantial barriers to perfusion, diffusion, and convection of
antitumor therapeutics into the PC tissues and leads to acquired resistance [34].
Desmoplasia contains extracellular matrix (ECM) proteins, myofibroblastic pancreatic
stellate cells (PaSCs), and immune cells, which modulate the growth of PC by providing
a scaffold for the cancer cells to grow as well as growth factors and immune modulators
(Scheme 1) [35]. Researchers reported that extensive fibroblastic cell proliferation in PC
relates to poor disease outcomes [36]. The prominence of desmoplastic reaction has
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caught researchers’ eyes as one of the major factors responsible for the severe and
malignant biologic behavior of PC. Tumor local environment plays any important role in
cancer initiation, progression, metastasis and resistance [37, 38]. Desmoplastic PC
microenvironment shows high interstitial pressure and a dense stroma with vascular
dysfuction, which results from the proliferation of fibroblasts and increased stromal fibrosis
[39, 40]. The key regulatory pathways to regulate desmoplasia include Hyaluroran-CD44
and Hedgehog (Hh), which are aberrantly overexpressed in PC [39, 41, 42].
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Scheme 1. Components of desmoplasia in PC. Pancreatic cancer cells and pancreatic
duct cells promote each other’s growth and proliferation and together regulate processes
of ECM deposition, angiogenesis, and disordered immune surveillance (Adapted from
[35]).
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1.3.1 Hyaluronan-CD44 pathway
One strategy to overcome the dense stromal barrier is to target the ECM
component. In the desmoplastic reaction, a key role of fibroblasts is hyaluronan synthesis
and its interaction with CD44. CD44 has been associated with malignant transformation
of pancreatic tumors. It is an integral cell-surface glycoprotein and overexpresses in its
variant forms, which is driven by IFN-γ [43]. Meanwhile, CD44 is also the major cell surface
receptor for hyaluronan as well as matrix metalloproteinases, playing a critical role in
pancreatic carcinogenesis. Hyaluronan is a non-sulphated glycosaminoglycan. In
response to factors released from tumor cells, such as lactate, or by direct cell-cell contact,
hyaluronan is produced by activated fibroblasts [44]. Hyaluronan-rich stroma is associated
with poor prognosis in many epithelial cancers including pancreatic and together with
CD44 promotes tumor cell growth, migration, and metastases [42]. Hyaluronan-CD44
interaction reorganizes the desmoplasmic barrier and enhances its integrity, so that the
drug is impeded from entering into the PC tissue and causes the failure of therapy [42].
Researchers have taken a lot of efforts to design novel strategies to minimize
desmoplasia and improve the delivery of therapeutics to PC tissues. Disruption of
hyaluronan-CD44 interaction would be a critical method to prevent drug resistance in PC.
Provenzano et al. reported that systemic administration of PEGPH20, a PEGylated human
recombinant PH20 hyaluronidase, could ablate stromal HA from autochthonous murine
PC, normalize interstitial fluid pressure and re-expand the microvasculature. Combination
of PEGPH20 with gemcitabine treatment resulted a near doubling of overall survival [45].
37]. 4-Methylumbelliferone (4-MU) is a hyaluronan synthesis inhibitor, which has been
shown to slow down the development of human PC cell lines both in vitro and in vivo as
well as inhibit cancer cell migration, proliferation and invasion [46, 47]. 4-MU also
prolonged the survival time of nude mice bearing abdominally transplanted pancreatic
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cancer cells and enhanced the efficacy of gemcitabine, suggesting that its potential usage
in patients with end-stage pancreatic cancer [48]. Diop-Frimpong et al. found that
angiotensin receptor inhibitor losartan led to a dose-dependent reduction in stromal
collagen and hyaluronan production in desmoplastic models of human breast, pancreatic,
and skin tumors in mice, thus enhanced the efficacy of chemotherapy [49].
1.3.2 Hedgehog pathway
Hh signaling pathway is genetically changed and aberrantly activated in most of
PC, which causes tumor initiation, progression, and metastatic spread. Moreover, it has
been involved in the initiation and maintenance of desmoplastic reaction Scheme 2 [50].
Hh pathway consists of Sonic (Shh), Indian (IHh), patched (PTCH) and smoothened
(SMO), which are almost undetectable in normal human pancreas, however, become
prominently visible during PC [41]. Myofibroblast differentiation and stroma-derived growth
promoting molecules are induced by Hh signaling pathway, which promote tumorigenesis.
Moreover, Hh ligands intensify desmoplastic reaction and fibrosis by stimulating the
interaction with TGF-β1 and MMPs [51]. This pathway is activated when Shh bind to the
PTCH receptor relieving the inhibitory effects of SMO receptor from PTCH and thus
activating the glioma-associated oncogene (GLI) family of transcription factors [52].
Activated GLI induces the expression of the Hedgehog genes such as PTCH, epidermalderived, platelet-derived, and vascular-endothelial growth factors, cyclins B, D, and E and
GLI1, which promotes the tumor progression and desmoplastic reaction [53].
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Scheme 2. The Hedgehog pathway (Adapted from [54]).
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Inefficient drug delivery may be an important contributor to chemoresistance in PC.
Inhibition of Hh signaling pathway is a promising strategy to overcome the desmoplastic
reaction in PC and thus increase the delivery of anticancer therapeutics into tumors. Olive
et al. reported that the efficacy of gemcitabine in the mice could be improved by coadministration of a small molecule inhibitor of Hh pathway (IPI-926). The combination
treatment depleted tumor-associated stromal tissue and produced a transient increase in
intratumoral vascular density, resulting in improved intratumoral concentration of
gemcitabine and transient stabilization of disease [55]. Kumar et al. designed a selfassembled copolymer to simultaneously encapsulate Hh inhibitor GDC-0449 and complex
tumor suppressor miR-let7b into micelles to treat athymic nude mice bearing ectopic
pancreatic tumor, resulting decreased tumor proliferation and enhanced apoptosis [56].
Feldmann et al. investigated that blocking the Hh pathway with the small molecule
cyclopamine, which is a naturally occurring inhibitor of SMO receptor, resulted in
prevention of PC metastases and enhancement in chemo-delivery to tumors [57].
The survival rate of PC patients has not been significantly improved during the past
30 years. Due to PC is highly resistant to the currently available chemotherapy and
radiotherapy, the new effective patterns for the treatment are urgently needed. In recent
a few years, gene engineering technology is becoming a rapidly and potentially developing
area of modern medicine to treat tumor with the promising progress of modern biology
and nanomedicine. Therefore, the treatment of patients who are not curable by current
therapies will be improved by gene modification [58].
1.4 Gene Therapy
Gene therapy is an experimental technique that uses genes to treat or prevent
disease by inserting a gene into patients’ nidus instead of using drug or surgery. Gene
therapy aims at delivering genetic material into target cells or tissue and to express it with
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the intention to gain a therapeutic effect. There are several approaches for gene therapy,
including replacing a mutated gene that causes disease with a healthy copy of the gene,
or inactivating a mutated gene that is functioning improperly, or introducing a new gene
into the body to help against a disease.
In 1989, the US Food and Drug Administration (FDA) approved the first gene
therapy protocol. A marker gene was ex vivo transduced into the tumor infiltrating
lymphocytes, which were collected from advanced melanoma patients. The transduced
cells were expanded in vitro and re-infused to the patients. In the following year, tumor
infiltrating lymphocytes were genetically modified ex vivo to express tumor necrosis factor
and used to treat patients with advanced melanoma, which was the first clinical trial on
cancer using gene therapy with an therapeutic intend [59]. Significant progresses in gene
therapy have been obtained since the first clinical trial in 1990. It was reported that two
patients with metastatic melanoma were received a successful immunogene therapy. Until
June 2012, the entries for 1843 trials undertaken in 31 countries were reported and most
of which were focused on cancer treatment [60]. Jones et al. performed a comprehensive
genetic analysis of 24 pancreatic cancers and determined the sequences of 23,219
transcripts, as well as representing 20,661 protein-coding genes. After they searched for
homozygous deletions and amplifications in the tumor DNA by using microarrays
containing probes for about 106 single-nucleotide polymorphisms, an average of 63
genetic alterations were found in pancreatic cancers, the majority of which were point
mutations. These alterations defined a core set of 12 cellular signaling pathways and
processes that were each genetically altered in 67 to 100% of the tumors [61]. Therefore,
genes in these cellular pathways would be potential targets for PC gene therapy. However,
the highly efficient gene therapy is based on selection of efficient targets, effective gene
delivery, tumor targeted therapy and low toxicity.
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1.4.1 Vector systems for gene delivery
An ideal gene delivery system is the foundation of gene therapy, which should
have the properties, such as non-invasive mode of administration, tumor-specific targeting,
including primary lesion and distant metastatic lesion, sustained gene expression, and
high insertion capacity, bio-safety, stability and easy preparation [58]. Vector systems are
divided as viral and non-viral methods. The advantages of viral vector system includes
higher transfection efficiency and long-term gene expression. However, viral method may
cause toxicity, immunogenicity, high cost and inability to transfer large size genes, which
can be avoided by non-viral delivery systems. Non-viral methods have the advantages of
easy preparation and modification with ligands for tissue and cell specific targeting [62].
In gene delivery systems, viral vectors are the most commonly studied and applied.
More than two-thirds of clinical trials used viral vectors, including adenovirus (AdV),
retrovirus (RV), adeno-associated virus (AAV), lentivirus, herpes simplex virus (HSV),
influenza virus, Newcastle disease virus, pox virus, and Epstein-Barr virus (EBV). Viruses
can take advantage of the innate mechanism of infection to enter and transfer DNA
molecules into cells without any physical or chemical processing. Then the therapeutic
gene would be expressed after entering the nucleus and integrating into the host gene
pool [63].
Non-viral vectors consist of physical methods, biological vectors, and chemical
vectors to introduce naked DNA (plasmid DNA), RNA molecules, or oligonucleotides into
cells. Microinjection, microparticle bombardment and electroporation are most commonly
used in physical delivery. Even though physical techniques can achieve high transfection
efficiency, they are laborious, impractical, invasion and difficult to apply in a clinical setting
[62]. Both bacteria and mammalian cells (hematological cells or mesenchymal stem cells)
can be used as biological vectors for gene therapy. Bacteria is engineered to express
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therapeutic genes and deliver both therapeutic gene and protein product to recipient cells.
For instance, a bacterial cancer vaccine was prepared using a live attenuated Listeria
strain of bacteria to express mesothelin and demonstrated antitumor effect in an earlyphase clinical trial [64]. The commonly used chemical vectors can be divided into two
types based on the materials, cationic lipids (liposomes) and cationic polymers. Cationic
lipids consist of an aqueous compartment enclosed in a phospholipid bilayer and bind with
nucleic acids based on the electrostatic interaction. After fusion with target cell membrane
and endocytosis, nucleic acid will be delivered into cytoplasm. Cationic polymers include
a wide range of chemical compounds, such as chitosan, polyamidoamine, polypeptides
and so on. They form nanosized particles with negatively charged nucleic acids through
electrostatic interaction. Cationic polymers increase cellular uptake by endocytosis,
protects nucleic acids from nuclease degradation and facilitate endosome escape. Then,
nucleic acids would be released into cytoplasm and regulate gene expression [58]. The
combination system of lipid/polymer/DNA has been developed to exhibit further
condensation, protection and increase circulating half-life in vivo [62]. Furthermore,
ligands or peptides can be conjugated to polymer to improve cell/tissue specificity by
receptor-directed gene delivery.
1.4.2 Nucleic acids
Plasmid is a double stranded circular DNA with transgene to encode for specific
protein. Besides the transgene, plasmid DNA consists other regulatory signals such as
the promoter, enhancer sequences, splicing and polyadenylation sites to regulate gene
expression [65]. The size of plasmid ranges from hundreds of to several thousand base
pairs. Engineering the plasmid with tissue or tumor specific promoters would improve the
efficiency of initiating the transcription process by recognizing the RNA polymerase. The
commonly used promoters are derived from viral origins such as cytomegalovirus (CMV)
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and roux sarcoma virus. Enhancers locate in either upstream or downstream of the
promoter region, which are the binding sites for proteins to enhance the initiation of gene
transcription [66]. Splicing and polyadenylation sites are responsible for the correction of
mRNA obtained from transcription.
Antisense Oligonucleotide (AON) is a short single-stranded segments (18-21 base
pairs) of DNA or RNA artificially synthesized in vitro. It has a complementary sequence to
the target mRNA to inhibit gene expression by different mechanisms, including
translational arrest by steric hindrance of ribosomal activity and the induction of RNase H
endonuclease activity [67]. RNase H enzyme cleaves the mRNA in the RNA-DNA
heteroduplex and leaves AON intact. AON can also inhibit gene expression by interfering
with mRNA maturation or destabilizing the pre-mRNA in the nucleus [68]. Therefore, AON
can be used to treat diseases which are associated with dysregulated gene expression.
RNA interference (RNAi) is emerging as a novel way for the treatment of PC. The
sequence-specific small interfering RNAs (siRNAs) are a length of 20–25 base pairs,
which mediate the degradation of the homologous mRNA and consequently regulate the
expression of the targeted gene [69, 70]. siRNAs can be artificially synthesized in vitro
and directly delivered into target cells. siRNAs also can be produced in the genetically
modified target cells, in which a gene encoding siRNA is introduced via appropriate
vectors with the help of endogenous RNAase [58]. After releasing into cytoplasm, siRNAs
bind to ribozyme compunds and form RNA-induced silencing complexes (RISCs). RISCs
bind to the target mRNA and induce the degradation of mRNA. RNAi takes more
advantages in comparison with other gene blockade technologies, such as high degree of
specificity to mRNAs, non-immunogenic property and high resistance to ribonucleases.
RNAi has turned into one of the most promising method for gene therapy. Yang et al.
developed a biodegradable charged polyester-based vector for K-ras siRNA delivery to
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MiaPaCa-2 PC cells and initiated a cascade gene regulation of downstream proteins,
which significantly reduced the growth, migration and invasion of MiaPaCa-2 cells were
as well as promoted the apoptosis [71]. Owing to high expression of hypoxia-inducible
factor 1α (HIF1α) increasing the resistance of gemcitabine for PC, Zhao et al employed
biocompatible lipid-polymer hybrid nanoparticles to co-deliver siHIF1α and gemcitabine
for PC treatment [72]. This nanoparticle absorbed negatively charged siHIF1α on the
surface and encapsulated gemcitabine to the hydrophobic core to prevented siRNA
degradation in serum as well as gemcitabine leakage, which exhibited significant
synergistic antitumor effects and inhibited metastasis in orthotopic PC model. To
investigate the efficiently systemic delivery of siRNA, Pittella et al. reported an efficient
and

biocompatible

nanocarrier

comprising

poly(ethylene

glycol)-block-charge-

conversional polymer (PEG-CCP)/calcium phosphate (CaP) hybrid micelles for systemic
delivery of siRNA to spontaneous PC model in transgenic mice [73]. All these results have
shown great potential towards a breakthrough in siRNA therapy for PC.
1.5 Nuclear Receptor Coactivator-3
Nuclear receptor coactivator (NCOA) belongs to the p160/steroid receptor
coactivator (SRC) family, which consists of SRC-1, TIF-2 (GRIP1) and AIB1
(ACTR/RAC3/TRAM-1/SRC-3/NCOA3) [74-77]. NCOA3 plays an important role in
hormone-sensitive tumors, such as breast cancer, ovarian cancer, prostate cancer, and
meningioma [78-80]. NOCA3 is the rate limiting step in estrogen-mediated growth
signaling, such as insulin-like growth factor I and epidermal growth factor, and increases
the transcriptional activity of many steroid nuclear receptors and growth factors,
suggesting that transcriptional activation medicated by estrogen receptor might provide a
growth advantage to cancer cells. For instance, Reiter et al reported that NCOA3
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overexpressed in breast cancers and strongly improved epidermal growth factormedicated transcription in squamous cell carcinoma cells [81].
NCOA3 is one of the frequently mutated genes in PC [82]. High-level amplification
of NCOA3 has been found in four of nine pancreatic cancer cell lines and >37% of archival
PC tissues [83, 84]. Henke et al reported that NCOA3 did not show in normal pancreatic
tissue, however, high expressed in pancreatic adenocarcinoma and high-grade pancreatic
intraepithelial neoplasia (PanIN) lesions [84]. Detectable levels of NCOA3 mRNA or
protein were rarely detected in normal pancreas ducts (<6% of sample positive). There
was an increase of NCOA3 expression in pancreatitis and low-grade intraepithelial
neoplasia with >14 and >23% of samples positive, respectively (P<0.01, vs. normal
tissues). The highest frequency of NCOA3 expression at mRNA or protein levels was with >
65% of samples positive, which were found in adenocarcinoma as well as high-grade
PanIN (P<0.0001 vs. the other groups). Moreover, NCOA3 is also elevated in lung, lymph
and liver metastatic lesions [85]. Therefore, NCOA3 can serve as an important diagnostic
indicator due to its overexpression in pancreatic adenocarcinoma and its precursor lesions.
In 2014, Kumar et al. found that NCOA3 worked as a chromatin remodeling
enzyme and modulated the expression of mucins via transcriptional and post-translational
changes in the development of PC [85]. Mucins, such as Muc1, Muc4, Muc5ac and Muc16,
aberrantly express early in PanIN and enhance with the PC progression, promoting the
processes of metastasis and chemoresistance [86-92]. In PC, constitutive active
mutations

of

K-ras

initiate

the

cellular

signaling

to

create

pro-inflammatory

microenvironment, which caused the development of dense stroma and de novo
expression of mucins. Mucins promote PC tumorigenicity via the interaction of their
cytoplasmic tails with intracellular signaling, such as enhancement of EGFR signaling
pathway and activation of focal adhesion kinases to increase cancer motility [90, 93-97].
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De novo expression of mucins would require chromatin modifications at transcription level.
NCOA3 interacts with nuclear receptors and transcription factors and remodels chromatin
for active transcription due to its intrinsic histone-acetyltransferase activity [98]. Silencing
of NCOA3 expression in PC cell lines led to significant reduction in transcripts and proteins
of both Muc4 and Muc1 [85].
In addition to regulation of mucin expression, NCOA3 also plays a critical role in
regulation of PC microenvironment. It upregulates the expression of multiple chemokines
that are responsible for the recruitment of immune cells to pancreatic tumors, and
perpetuation of pro-inflammatory conditions. Activated pancreatic stellate cells secret
collagen and other extracellular matrix proteins in the tumor microenvironment, which
were crosslinked by lysyl oxidases (LOX). NCOA3 may involve in the development of ECM
by upregulating the expression of lysyl oxidase-like-2 (LOXL2). LOXL2 is associated with
the aggressiveness of PC [99]. It participates in fibroblast activation and results in
hardening of desmoplasia and subsequent collapse of the blood vessels, poor tumor
perfusion, increased interstitial pressure, extreme hypoxia, and poor delivery of
therapeutics [99]. Therefore, NCOA3 will be a novel target for PC diagnosis and therapy.
1.6 C-X-C chemokine receptor type 4
Chemokines are signaling proteins secreted by various stromal and epithelial cells
capable of inducing concentration gradient-driven chemotactic migration of cells through
interaction with their respective chemokine receptors [100]. Based on the number and
spacing of N-terminal cysteines, chemokine receptors are divided into four groups (CXC,
CX3C, CC and CX) [101]. There are 19 different chemokine receptors that all belong to
the seven-transmembrane G-protein-coupled receptor family. In tumors, a complex
network of chemokines and chemokine receptors controls cell trafficking into and out of
the tumor microenvironment and thus mediate crucial parts of the metastatic spread of
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tumor cells [102]. The corresponding chemokines expressed at the site of metastasis
provide chemo-attractive signaling that guides trafficking of tumor cells to distant organ
sites. Even though cells from different types of cancer may have different expression
profiles of chemokine receptors, CXC receptor 4 (CXCR4) is the most widely expressed
chemokine receptor in human cancers, which makes it among the most-promising targets
within the chemokine network for cancer therapy.
1.6.1 CXCR4/CXCL12 signaling
CXCL12 binding to CXCR4 initiates multiple downstream signaling pathways and
results in various responses, such as increasing intracellular calcium flux, gene
transcription, chemotaxis, cell survival, and proliferation [103]. The heterotrimeric G
protein is activated and dissociated into GTP-bound α and βγ subunits [104]. Gβγ subunits
activate two major enzymes, phospholipase C-β (PLC-β) and a phosphatidylinositol-3-OH
kinase (PI3K). Phosphatidylinositol (4, 5)-bisphosphate is cleaved by PLC-β into two
secondary messengers, inositol (1, 4, 5)-trisphosphate (IP3) and diacylglycerol (DAG). IP3
causes the release of Ca2+ from intracellular stores and DAG activates protein kinase C
and mitogen-activated protein kinase (MAPK) in conjunction with Ca2+, thus contributing
to cell migration [105]. Gα or Gβγ subunits activate PI3K leading to tyrosine
phosphorylation of components of focal adhesions, including the related adhesion focal
tyrosine kinase (RAFTK), the adaptor molecule p130 Cas, and the cytoskeletal protein
paxillin, thus contributing to reorganization of the actin cytoskeleton and changes
necessary for cell migration [106]. Transcription and gene expression are regulated by
Gαi signaling through the PI3K-AKT-NF-κB, MEK1/2, and ERK1/2 axes [107]. The
activated AKT can regulate the survival of cells. Dimerization of CXCR4 leads to G protein
independent signaling via JAK/STAT pathway, which promotes cell morphology changes
and chemotactic responses [108].
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1.6.2 The role of CXCR4 in cancer and cancer metastasis
CXCR4 overexpression has been reported in more than 20 human tumor types,
including mammary, ovarian, prostate, esophageal, pancreatic, melanoma, and renal cell
carcinoma [109]. The upregulation of CXCR4 is associated with changes in multiple
growth factors, transcription factors, and hypoxia-inducible factors [110-112]. Many
preclinical and clinical studies observed significant correlation between CXCR4
expression and metastasis and found that CXCR4 expression is associated with poor
survival and aggressive type of cancers. CXCR4 overexpression has been identified as a
poor prognostic biomarker. For instance, a microarray study of 2,000 invasive breast
carcinomas and 214 pre-invasive breast samples revealed the critical role of CXCR4 in
cancer progression [113]. Elevated levels of CXCR4 in primary tumors were associated
with a higher risk of developing bone metastasis [114]. Another clinical studies showed
that CXCR4 promotes metastasis through the lymphatic system [115]. Elevated levels of
CXCR4 in cancer cells have also correlated with increasing risk of cancer recurrence [116].
By activating intracellular signaling pathways, such as PI3K, MAPK and Erk1/2,
CXCR4 plays a critical role in cancer cell survival, proliferation, invasion and migration
[117-120]. The influence of CXCR4-induced activation of focal adhesion complexes and
matrix metalloproteinases mediates degradation of extracellular matrix and contributes to
invasion of cancer cells. CXCL12 expression levels are elevated in brain, bone marrow,
lungs, and liver. The CXCL12 concentration gradients then drive movement of CXCR4positive tumor cells in circulation and are responsible for the process of extravasation and
organ-specific metastasis [121].
Among various chemokine pathways associated with the pathology of PC, the
CXCR4/SDF1 axis plays critical role in the invasion and metastasis of PC [122-124]. The
stromal cells produce abundant SDF-1, which activates CXCR4 in PC cells and results in
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enhanced chemotaxis, transendothelial migration, and invasion [125]. CXCR4
upregulation can also augment the Sonic Hedgehog pathway, promotes stem-cell-like
phenotype, enhanced desmoplasia, chemoresistance, and invasiveness of PC [126].
Multiple retrospective clinical studies have directly linked the expression of CXCR4 with
poor survival and metastasis in PC patients [127, 128].
CXCR4/CXCL12 axis is an important emerging target for developing novel delivery
strategies for improved cancer therapies [129, 130]. In addition to utilizing CXCR4
overexpression as a simple target for improved ligand-mediated delivery of drugs to
tumors, blocking CXCR4/CXCL12 interaction using CXCR4 antagonists or silencing
CXCR4 expression by siRNA has potential to prevent primary tumor growth and reduce
metastasis, especially when combined with chemotherapy and radiotherapy. This review
focuses on the role of CXCR4 in cancer metastasis and its potential in drug delivery
systems for cancer therapy. Multiple targeting ligands and CXCR4 antagonists have been
developed, including peptides, antibodies and small organic molecules. The main uses of
CXCR4 in drug delivery for cancer therapy are summarized in Scheme 3 and
representative examples that explore CXCR4 in drug delivery are summarized in Table 1.
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Scheme 3. Summary of the main approaches utilizing CXCR4 in cancer drug delivery
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Table 1. Examples of CXCR4-targeted drug delivery systems
Targeting
moiety
T22 peptide

Delivered
cargo
Green
fluorescent
protein

Refere
nces
Increase
nanoparticle [131]
delivery to colorectal
cancer (in vivo)

Docetaxel
and
doxorubicin
Anticancer
peptides

Increase anticancer drug [132,
delivery in lung cancer (in 133]
vitro)
Increase targeting and [134]
killing of CXCR4-positive
lymphoma cells

Azidecontaining
T22
analogue
peptide
N-terminal
Polyplexes
sequence of
CXCL12

Doxorubicin

Increase anticancer drug [135]
delivery in lymphoma
cells (in vitro)

Reporter
plasmid
DNA

Peptide
Lipoplexes
analog 4FbenzoylTE14011
Ac-TZ14011 Radiopharm
peptide
aceutical

Reporter
plasmid
DNA

Increase gene delivery to [136,
CXCR-positive
human 137]
glioblastoma and cervical
carcinoma cells
Increase gene delivery to [138]
rat glioma cells

LFC131
peptide
DV3 peptide

Delivery
system
Fused
fluorescent
protein
nanoparticle
Chitosan and
PLGA
nanoparticles
Cationic
peptide
transduction
domain
(PTD)
Mesoporous
silica
nanoparticles

111

In

Image
CXCR4
expression in metastatic
pancreatic tumors in vivo
111
In
and Image
CXCR4
Cy5.5 dye
expression in breast
cancer in vivo
Anticancer
Inhibit
breast
tumor
drug HKH- metastasis in vivo
40A

Ac-TZ14011
peptide

Dendrimers

X4-2-6
peptide

Selfassembled
peptide
nanoparticles
Liposomes
Doxorubicin

Anti-CXCR4
antibody

Anti-CXCR4
antibody

Liposomes

Application

Antilipocalin-2
siRNA

[139]

[140,
141]
[142]

Increase delivery and [143]
efficacy of anticancer
drug in breast cancer (in
vitro)
Inhibit both the CXCR4 [144]
and
Lcn2
mediated
migratory pathways in
metastatic breast cancer
(in vitro)
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Anti-CXCR4
antibody
AMD3100

AMD3100

AMD3100

AMD3100

AMD3100
derivatives

Viologen
dendrimers

AMD3100

AMD3465

Radiopharm
aceutical
Lipoplexes
and
polyplexes

111

In

Image brain tumor by
SPECT/CT (in vivo)
Reporter
Increase
gene
plasmid
transfection in CXCR4DNA
positive human
lymphoma Jurkat cells
PLGA
siRNA (anti- Increase
uptake,
nanoparticles GFP)
suppress
CXCR4
signaling and deliver
siRNA in triple negative
breast
cancer
and
metastatic breast cancer
(in vitro)
PLGA
Sorafenib
Target
malignant
nanoparticles
hepatocellular carcinoma
and improve anticancer
effect with sorafenib (in
vivo)
Polyplexes
siRNA
Simultaneously
deliver
(siPLK1)
gene and block CXCR4 to
inhibit metastasis (in vivo,
in vitro)
Polyplexes
Reporter
Simultaneously
deliver
plasmid
gene and block CXCR4 to
DNA
inhibit cell invasion (in
vitro)
Dendrimer
TNFα
Simultaneously prevent
polyplexes
plasmid
CXCR4-mediated cancer
DNA
cell invasion and facilitate
TNFα-mediated cancer
cell killing (in vitro)
64
Radiopharm
Cu
Image lung metastasis
aceutical
derived from human
breast cancer by PET (in
vivo)
64
Radiopharm
Cu
Image brain tumor and
aceutical
colon tumor by PET/CT
(in vivo)

[145]
[146]

[147]

[148]

[149152]

[153]

[154]

[155]

[156]
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1.6.3 CXCR4 as target for ligand-mediated delivery and imaging
Multiple reports explored the use of CXCR4-binding ligands as a way of improving
drug delivery to CXCR4-overexpressing tumors. The most popular ligands are based on
short CXCR4-binding peptides, but small organic molecules and antibodies have also
been explored and are discussed in this section.
1.6.3.1 CXCR4-binding peptides
Peptide ligands that bind CXCR4 has been widely used to direct drug delivery
systems to CXCR4 overexpressing tumor cells with the goal of improving intracellular
delivery of antitumor agents by receptor-medicated cellular uptake. Among the most
successful has been a peptide T22 derived from horseshoe crab polyphemusin II. The
T22 peptide binds CXCR4 and efficiently penetrates target cells via a rapid receptorspecific endosomal route. When conjugated to nanoparticles, T22 mediates delivery and
accumulation of the nanoparticles in the perinuclear region of the target cells both in cell
culture and in metastatic cancer models in vivo. The T22 peptide has been used for
intracellular delivery of proteins, nanoparticles, and imaging agents [131]. Torre et al. have
described a CXCR4-targeted delivery system using mesoporous silica nanoparticles that
were loaded with doxorubicin and capped with an azide-containing modified T22 peptide
by a click reaction [135]. Residues Tyr5, Lys7, and Tyr12 dramatically enhanced the affinity
of the T22 peptide for the CXCR4 receptor overexpressed in B-cell non-Hodgkin’s
lymphoma cells. The peptide capped the pores in the porous nanoparticles to block the
release of doxorubicin and facilitated uptake via the CXCR4 receptor. In lysosomes,
proteolytic enzymes degraded the T22 peptide and allowed intracellular doxorubicin
release.
Wang et al. have investigated a low-molecular-weight CXCR4 peptide antagonist
LFC131 (Tyr-Arg-Arg-Nal-Gly). The authors conjugated the LFC131 peptide to O-
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carboxymethyl

chitosan

nanoparticles

and

poly(lactide-co-glycolide)

(PLGA)

nanoparticles for enhanced targeted delivery of docetaxel and doxorubicin to CXCR4
overexpressing lung cancer cells [132, 133].
To enhance the targeting and killing of tumor cells, Snyder et al. linked another
CXCR4 ligand, DV3, to two transducible anticancer peptides: a p53-activating peptide
(DV3-TATp53C’) and a cyclin-dependent kinase 2 antagonist peptide (DV3-TAT-RxL).
Treatment with either of the targeted peptides resulted in an enhancement of tumor cell
killing compared with treatment with non-targeted parent peptides [134].
CXCR4-binding peptides have also been successfully used to improve nucleic acid
delivery with cationic peptides and cationic polymers. Egorova et al. have developed
chemokine-derived peptides as carriers for gene delivery [136]. The authors used three
synthetic peptides for CXCR4 receptor targeting: two derived from N-terminal sequence
of CXCL12 and one from viral macrophage inflammatory protein (vMIP)-II. One of the
peptides (KPVSLSYRSPSRFFESH-K9-biotin) derived from CXCL12, consisting of an Nterminal sequence of CXCL12 (KPVSLSYR) and an RFFESH motif (residues 12–17), was
able to specifically target cells overexpressing CXCR4 and to exhibit high transfection
efficacy. In a follow-up study, the authors found that the use of the oligolysine (K9) as the
DNA-binding moiety compromised the gene delivery due to instability in physiological
conditions and lack of endosomolytic properties. To circumvent these problems, the
authors developed a gene delivery system using CXCL12-derived cross-linking peptides
and

demonstrated

that

a

modular

peptide

KPVSLSYRSPSRFFESH-Ahx-Ahx-

CHRRRRRRHC could be used as efficient gene delivery carrier. The flanking cysteines
formed intermolecular disulfide bonds to stabilize the particles and tightly condense DNA.
Subsequent internalization and intracellular disulfide breakage resulted in enhanced gene
expression when compared with the K9-based peptides, in part also because of the
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buffering capacity and membrane activity of the peptide containing histidine and arginine
residues [137].
Feasibility of CXCR4 targeting using lipoplexes containing peptide analog 4Fbenzoyl-TE14011 was also demonstrated [138]. The peptide ligand (4-fluorobenzoyl-RRNal-CY-Cit-KEPYR-Cit-CR) binds CXCR4 with high affinity (Kd 1.5 nM) and when
covalently linked to a phospholipid used in lipoplex formulation resulted in CXCR4targeted gene delivery.
1.6.3.2 CXCR4-binding small molecule organic ligands
Synthetic small molecule organic molecules that bind CXCR4 have been among
the most successful CXCR4 antagonists. In fact, the only currently FDA-approved CXCR4
antagonist is a cyclam derivative AMD3100 (Plerixafor). AMD3100 has been shown to
bind and block CXCR4 signaling in multiple animal models as well as in clinical trials [157,
158]. Several reports exist on the use of drug and gene delivery systems conjugated with
small molecule ligands like AMD3100. Probably the first report described a nonviral carrier
in which AMD3100 was covalently attached to polyethylenimine (PEI) and cationic lipids
[146]. The study showed that the CXCR4-targeted polyplexes could effectively deliver
genes into CXCR4-positive Jurkat cells. The role of CXCR4 in the uptake of the polyplexes
was clearly demonstrated when nonspecific internalization pathways were minimized or
when phorbolmyristate acetate (PMA) was used to enhance CXCR4 receptor endocytosis.
AMD3100 has also been successfully used to target multicompartment PLGA
nanoparticles to CXCR4-overexpressing breast cancer cells [147]. In this case, AMD3100
was conjugated to the surface of the nanoparticles by using PLGA with terminal acrylate
groups that were reacted with AMD3100 amines via Michael addition. The targeted
nanoparticles were then selectively taken up by CXCR4-overexpressing breast cancer
cells and they also effectively blocked CXCR4 signaling. When loaded with siRNA, the
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AMD3100-PLGA nanoparticles allowed for more effective gene silencing in vitro than their
corresponding nontargeted nanoparticles.
1.6.3.3 Anti-CXCR4 antibodies
Multiple anti-CXCR4 antibodies have been developed and applied as experimental
treatments in animal models of cancer metastasis [159, 160]. Such antibodies can be also
used as ligands to facilitate improved delivery of drug carriers, similar to the peptide and
small molecule ligands discussed above [143, 144]. For example, liposomes targeted with
anti-CXCR4 antibody were used to improve doxorubicin activity in CXCR4-overexpressing
breast cancer cells [143]. The liposomes were prepared by the extrusion using 1,2dioleoyl-sn-glycero-3-phosphoethanolamine-N-dodecanoyl (N-dod-PE) and 1,2-dioleoylsn-glycero-3-phosphocholine (DOPC), followed by conjugation of mouse anti-human
CXCR4

monoclonal

antibody

via

N-dod-PE

anchor

by

EDC/NHS

chemistry.

Overexpression of CXCR4 was observed in HCC1500 and MDA-MB-175VII breast cancer
cells relative to normal control cells MCF10As. Expression levels of CXCR4 in the breast
cancer cells directly correlated with increased liposome binding and enhanced drug
activity. Based on this study, the knowledge of the levels of CXCR4 expression may be
used to predict the efficacy of CXCR4-targeted drug delivery systems.
1.6.3.4 Imaging agents that target CXCR4
Due to the established role of CXCR4 in cancer metastasis, there is a growing
interest and potential in using CXCR4-binding ligands for imaging of primary and
metastatic tumors. CXCR4-binding imaging agents have been developed based on
peptide and small molecule organic ligands. For example, using systematic structureactivity relationship study, Hanaoka et al. have developed a radiopharmaceutical for the
imaging of CXCR4-expressing tumors in vivo based on the T22 peptide [139]. The authors
designed a peptidic CXCR4 ligand named Ac-TZ14011 (Ac-RR-Nal-CY-Cit-RKPYR-Cit-
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CR). The ligand contains four residues (Arg2, Nal3, Tyr5, and Arg14) that formed the intrinsic
pharmacophore and were necessary for the CXCR4 inhibition.

111

In was then used as

radionuclide for radiolabeling of the peptide containing diethylenetriaminepentaacetic acid
(DTPA) attached to the side chain of D-Lys8. The resulting

111

In-DTPA-Ac-TZ14011

inhibited the binding of CXCL12 to CXCR4 in a concentration-dependent manner with an
IC50 of 7.9 nM. Biodistribution studies in athymic nude mice bearing subcutaneous
CXCR4-overexpressing pancreatic carcinoma cells showed preferential accumulation of
111

In-DTPA-Ac-TZ14011 in the tumor. Similarly, Kuil et al. have developed peptide-

conjugated dendrimers using Ac-TZ14011 peptide to obtain constructs capable of
multimodal imaging. The constructs consisted of a Cy5.5-like fluorophore and a DTPA
chelating group for

111

In labeling and were used to image CXCR4 expression in breast

cancer animal model using both SPECT/CT and fluorescence imaging [140, 141].
The cyclam-based CXCR4 antagonists like AMD3100 constitute a diverse class of
compounds with common ability to chelate transition metals in the cyclam macrocycle.
These compounds have been used in multiple studies to chelate PET-positive
radioisotope

64

Cu for imaging of CXCR4-expressing tumors. For example, Nimmagadda

et al. have reported the development and evaluation of [64Cu]-AMD3100 to image lung
metastasis derived from human MDA-MB-231 breast cancer by PET [155]. Another
cyclam-containing CXCR4 ligand, AMD3465, was also used for imaging CXCR4
expression. De Silva et al. reported that [64Cu]-AMD3465 was capable of detecting tumor
lesions using dynamic and whole-body PET/CT in a CXCR4 dependent fashion with high
target selectivity in both U87 brain tumor and HT-29 colon tumor animal models [156].
Anti-CXCR4 antibodies are commonly used for fluorescence microscopy imaging
but they also showed potential in SPECT/CT imaging in vivo. Using

125

I-labeled anti-

CXCR4 monoclonal antibody (12G5), the results of a recent study showed successful
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SPECT/CT imaging of CXCR4-positive U87 brain tumors [145]. Compared with isotype
control, the tumor-to-tissue uptake ratio for

125

I-12G5 was 2.5-fold higher at 48 h after

injection, indicating the feasibility of antibody-targeted tumor imaging.
1.6.4 Inhibition of CXCR4 in anticancer therapies
Due to its significant role in multiple steps involved in cancer progression, inhibition
of CXCR4 has been explored in various drug delivery systems with the goal of reducing
cancer cell proliferation and metastasis. Several strategies have been employed to either
directly silence expression of CXCR4 gene in malignant cells using siRNA or to codeliver
small-molecule CXCR4 antagonists with other antitumor therapeutics to achieve
enhanced anticancer effect.
1.6.4.1 Silencing of CXCR4 gene
Specific targeting and silencing of CXCR4 expression with siRNAs has been
proposed to slow down cancer cell growth and metastasis both in vitro and in vivo. CXCR4
expression was significantly downregulated in liver metastasis of colorectal cancer when
anti-CXCR4 siRNA was delivered by nanoparticles based on spermine-modified dextran
[161, 162]. In the study, spermine was conjugated to oxidized dextran by reductive
amination process to obtain cationic dextran and the results showed that CXCR4 silencing
decreased the extent of cancer cell and lymphocyte infiltrationin in the liver of treated
animals. In a study of the effect of CXCR4 silencing on metastasis of breast cancer, a
fusion protein based on HER2-scFv and arginine nonamer peptide (e23sFv-9R) was
developed and tested as siRNA carrier [163]. Delivery of anti-CXCR4 siRNA by the
e23sFv-9R carrier resulted in decreased CXCR4 expression and subsequent reduction in
proliferation and metastasis in HER2-positive breast cancer BT-474 cell line in vitro.
Importantly, systemic delivery of the anti-CXCR4 siRNA by the fusion protein was able to
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suppress tumor growth, reduce metastasis, and prolong survival in mice bearing HER2positive xenografts.
Tumor progression is associated with intratumoral hypoxia and an abnormal
vascular architecture, which provides heterogeneous perfusion within the tumor tissue
[164]. Hypoxia regulates the expression of multiple genes involved in angiogenesis,
epithelial-mesenchymal transition, extracellular matrix degradation, and chemotaxis [165].
CXCR4 is a potential target in the events associated with hypoxia because of its hypoxiatriggered upregulation. Romain et al. have demonstrated that hypoxia upregulated CXCR4
expression in colon cancer cells and that CXCR4 expression remained elevated for up to
48 h even when the cancer cells were returned to normoxic conditions [166]. As a result
of the CXCR4 upregulation, the migration of the colon cancer SW480 cells increased up
to 6-fold in hypoxia when compared with normoxic conditions. Importantly, the increased
invasiveness of the cancer cells could be reduced significantly by CXCR4 gene silencing.
1.6.4.2 Inhibition of CXCR4 in cancer metastasis
In addition to offering a simple targeting to CXCR4-overexpressing cancer cells,
many of the existing CXCR4-binding ligands also function as receptor antagonists and
thus inhibit CXCR4/CXCL12 signaling. The inhibition of the CXCR4 signaling can utilized
to achieve additional antitumor and antimetastatic benefits, especially when combined
with other simultaneously delivered drugs. There has been a growing number of
successful examples of drug and gene delivery vectors that combine delivery function with
a pharmacological CXCR4-inhibiting activity and they will be discussed in this section.
Multiple innovative drug delivery systems that combine CXCR4 inhibition and drug
delivery have been reported in recent years. Taking advantage of the structural plasticity
of transmembrane peptides, biologically active nanoparticles that effectively inhibit tumor
metastasis in vivo have been developed based on a 24-amino acid peptide X4-2-6 which
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corresponds to the second transmembrane helix of the CXCR4. The peptide selfassembled into nanoparticles that inhibited CXCR4 function in vitro and prevented
CXCR4-dependent tumor metastasis in MDA-MB-231 breast cancer xenograft model
[142]. These nanoparticles could additionally encapsulate hydrophobic antitumor drugs,
thus providing an effective combination delivery system. The peptides were capable of
assembling into a variety of structures including spherical, fibrous, tubular and discoid
shapes [167]. The ability to control the morphology of the assemblies may allow improved
delivery of such peptide particles as it was found that stronger intermolecular interactions
observed in nanospheres than in fibrils resulted in slower rates of particle disassembly
and in improved protection against proteolytic degradation.
As part of our long-term efforts to develop dually functioning polycations for
combination drug/gene delivery, we have designed polycations (PAMD) based on the
cyclam CXCR4 antagonist AMD3100. The PAMD polymers showed dual functionality as
efficient nucleic acid (gene and siRNA) delivery vectors and CXCR4 antagonists that
inhibited invasion of cancer cells in vitro and decreased metastasis in several tumor
models in vivo [149, 150]. Modification of PAMD with PEG was used to improve the in vivo
applicability [151]. Modification with cholesterol was used as a way of enhancing siRNA
delivery efficacy of PAMD, while preserving the CXCR4-inhibiting activity of the polymers
[152]. Although based on an approved drug and easy to synthesize, PAMD synthesis
resulted in the formation of highly branched polymers and in a relatively low CXCR4
antagonistic activity when compared with the original AMD3100. Based on the knowledge
of the AMD3100 pharmacophore, we developed a second generation of CXCR4-inhibiting
polycations based on a series of linear poly(amido amine)s using Michael-type
polyaddition of novel monocyclam monomers. The use of monocyclam monomers allowed
preparation of polymers with well-defined architecture and the CXCR4-binding moieties
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present in the sidechain of the polymers, which resulted in improved presentation and
accessibility for CXCR4 binding, resulting in greatly increased CXCR4 antagonism [153].
In addition to naturally derived peptides and lipids and polymers based on existing
small molecule CXCR4 inhibitors, dendrimers based on viologen (dialkylated 4, 4’bipyridinium salts) have been found to exhibit potent antagonistic activity against CXCR4
[168]. Viologen dendrimers (VGD) were also recently used as a promising class of gene
delivery vectors when they demonstrated promising synergistic anticancer activity when
used to deliver TNFα plasmid DNA [154].
Similar to the other types of CXCR4 inhibitors, anti-CXCR4 antibodies have been
used both for their drug targeting ability to CXCR4-overexpressing cancers as well as for
their ability to block the CXCR4/CXCL12 signaling in antimetastatic approaches. For
example, pH-responsive CXCR4-targeted liposomes were prepared to achieve combined
inhibition of CXCR4 and siRNA silencing of lipocalin-2 (Lcn2) [144]. The liposomes were
composed of a mixture of DOPC, 1, 2-dioleoyl-3-dimethylammoniumpropane (DODAP)
and N-dod-PE and were modified with anti-CXCR4 antibody to target metastatic breast
cancer cells and block cell migration. Liposomes incorporating DODAP responded to the
acidic endosomal environment by increasing the cationic character, fusing with the
endosomal membrane, and delivering siRNA into the cytoplasm. The combined liposomes
significantly reduced migration in triple negative human breast cancer cells (88% for MDAMB-436 and 92% for MDA-MB-231) when compared with inhibition of the CXCR4 or Lcn2
pathways alone.
1.6.4.3 Inhibition of CXCR4 as a chemosensitizing approach
Drug resistance remains a serious problem in cancer chemotherapy. Anticancer
potency can be greatly improved by combining chemotherapy with a chemosensitizing
effect of CXCR4 inhibition. For example, a multikinase inhibitor sorafenib is an anti-
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angiogenic agent used in the treatment of advanced hepatocellular carcinoma (HCC) and
its use results in a significant increase in overall patient survival. However, prolonged
sorafenib treatment increases tumor hypoxia due to decreased neovasculature, which in
turn upregulates the expression of CXCR4. This causes HCC to acquire more invasive
phenotype and to rapidly develop resistance to antiangiogenic therapy with sorafenib [169171]. AMD3100 can sensitize HCC to sorafenib treatment by inhibiting CXCR4 axisinduced
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the

tumor-promoting

microenvironment [171]. To take advantage of the chemosensitizing ability of AMD3100,
Gao et al. encapsulated sorafenib in lipid-coated PLGA nanoparticles. The surface of the
nanoparticles was modified with AMD3100 to allow systemic delivery of the
sorafenib/AMD3100 combination into HCC [148]. The results of the study demonstrated
that the nanoparticles could efficiently deliver sorafenib and AMD3100 in HCC and that
the combined treatment showed improved anti-angiogenic effect and decreased infiltration
of tumor-associated macrophages in vivo. The combined nanoparticle treatment
significantly inhibited primary HCC growth and distal metastasis and thus increased
overall survival in vivo, indicating clinical potential of CXCR4 inhibition in overcoming
acquired drug resistance in HCC.
1.6.5 CXCR4 and PC
CXCR4/SDF-1 axis plays an important role in PC pathology, involving in
metastasis, invasion, angiogenesis, and proliferation [123, 124]. Clinical data indicates
that CXCR4 has been directly linked to poor survival of PC patients [127, 128, 172].
CXCR4 expression is overexpressed in majority of PC tissues and precancerous lesions,
suggesting its role in PC pathogenesis [173]. The stromal cells produce abundant CXCL12,
which activates CXCR4-expressing PC cells and results in enhanced chemotaxis,
transendothelial migration and invasion [125]. PC cells are easily mediated by CXCR4
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activation and migrate towards the gradient of SDF-1 in distant organs, such as lymph
nodes, lung and liver [174]. Furthermore, activation of CXCR4/SDF-1 signaling confers
drug resistance to pancreatic cancer cells by potentiating survival. Singh et al. reported
that gemcitabine induced chemoresistance was partly mediated by the activation of Akt
and Erk signaling pathways [175]. However, a small-molecule antagonist AMD3100
against CXCR4 could effectively abrogate the survival signals and resensitise the PC cells
to gemcitabine cytotoxicity. Moreover, CXCR4/SDF-1 signaling confers chemoresistance
not only by directly impacting the tumor cells but also indirectly through SHH-induced
pancreatic fibrosis, suggesting the potential of the CXCL12-CXCR4 pathway as a
therapeutic target in PC [176].
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Chapter 2. Statement of the Problem and Hypothesis
Metastasis is the one of the major reasons for cancer mortality and morbidity. Each
year, several million patients died from cancer metastasis. Existing therapeutic
approaches rarely reverse or stop metastatic progression. Late diagnosis, early
metastasis, and complex microenvironment caused extremely low survival rate of PC. The
one-year and five-year survival rates are ~29% and ~7% respectively. Complicated PC
microenvironment contributes to inherent resistance to available therapies and severely
limits drug delivery [30-32]. Gemcitabine is the first-line treatment for metastatic pancreatic
cancer. However, the objective response is less than 10%. Thus, there is an urgent need
to develop novel therapies for the treatment of PC [33, 177].
PC is unique among solid tumors because of the extremely dense desmoplstic
reaction which wraps the cancer cells. It forms a barrier to chemotherapy penetration due
to the growth of dense, collagen rich, extracellular matrix and stroma with high interstitial
pressure around PC tumors. Desmoplastic reaction creates a unique microenvironment
that paradoxically promotes both tumor growth and metastatic spread. Furthermore,
mucins, such as Muc1, Muc4, Muc5ac and Muc16, aberrantly express early in PanIN and
enhance with the PC progression, promoting the processes of metastasis and
chemoresistance [86-92].
NCOA3 is one of the frequently mutated genes in PC [82]. High-level amplification
of NCOA3 has been found not only in PC cell lines, but also in PC tissues and metastatic
lesions [83, 84]. It works as a chromatin remodeling enzyme and modulates the
expression of mucins via transcriptional and post-translational changes in the
development of PC [85]. In addition to regulation of mucin expression, NCOA3 may involve
in the development of ECM by upregulating the LOXL2. LOXL2 participates in fibroblast
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activation and results in hardening of desmoplasia, which is associated with the
aggressiveness of PC [99].
CXCR4/SDF-1 axis plays a critical role in PC metastasis, invasion, angiogenesis,
and proliferation [123, 124]. Abundant SDF-1 is produced by PC stromal cells and
activates CXCR4 expression in PC cells, which also augments Shh pathway to elevate
desmoplasia, enhance chemoresistance as well as promote invasion in PC [125, 126].
Gemcitabine induced chemoresistance was medicated by activation of CXCR4/SDF-1
signaling pathway [175]. However, a small-molecule CXCR4 inhibitor AMD3100 could
effectively abrogate the survival signals and resensitize the PC cells to gemcitabine
cytotoxicity. Multiple retrospective clinical studies have directly linked the expression of
CXCR4 with poor survival and metastasis in PC patients [127, 128].
Targeting components of the tumor stroma that contribute to the desmoplastic
reaction is a promising new platform of investigation. Most strategies aim to enhance
chemotherapeutic and even radiotherapeutic efficacy, by increasing tumor accumulation,
penetration, and drug-distribution and targeting signaling pathways, which are directly
implicated in the formation of desmoplastic reaction. Changes in the tumor
microenvironment that decrease desmoplasia can improve access of drugs to the tumor
but they may also inadvertently promote metastasis. PC metastasizes readily and early in
its progression.
Based on the critical role of NCOA3 and CXCR4 as well as the therapeutic
challenges of PC, we designed novel treatment that relies on delivery of NCOA3-silencing
siRNA using polyplexes formed by polymeric CXCR4 inhibitors (PCX). We hypothesized
that the ability of the developed polyplexes to simultaneously downregulate mucin
expression via NCOA3 silencing and inhibition of CXCR4 will lead to improved antitumor
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and antimetastatic activity. The use of PCX to deliver siNCOA3 is in part selected to
minimize the chances of increased metastasis.
The working hypothesis for this dissertation is that PCX will not only exhibit CXCR4
antagonism but will also effectively deliver siRNA to inhibit NCOA3. The hypothesis is
supported by successful synthesis of PCX and the demonstration of PCX’s ability to
deliver multiple types of nucleic acids (DNA, siRNA). Development of functional
poly(amido amine) CXCR4 antagonists with increased CXCR4 inhibitory activity is
explored in the results and discussion part of 4.1. Part 4.2 focuses on modification of PCX
with PEGylation to enhance colloidal stability and safety for gene therapy in cancer. In 4.3
we investigate cholesterol modification of PCX to improve siRNA delivery for combined
anticancer therapies. The combination of NCOA3 silencing and CXCR4 inhibition by PCX
nanoparticles to improve antitumor and antimetastasis in PC is described in 4.4. The
central hypothesis is that the combination of NCOA3 gene silencing and CXCR4
antagonism by PCX will decrease mucin expression, regulate tumor microenvironment,
reduce metastasis, and chemosensitize PC to improve the treatment. We will pursue the
following specific aims.
Aim 1. Develop and modify PCX polymers to inhibit CXCR4 and deliver nucleic
acids to cancer cells.
Aim 2. Screen PCX capable of efficient delivery of siRNA to inhibit NCOA3 in PC.
Aim 3. Determine if combination of NCOA3 silencing and CXCR4 inhibition by
PCX nanoparticles improves antitumor and antimetastatic activity in orthotopic PC model.
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Chapter 3 - Materials and Methods
3.1 Materials
N,N’-hexamethylenebisacrylamide (HMBA) was purchased from Polysciences, Inc.
(Warrington, PA). Cyclam (1,4,8,11-tetraazacyclotetradecane) was from Alfa Aesar (Ward
Hill, MA). Cholesteryl chloroformate and branched polyethylenimine (PEI, 25 kDa) was
obtained from Sigma-Aldrich (St. Louis, MO). mPEG-Acrylamide (2 kDa) was from
Creative PEGworks (Winston-Salem, NC). N,N-diisopropylethylamine (DIPEA) was from
Acros Organics (New Jersey, US). Trifluoroacetic acid (TFA) and 4-amino-1-butanol
(ABOL) were purchased from ACROS Organics (Fair Lawn, NJ). AMD3100 (base form)
was from Biochempartner (Shanghai, China). Plasmid DNA, gWiz high-expression
luciferase (gWiz-Luc), containing luciferase reporter gene was from Aldevron (Fargo, ND).
Dulbecco’s modified Eagle medium (DMEM), Dulbecco’s phosphate buffered saline (PBS),
and fetal bovine serum (FBS) were from Thermo Scientific (Waltham, MA). Cell culture
inserts (for 24-well plates, 8.0 μm pores, Translucent PET Membrane, cat# 353097) and
BD MatrigelTM Basement Membrane Matrix (cat# 354234) were purchased from BD
Biosciences (Billerica, MA). Human SDF-1α was from Shenandoah Biotechnology, Inc.
(Warwick, PA). Non-targeting siRNA control (siScr, 5’-UUCUCCGAACGUGUCACGUUU3’), siGENOME human polo-like kinase 1 (PLK1) siRNA Smartpool (siPLK1) and stability
enhanced NCOA3 siRNA (siNCOA3, 5’-GACAGGCACUUGAAUUGAAUU-3’) were
purchased from GE Healthcare Dharmacon, Inc. (Lafayette, CO). Succinimidyl ester of
Alexa Fluor® 647 carboxylic acid was from Life Technologies (Eugene, OR). Rotor-Gene
SYBR Green RT-PCR Kit was from QIAGEN (Hilden, Germany). TRIzol® reagent, human
CXCR4
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Life Technologies (Carlsbad, CA). Allophycocyanin (APC) mouse anti-human CXCR4
antibody and APC mouse lgG2a, ĸ isotype controls were from BD Biosciences (San Jose,
CA). Anti-CXCR4 antibody [UMB2] was purchased from Abcam (ab124824, Cambridge,
MA). Anti-NCOA3 antibody was purchased from Santa Cruz Biotechnologies (sc25742,
Dallas, TX). The MUC4 monoclonal antibody (8G7) used in this study was developed by
Dr. Batra group [178]. All other reagents were from Fisher Scientific and used as received
unless otherwise noted.
3.2 Synthesis of monocyclam-based monomers
Tri-tert-butyl-1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (2): A solution
of Boc2O (3.27 g, 15.0 mmol) in CH2Cl2 (75 mL) was added dropwise over a period of 2 h
to a solution of 1 (1.00 g, 5.0 mmol) in CH2Cl2 (200 mL) at 0°C. The mixture was allowed
to warm to room temperature and stirred overnight. The mixture was concentrated and
purified by chromatography (AcOEt→10:1 AcOEt:CH3OH) to first give tetra-Boc cyclam
as a white foam and then tri-Boc cyclam (compound 2, 2.10 g, 84%) as a white set foam:
H NMR (400 MHz, CDCl3, δ) 1.46 (s, 27H), 1.65–1.76 (m, 2H), 1.80–2.00 (m, 2H), 2.62
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(bt, J = 5.6 Hz, 2H), 2.79 (t, J = 4.8 Hz, 2H), 3.31 (t, J = 6.4 Hz, 8H), 3.34–3.47 (m, 4H).
Tri-tert-butyl-11-(4-(chloromethyl)benzyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8tricarboxylate (3): to a solution α,α’-dichloro-p-xylene (7.44 g, 41.6 mmol) in CH3CN (100
mL), anhydrous K2CO3 (1.44 g, 10.4 mmol) was added followed by 2 (4.17 g, 8.33 mmol)
dissolved in CH3CN (50 mL). The mixture was refluxed for 6 h before filtering and washing
the solid with acetone. The filtrate was concentrated to give a white solid that was heated
with 2:1 hexanes:AcOEt and concentrated to a small volume to allow the excess
dichloroxylene to crystallize out. The filtrate was then further purified by chromatography
(2:1→1:1 hexanes:AcOEt) to first give more excess dichloroxylene and then the desired
mono-cyclam product (compound 3, 4.31 g, 81%) as a white set foam: 1H NMR (400 MHz,
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CDCl3, δ) 1.44 (s, 18H), 1.47 (s, 9H), 1.68 (bs, 2H), 1.90 (bs, 2H), 2.30–2.47 (m, 2H),
2.50–2.70 (m, 2H), 3.15–3.48 (m, 12H), 3.52 (s, 2H), 7.23 (d, J = 8.0 Hz, 2H), 7.32 (d, J =
7.2 Hz, 2H).
Tri-tert-butyl-11-(4-((2-hydroxyethylamino)methyl)benzyl)-1,4,8,11-tetraaza
cyclotetradecane-1,4,8-tricarboxylate (4a): To a mixture of 3 (2.17 g, 3.39 mmol) and
anhydrous K2CO3 (0.70 g, 5.1 mmol) in CH3CN (15 mL), ethanolamine (2.1 mL, 2.1 g, 34
mmol) was added and the mixture stirred overnight. The formed solid was filtered and
washed with AcOEt (50 mL). The filtrate was washed with water (2  10 mL), saturated
NaCl (10 mL), then dried (MgSO4) and concentrated to give a viscous liquid, which was
purified by chromatography (10:1 CH2Cl2:CH3OH, adding 0.5% NH3 later) to give the
amino alcohol as a white foam (compound 4a, 2.08 g, 92%): 1H NMR (400 MHz, CDCl3,
δ) 1.44 (s, 18H), 1.47 (s, 9H), 1.67 (bs, 2H), 1.90 (bs, 2H), 2.20–2.46 (m, 4H), 2.52–2.70
(m, 2H), 2.80 (t, J = 6.0 Hz, 2H), 3.18–3.44 (m, 12H), 3.50 (s, 2H), 3.67 (t, J = 5.2 Hz, 2H),
3.80 (s, 2H), 7.19–7.26 (m, 4H).
Tri-tert-butyl-11-(4-((3-hydroxypropylamino)methyl)benzyl)-1,4,8,11-tetraazacyclo
tetradecane-1,4,8-tricarboxylate (4b): To a solution of 3 (2.14 g, 3.35 mmol) and
anhydrous K2CO3 (0.69 g, 5.0 mmol) in CH3CN (15 mL), 3-amino-1-propanol (2.6 mL, 2.55
g, 33.5 mmol) was added and the mixture stirred overnight. The formed solid was filtered
and washed with AcOEt (50 mL). The filtrate was washed with water (2  10 mL), saturated
NaCl (10 mL), dried (MgSO4) and concentrated to give a viscous liquid, which was then
purified by chromatography (10:1 CH2Cl2:CH3OH, adding 0.5% NH3 later) to give the
amino alcohol as a white foam (compound 4b, 2.16 g, 95%): 1H NMR (400 MHz, CDCl3,
δ) 1.44 (s, 18H), 1.47 (s, 9H), 1.67 (bs, 2H), 1.74 (quintet, J = 5.6 Hz, 2H), 1.90 (bs, 2H),
2.36 (bs, 2H), 2.52–2.68 (m, 2H), 2.91 (t, J = 5.6 Hz, 2H), 3.18–3.44 (m, 12H), 3.51 (s,
2H), 3.79 (s, 2H), 3.81 (t, J = 5.2 Hz, 2H), 7.22 (s, 4H).
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Tri-tert-butyl-11-(4-((tert-butoxycarbonyl(2-hydroxyethyl)amino)

methyl)benzyl)-

1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (5a): To a solution of 4a (1.67 g,
2.52 mmol) in CH2Cl2 (25 mL), Boc2O (0.82 g, 3.8 mmol) in CH2Cl2 (5 mL) was added and
the mixture stirred overnight. It was concentrated to give a light yellow liquid and purified
by chromatography (1:1 hexanes:AcOEt) to give the Boc protected amino alcohol as a
white set foam (compound 5s, 1.90 g, 99%): 1H NMR (400 MHz, CDCl3, δ) 1.44 (s, 18H),
1.47 (s, 18H), 1.67 (bs, 2H), 1.90 (bs, 2H), 2.36 (bs, 2H), 2.53–2.68 (m, 2H), 3.18–3.44
(m, 14H), 3.51 (bs, 2H), 3.68 (bs, 2H), 4.40–4.54 (m, 2H), 7.12–7.25 (m, 4H).
Tri-tert-butyl-11-(4-((tert-butoxycarbonyl(3-hydroxypropyl)amino)methyl)benzyl)1,4,8,11-tetraazacyclotetra decane-1,4,8-tricarboxylate (5b): To a solution of 4b (2.16 g,
3.18 mmol) in CH2Cl2 (30 mL), Boc2O (1.08 g, 4.77 mmol) in CH2Cl2 (5 mL) was added
and the mixture stirred overnight. It was concentrated to give a light yellow liquid and
purified by chromatography (1:1 hexanes:AcOEt) to give the Boc protected amino alcohol
as a white set foam (compound 5b, 2.24 g, 91%): 1H NMR (400 MHz, CDCl3, δ) 1.44 (s,
18H), 1.47 (s, 18H), 1.57–1.78 (m, 4H), 1.91 (bs, 2H), 2.36 (bs, 2H), 2.51–2.70 (m, 2H),
3.18–3.44 (m, 14H), 3.47–3.59 (m, 4H), 3.82 (bs, 2H), 4.35 (bs, 2H), 7.11–7.25 (m, 4H).
Tri-tert-butyl-11-(4-((tert-butoxycarbonyl(2-(1,3-dioxoisoindolin-2yl)ethyl)amino)methyl)

benzyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate

(6a): A mixture of 5a (1.41 g, 1.85 mmol), PPh3 (0.98 g, 3.7 mmol), phthalimide (0.29 g,
1.93 mmol) and anhydrous THF (20 mL) was heated under N2 until all the solid dissolved.
The mixture was cooled to 0°C and diethyl azodicarboxylate (DEAD) (0.60 mL, 0.67 g, 3.7
mmol) was added dropwise and the mixture warmed to room temperature, after which it
was concentrated to give a white solid. The solid was heated with 2:1 hexanes:AcOEt until
all the solid dissolved and filtered through silica gel, collecting the fractions that contained
product. These fractions where concentrated to a small volume and any solid that
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crystallized out was removed by filtration. The filtrate was further purified by
chromatography (2:1 hexanes:AcOEt) to give the phthalimide as a white set foam
(compound 6a, 1.65 g, 100%): 1H NMR (400 MHz, CDCl3, δ) 1.43 (s, 18H), 1.47 (s, 18H),
1.66 (bs, 2H), 1.89 (bs, 2H), 2.35 (bs, 2H), 2.58 (bs, 2H), 3.14–3.40 (m, 12H), 3.40–3.48
(m, 3H), 3.51 (t, J = 5.2 Hz, 1H), 3.81 (t, J = 5.6 Hz, 1H), 3.86 (t, J = 5.2 Hz, 1H), 4.41 (s,
1H), 4.47 (s, 1H), 7.17 (s, 4H), 7.65–7.75 (m, 2H), 7.80–7.86 (m, 2H).
Tri-tert-butyl-11-(4-((tert-butoxycarbonyl(3-(1,3-dioxoisoindolin-2-yl)propyl)amino)
methyl) benzyl)- 1,4,8,11-tetraazacyclo tetradecane-1,4,8-tricarboxylate (6b): A mixture of
5b (0.89 g, 1.14 mmol), PPh3 (0.61 g, 2.3 mmol), phthalimide (0.19 g, 1.3 mmol) and
anhydrous THF (15 mL) was heated under N2 until all the solid dissolved, before it was
cooled to 0°C. DEAD (0.37 mL, 0.41 g, 2.3 mmol) was added dropwise and the mixture
warmed to room temperature, after which it was concentrated to give a white solid. This
was heated with 2:1 hexanes:AcOEt until all the solid dissolved and filtered through silica
gel, collecting the fractions that contained product. These fractions where concentrated to
a small volume and any solid that crystallized out was removed by filtration. The filtrate
was further purified by chromatography (2:1 hexanes:AcOEt) to give the phthalimide as a
white set foam (compound 6b, 1.03 g, 100%): 1H NMR (400 MHz, CDCl3, δ) 1.44 (s, 27H),
1.47 (s, 9H), 1.67 (bs, 2H), 1.88 (bs, 4H), 2.36 (bs, 2H), 2.61 (bs, 2H), 3.12–3.45 (m, 12H),
3.50 (s, 2H), 3.65 (bs, 2H), 4.18–4.25 (m, 2H), 4.43 (bs, 2H), 7.10–7.20 (m, 4H), 7.69–
7.75 (m, 2H), 7.81–7.86 (m, 2H).
Tri-tert-butyl-11-(4-(((2-aminoethyl)(tert-butoxycarbonyl)amino)methyl)benzyl)1,4,8,11-tetraazacyclotetrade cane-1,4,8-tricarboxylate (7a). To a solution of 6a (1.54 g,
1.7 mmol) in CH3OH (20 mL), NH2NH2 (0.54 mL, 0.55 g, 17 mmol) was added and the
mixture stirred overnight. It was concentrated to give a white solid that was mixed with
CH2Cl2 and filtered. This was repeated until no more amine was extracted from the solid.
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The combined filtrates were concentrated to give a white foam (compound 7a, 1.31 g,
100%). This was further purified by chromatography (10:1 CH2Cl2:CH3OH, adding 0.5%
NH3 latter). 1H NMR (400 MHz, CDCl3, δ) 1.44 (s, 18H), 1.47 (s, 18H), 1.67 (bs, 2H), 1.91
(bs, 2H), 2.06 (bs, 2H), 2.36 (bs, 2H), 2.62 (bs, 2H), 2.79 (bs, 2H), 3.13–3.45 (m, 14H),
3.51 (s, 2H), 4.43 (bs, 2H), 7.11–7.24 (m, 4H).
Tri-tert-butyl-11-(4-(((3-aminopropyl)(tert-butoxycarbonyl)amino)methyl)benzyl)1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (7b): To a solution of 6b (1.03 g,
1.1 mmol) in CH3OH (20 mL), NH2NH2 (0.36 mL, 0.36 g, 11 mmol) was added and the
mixture stirred overnight. It was concentrated to give a white solid that was mixed with
CH2Cl2 and filtered. This was repeated until no more amine was extracted from the solid.
The combined filtrates were concentrated and purified by chromatography (10:1
CH2Cl2:CH3OH, adding 0.5% NH3 latter) to give a white foam (compound 7b, 0.66 g, 75%).
H NMR (400 MHz, CDCl3, δ) 1.44 (s, 18H), 1.47 (s, 18H), 1.66 (bs, 4H), 1.91 (bs, 2H),
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2.17 (bs, 2H), 2.36 (bs, 2H), 2.52–2.78 (m, 4H), 3.13–3.44 (m, 14H), 3.51 (s, 2H), 4.33–
4.47 (m, 2H), 7.09–7.23 (m, 4H).
3.3 Polymer synthesis
3.3.1 Synthesis of PCXG1
Polymeric Plerixafor PCXG1 was synthesized by Michael-type polyaddition of equal
molar ratio of HMBA and a corresponding cyclam monomer AMD3100. Typically, each
reactant was dissolved at a concentration at 80 mg/mL in a glass vial containing
MeOH/water (7/3 v/v) mixture. Polymerization was carried out under nitrogen atmosphere
and in dark at 37 °C for 4 days. Then, additional 10% of AMD3100 was added and the
reaction mixture was stirred for further one day to consume all residual acrylamide groups.
PCXG1 was isolated by double precipitation in diethyl ether, collected by centrifugation,
and dried in vacuum for further modification. The final PCXG1 was obtained by adjustment
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of pH to 4 using 1 M HCl and dialysis against deionized water (membrane molecular
weight cut-off 3.5 kDa) with yield higher than 80%.
3.3.2 Synthesis of PCXG2
Polymeric CXCR4 antagonists PCXG2 based on the monocyclam monomers were
synthesized by Michael-type addition copolymerization of HMBA with a mixture of 7a or
7b and different amount of ABOL. In a typical polymerization reaction, 7a (76.3 mg, 0.1
mmol), ABOL (8.9 mg, 0.1 mmol) and HMBA (44.8 mg, 0.2 mmol) were dissolved in 0.65
mL of MeOH/water (7/3 v/v). Polymerization was carried out for 14 days at 50 °C in dark
under nitrogen. Then, in order to remove any residual acrylamide groups, excess of
cyclam (4 mg, 0.02 mmol) was added and the reaction mixture was stirred for additional
2 days. The resultant Boc-protected polymers were isolated by evaporating solvent using
oil vacuum pump. The protecting Boc groups were then removed by dissolving the
obtained polymers in TFA at concentration of 20 mg/mL and stirring for 15 h at room
temperature. The product was dried under oil vacuum pump and dissolved in acidified
water (pH 4). The product was then dialyzed against acidified water (pH 4) with molecular
weight cut-off of 3.5 kDa. Final product was obtained by lyophilization as hydrochloride
salt. The typical yield after dialysis was 58-63%. Control polymer PABOL without cyclam
moiety was synthesized as hydrochloride salt using the same conditions described as
above by copolymerization of equal molar ratio of ABOL (89.1 mg, 1 mmol) and HMBA
(224.2 mg, 1 mmol) with yield of 30.4% after dialysis.
3.3.3 PEGylation of PCXG1
The PEGylation of PCXG1 was carried out by Michael addition between the
secondary amines in the cyclam groups of PCXG1 and acrylamide group of mPEGacrylamide. PCXG1 (72.3, 66.4 or 69.7 mg) and mPEG-acrylamide (8.0 mg, 35.8 mg or
69.7 mg) were dissolved in MeOH/water mixture (7/3 v/v) at a total concentration of 120

48
mg/mL and the solution was stirred for 2 days at 37 °C, followed by 1 day at 50 °C. The
reaction was cooled to room temperature and the pH was adjusted to 4 using 1 M HCl.
The resulting copolymers (PEG-PCXG1) were isolated by precipitation in diethyl ether,
centrifugation, and drying in vacuum, and finally dialyzed against deionized water (pH 4,
membrane molecular weight cut-off 3.5 kDa). Typical yield was 70-80%.
3.3.4 Cholesterol modification of PCXG1
In order to synthesize Chol-PCXG1 with various degrees of cholesterol substitution,
PCXG1 was first dissolved in a mixture of anhydrous methylene chloride and DIPEA.
Different calculated amounts of cholesteryl chloroformate (15.4 mg, 32 mg or 55.62 mg)
in anhydrous methylene chloride were added drop wise to the ice-cold PCXG1 (83.4 mg,
86.3 mg or 90 mg) solution over 1 h. The reaction was continued under stirring for another
24 h. The product was isolated by evaporating the solvent and washing with diethyl ether
three times to remove unreacted cholesteryl chloroformate. The product was further
dissolved in ethanol/water (v/v 1/1) mixture, followed by adjusting the pH to 4.0 using 1 M
HCl. The polymers were then obtained by lyophilization after extensive dialysis against
ethanol/water mixture (v/v 1/1) for 2 days and distilled water for another day (membrane
molecular weight cut-off 3.5 kDa). Typical yield of Chol-PCXG1 ranged from 61% to 88%.
3.4 Polymer characterization
The molar mass of PCX was analyzed by gel permeation chromatography (GPC)
operated in 0.3 M sodium acetate buffer (pH 5) using Agilent 1260 Infinity LC system
equipped with a miniDAWN TREOS multi-angle light scattering (MALS) detector and a
Optilab T-rEX refractive index detector from Wyatt Technology (Santa Barbara, CA). GPC
data were analyzed using Astra 6.1 software from Wyatt Technology. The content of PEG
or cholesterol in modified PCXG1 was determined using 1H-NMR on Varian INOVA (500
MHz). The molecular weights of PEG-PCXG1 or Chol-PCXG1 were calculated on the basis
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of the determined molar mass of PCXG1 by GPC and the known PEG or cholesterol
substitution degree determined by 1H-NMR.
3.5 Critical Micelle Concentration (CMC)
Fluorescence spectroscopy was used to determine CMC of Chol-PCXG1 polymers
using pyrene as a hydrophobic fluorescent probe. Different concentrations of Chol-PCXG1
in water were allowed to equilibrate with 600 nM pyrene overnight at room temperature
after 1 h sonication. Each fluorescence intensity index ratio at 335ex/384em nm (I3) vs.
335ex/373em nm (I1) (I3/I1) was measured, and plotted against the logarithmic concentration
of the polymer. The concentration at the inflection point was determined as CMC [179].
3.6 DNA condensation by ethidium bromide exclusion assay
The ability of the synthesized polymers to condense DNA was determined by
ethidium bromide (EtBr) exclusion assay by measuring the changes in EtBr/DNA
fluorescence. 1 mL of DNA solution (20 μg/mL) was prepared in 10 mM HEPES buffer (pH
7.4) and mixed with EtBr (1 μg/mL). Raw fluorescence intensity was measured and set to
100% using an excitation wavelength of 540 nm and an emission wavelength of 590 nm.
The fluorescence of ethidium bromide only in HEPES buffer was defined as background
and set as 0%. Fluorescence readings were recorded following a stepwise addition of
polymer solution and condensation curves (relative fluorescent intensity % vs. w/w ratio)
were constructed.
3.7 Preparation and characterization of DNA polyplexes
Plasmid DNA solution at a concentration of 20 µg/mL was prepared in 10 mM
HEPES buffer (pH 7.4). Polyplexes were formed by adding predetermined volume of a
polymer to achieve desired polymer/DNA w/w ratio. The mixture was vigorously vortexed
for 10 s and then stablized at room temperature for 30 min before further analysis. To
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prepare mixed polyplexes, solutions of PCXG1 and PEG-PCXG1 were initially mixed at
desired ratios and then added to the DNA solution. Hydrodynamic diameter and zeta
potential of the polyplexes were determined by dynamic light scattering (DLS) using a
ZEN3600 Zetasizer Nano-ZS (Malvern Instruments Ltd., Worcestershire, UK). The results
were expressed as mean ± standard deviation (SD) of three measurements.
3.8 Preparation and characterization of siRNA polyplexes
siRNA polyplexes were formed by mixing equal solution volumes of siRNA (20
μg/mL) and polymer by pipetting, followed by incubation at room temperature for 20 min
before further use. Complexation of siRNA by polymers was examined by agarose gel
electrophoresis. PCX/siRNA polyplexes were prepared at various polymer/siRNA w/w
ratios, loaded onto a 2% agarose gel containing 0.5 μg/mL ethidium bromide. Gels were
run at 75 V in 0.5x Tris/Borate/EDTA (TBE) buffer for 30 min and then imaged under UV.
Hydrodynamic diameter and zeta potential of the polyplexes in 10 mM HEPES buffer (pH
7.4) were determined by DLS. The results were expressed as mean ± standard deviation
(SD) of three measurements.
3.9 Colloidal stability
Polypelxes were prepared accordingly as described above. To evaluate colloidal
stability of the polyplexes, 10x phosphate-buffered saline (PBS) was added to the
polyplexes to obtain a final 1x PBS solution (pH 7.4) with the following composition: 137
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4. The hydrodynamic diameter
was then measured using DLS after 15 min, 1 h, and 12 h incubation at 25 °C. Results
were expressed as mean ± standard deviation (SD) of three measurements.
3.10 Enzymatic stability
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To study the resistance of PCX/siRNA polyplexes to RNase I, polyplexes
containing a total amount of 0.2 μg siRNA were incubated with 2.5 units of RNase I at
37 °C for 30 min, followed by incubation at 90°C for 30 min to inactivate the enzyme.
Heparin (200 µg/mL) was added to the samples and the mixture was incubated for
additional 30 min to release the siRNA. Gel electrophoresis was then used to determine
siRNA integrity.
3.11 Cell culture
Human hepatocellular carcinoma, HepG2 cells were purchased from ATCC
(Manassas, VA) and cultured in MEM supplemented with 10% FBS. Human epithelial
osteosarcoma U2OS cells stably expressing functional EGFP-CXCR4 fusion protein were
purchased from Fisher Scientific and cultured in DMEM supplemented with 2 mM Lglutamine, 1% Pen-Strep, 0.5 mg/ml G418 and 10% FBS. Mouse melanoma B16F10 cells
were a kind gift from Dr. Rakesh Singh (UNMC) and maintained in DMEM supplemented
with 10% FBS. Mouse mammary carcinoma 4T1 cell line was from ATCC (Manassas, VA)
and cultured in RPMI supplemented with 10% FBS. Human PC cell line CD18/HPAF was
originally derived from the parental heterogeneous HPAF pancreatic tumor cell line by a
limiting dilution technique [180]. Luciferase-expressing CD18/HPAF (CD18/HPAF.luc) cell
line was obtained by transfecting CD18/HPAF cells with pbabe.puro-Fluci vector as
described previously [181]. The cell line was cultured in DMEM with 1% Pen-Strep and
10% FBS. All cells were maintained in an incubator at 37 °C and 5% CO2.
3.12 Cytotoxicity
Cytotoxicity of the synthesized polycations was evaluated by CellTiter
96®AQueous Non-Radioactive Cell Proliferation Assay or CellTiter-Blue Cell Viability
Assay (Promega, Madison, WI). Single cell suspension was seeded in 96-well plates and
incubated overnight. Culture medium was then replaced by 150 µL of serial dilutions of a

52
polymer in serum-supplemented medium. Cells were incubated at 37 °C for 24 h, and the
medium was replaced with a mixture of 100 μL medium and 20 μL of assay reagent. After
1 h incubation, the absorbance [A] or fluorescence intensity [I] was measured using
SpectraMax®M5e Multi-Mode Microplate Reader (Molecular Devices, CA) at a
wavelength of 490 nm or at λex/λem 560/590 nm.. The relative cell viability (%) was
calculated as [A]sample/[A]untreated × 100% or [I]sample/[I]untreated × 100%. The IC50 were
calculated in GraphPad Prism using a built-in dose-response analysis as the polymer
concentration that causes 50% decrease in cell viability relative to untreated cells.
3.13 CXCR4 antagonism
CXCR4 antagonism of the polycations and polyplexes was measured by CXCR4
redistribution assay using a high-contant fluorescence microscopy analysis. U2OS cells
stably expressing functional EGFP-CXCR4 fusion protein were seeded at a density of
8,000 cells/well in 96-well black plates with optical bottom 24 h before the experiment. On
the day of the assay, cells were washed twice with 100 μL assay buffer (DMEM
supplemented with 2 mM L-glutamine, 1% FBS, 1% Pen-Strep, and 10 mM HEPES) and
incubated with different concentrations of the polycations, polyplexes, or AMD3100 in the
assay buffer containing 0.25% DMSO at 37 °C for 30 min. Then, 10 nM SDF-1 was added
to each well and the cells were incubated at 37 °C for 1 h. Cells were fixed with 4%
paraformaldehyde at room temperature for 20 min, washed 4 times with PBS and stained
in 1 µM Hoechst 33258 solution for 30 min before imaging (EVOS fl microscope).
Cellomics ArrayScan VT1 High Content Analysis Reader (Thermo Scientific) was then used
to quantify the internalization of the CXCR4 receptors, and the images were analyzed by
SpotDetectorV3 BioApplication software. CXCR4 antagonism was determined based on %
CXCR4 internalization inhibition calculated relative to the positive (AMD3100, 100%) and
negative (SDF-1 only, 0%) controls, and the results were expressed as mean % inhibition
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± SD (n = 3 or 4). EC50 values (polymer concentrations that cause 50% CXCR4 inhibition)
were determined in Prism Graghpad software using a three-parameter inhibitor doseresponse analysis method.
3.14 Cell invasion
Transwell cell culture inserts were coated with 40 μL ice-cold Matrigel which was
diluted 1:3 (v/v) with serum-free medium. The 24-well plates with coated inserts were then
placed in 37 °C incubator for 2 h. U2OS cells were harvested and resuspended with PCX
polymers or polyplexes before adding to the inserts at a final concentration of 50,000 cells
in 300 μL serum-free medium per insert. 20 nM SDF-1 in serum-free medium was added
as the chemoattractant to the lower chamber of the wells. After 19 h, the non-invaded cells
on the top surface of the insert membrane were removed by cotton swabs and the invaded
cells on the bottom surface were fixed in 100% methanol and stained with 0.2% Crystal
Violet solution for 10 min at room temperature. The number of invaded cells was counted
under microscope set to 20× magnification. The results were expressed as average
number of cells/imaging area ± SD (n = 5-10 random imaging areas).
3.15 Cell uptake DNA polyplexes by flow cytometry
Fluorescent gWiz-Luc DNA was prepared by using Label IT-TrackerTM CXRhodamine Kit (Mirus, Madison, WI) according to manufacturer’s protocol. B16F10 and
U2OS cells were seeded in 24-well plate at density of 200,000 and 100,000 cells/well 24
h prior to transfection. On the next day, cells were incubated with PCXG2/DNA polyplexes
containing 0.8 μg labeled DNA per well at w/w 5 in 300 μl of medium with or without 10%
FBS. After incubation for 4 h, polyplexes were removed, and cells were washed with PBS,
detached and resuspended for flow cytometry. The results were processed using flow
cytometry data analysis software Flowjo (Tree Star Inc., Ashland, OR) and expressed as
mean relative fluorescence intensity (n=3). To detect the possibility of CXCR4 receptors

54
involving into the process of cellular uptake of PCXG2 polyplexes, U2OS cells were
pretreated with 0.3 µM AMD3100 in serum-free medium for 1 h before adding PCXG2/DNA
polyplexes (n=2).
3.16 DNA transfection activity
The transfection experiments were carried out in 48-well cell culture plates with
cells at logarithmic growth phase. B16F10 (40,000 cells/well) and U2OS (20,000 cells/well)
cells were seeded 24 h prior to transfection. On the day of transfection, culture medium in
each well was removed and replaced with 150 μL of antibiotic-free medium with or without
10% FBS before adding 20 μL of polyplexes (DNA dose 0.4 μg/well). After 4 h incubation,
polyplexes were completely removed and the cells were cultured in complete culture
medium for 24 h prior to measuring luciferase expression. The medium was discarded
and the cells were lysed in 100 μL of 0.5x cell culture lysis reagent buffer (Promega,
Madison, WI) for 30 min. To measure the luciferase content, 100 μL of 0.5 mM luciferin
solution was automatically injected into each well of 20 μL of cell lysate and the
luminescence was integrated over 10 s using GloMax 96 Microplate Luminometer
(Promega). Total cellular protein in the cell lysate was determined by the bicinchoninic
acid protein assay using calibration curve constructed with standard bovine serum
albumin solutions (Pierce, Rockford, IL). Transfection activity was expressed as relative
light units (RLU)/mg cellular protein ± SD (n=3).
3.17 Mobilization of peripheral blood leukocytes (PBL)
6 weeks old female BALB/c mice were purchased from Charles River Laboratories
and housed under controlled temperature, humidity and lighting conditions in facilities
accredited by the American Association for Accreditation of Laboratory Animal Care,
operating in accordance with standards set by the Guide for the Care and Use of
Laboratory Animals (The National Academies Press, 1996). All procedures were approved
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by the University of Nebraska Medical Center Institutional Animal Care and Use
Committee. For cell mobilization studies, mice were randomized into three groups (n=5).
Mice in the experiment group were administered intravenously with PCX G2-4 at 1.25 mg
kg−1 in 100 μL PBS. Positive control group was administered subcutaneously with
AMD3100 at the dose of 5 mg/kg in 100 μL PBS. Negative control mice received matched
subcutaneous injection of 100 μL PBS. Whole blood samples were collected into
heparinized tubes after 1 h of injection and PBL were counted with an automatic
hematology analyzer HEMAVET 950FS (Drew Scientific Inc., Dallas, TX).
3.18 siRNA transfection of siPLK1 polyplexes
siRNA transfection efficiency of the polyplexes was evaluated in U2OS cells using
human siPLK1 as a therapeutic siRNA. Cells were seeded at a density of 2,500 cells/well
in 96-well plates 24 h prior to the experiment. On the next day, culture medium was
carefully removed and replaced with 50 µL medium with or without 10% FBS and 12.5 µL
polyplexes (siRNA dose: 5 pmol per well). After 4 h of incubation, polyplexes were
removed and cells were maintained in 200 µL fresh culture medium for another 44 h.
CellTiter-Blue Cell Viability Assay (Promega) was used to measure % cell viability. Activity
was expressed as % cell death induced by PLK1 gene silencing compared with scrambled
siRNA (n=3 or 4).
3.19 Cellular uptake and intracellular distribution of polyplexes by confocal
microscropy
Chol-PCXG1 polymers were fluorescently labelled with AlexaFluor 647 following
manufacturer’s instructions and purified by dialysis against distilled water to remove
unreacted dye. Fluorescently labelled siRNA (Block-iTTM Alexa Fluor® Red) was
purchased from Invitrogen (Carlsbad, CA). 100,000 of U2OS cells were seeded in a 23
mm glass-bottom dish (Nioptechs Inc. Cat# 0420041500C) one day before the experiment.
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Cells were then incubated with Chol-PCXG1/siRNA polyplexes (containing 25 nM siRNA)
for 1 h, washed twice with PBS, fixed with 4% paraformaldehyde, washed with PBS for
additional 4 times and stained in 1 µM Hoechst 33258 solution. All the images were taken
using Zeiss 710 confocal laser scanning microscope equipped with a 63x oil objective
and 4 lasers (Blue Diode 405 nm, Argon 458/488/514 nm, DPSS 561 nm and He-Ne 633
nm).
3.20 DNA biodistribution in mice
6 weeks old female BALB/c mice were purchased from Charles River Laboratories
and housed under controlled temperature, humidity and lighting conditions in facilities
accredited by the American Association for Accreditation of Laboratory Animal Care,
operating in accordance with standards set by the Guide for the Care and Use of
Laboratory Animals (The National Academies Press, 1996). All procedures were approved
by the University of Nebraska Medical Center Institutional Animal Care and Use
Committee. The mice were inoculated with 5 ×105 4T1 cells in left hind flank zone. After
two weeks, mice were sacrificed 1 h after tail-vein injection of polyplexes (15 µg DNA/mice,
w/w 3 in 200 µL HEPES-buffered glucose (20 mM HEPES, 5% Glucose, pH 7.4; HBG))
and organs were harvested. The samples were suspended in PCR lysis buffer (0.5 mg/ml
Proteinase K, 2 mg/ml poly-L-aspartic acid) at a concentration of 50 mg of tissue per
milliliter and homogenized using TissueLyser II (Qiagen, Hilden, Germany). After
homogenization, 2 μl of homogenized solution was mixed with 25 μl PCR lysis buffer and
incubated in 37°C for 12 h. The luciferase DNA contents in different organs were analyzed
by RT-PCR. The PCR cycle was 2 min at 50°C, 10 min at 95°C, 40 cycles for 15 s at 95°C,
and 1 min at 60°C. A series of luciferase plasmid DNA dilution solutions (20 μg/ml, 2 μg/ml,
200 ng/ml, 20 ng/ml, 2 ng/ml, and 0.2 ng/ml) were used to construct the calibration curve.
3.21 NCOA3 knockdown
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The efficiency of the PCX to deliver siNCOA3 and to downregulate NCOA3 gene
was evaluated in CD18/HPAF.luc cells. Cells were seeded at a density of 100,000
cells/well in 12-well plates one day before experiment. On the next day, culture medium
was carefully removed and replaced with 800 µL medium and 200 µL polyplexes. The
PCX polyplexes were prepared at w/w ratio of 2 using either siNCOA3 or a negative control
siRNA (siScr). PEI/siRNA polyplexes prepared at w/w of 1.5 were used as controls. After
4 h of incubation, polyplexes were removed and cells were maintained in 2 mL fresh
culture medium for another 72 h. Cells were washed with PBS twice and prepared for
western blot. NCOA3 silencing at protein level was compared with that of scrambled
siRNA.
3.22 CXCR4 expression by flow cytometry
CD18/HPAF.luc cells were seeded in 6-well plates in DMEM with 10% FBS
overnight. On the day of experiment, fresh DMEM with or without 10 µM gemcitabine was
added. After 24 h of incubation, cells were washed with PBS twice, detached using
enzyme-free PBS-based cell dissociation buffer (Gibco by Life Technologies, Grand Island,
NY), and resuspended in PBS. After centrifugation at 800 rpm for 5 min, the supernatant
was removed and the cells were resuspended in FACS buffer (1% BSA, 0.1% NaN3 in
PBS) to obtain final cell concentration of 5 x 106/mL. The cell suspension (100 μL) was
mixed with 20 µL of APC mouse anti-human CXCR4 antibody or the corresponding isotype
control. After incubation at room temperature for 30 min, the cells were washed three times
with FACS buffer to remove free antibody and resuspended in 500 µL of FACS buffer for
the measurement by flow cytometry. The data were processed and analyzed using FlowJo
software (Tree Star Inc., Ashland, OR) and expressed as percentage of CXCR4-positive
cells.
3.23 Western blotting
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Whole-cell lysate was prepared in Pierce® RIPA lysis buffer (Thermo Scientific,
Rockford, IL) supplemented with 1x protease and phosphatase inhibitor cocktail. Total
protein content was quantified using BCA assay, and samples were normalized by dilution
with RIPA buffer to obtain equal protein concentration. Equal volume of 2x Laemmli
sample buffer (BIO-RAD, Hercules, CA) was added, followed by boiling in water for 5 min.
Equal amounts of total protein (20-40 µg) were loaded to SDS-polyacrylamide
electrophoresis gel, run first at 80 V for 30 min and then at 120 V for 2 h. The protein
contents were transferred to polyvinylidene difluoride (PVDF) membrane, and the
membrane was blocked with 5% skim milk at room temperature for 1 h, and incubated
overnight with the primary antibodies at 4 °C. Next day, the blot was washed three times
with TBST buffer (20 mM Tris, 500 mM NaCl, 0.1% Tween 20, pH 7.5) and incubated with
horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The
protein signals were visualized by Pierce® ECL Western blotting substrate (Thermo
Scientific, Rockford, IL). The band intensity was evaluated using ImageJ software.
3.24 RNA isolation and Real Time PCR analysis
The total RNA from the cells was isolated using TRIzol® reagent and the RNA from
tissues was isolated using mirVana miRNA isolation kit according to the protocols from
Life Technologies. Cells were washed with PBS and lysed in the TRIzol® Reagent. The
homogenized samples were incubated at room temperature for 5 min to complete
dissociation of the nucleoprotein complex. Chloroform was added and the samples were
centrifuged. RNA was precipitated by addition of 0.5 mL of isopropanol to the aqueous
phase. RNA pellet was resuspended in RNase-free water and stored at -80 °C. For
isolation of RNA from tissues, tumor tissues were homogenized in liquid nitrogen and
lysed in the lysis/binding buffer. miRNA Homogenate Additive was added to the tissue
lysates and acid-phenol: chloroform was added and vortexed for 1 min. The aqueous
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phase was collected, mixed with equal volume of ethanol, and the mixture was passed
through a filter cartridge. The RNA isolated from cells and tissues was reverse-transcribed
to cDNA using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems,
Foster City, CA) using a thermal cycler in Rotor-Gene Q RT-PCR (Qiagen, Hilden,
Germany). The thermal cycling conditions used were 25 °C for 10 min, 37 °C for 120 min,
and 85 °C for 5 min. The expression pattern of the gene of interest was analyzed and the
fold change in gene expression was calculated using the 2-ΔΔCT method. Results were
expressed as mean expression compared with untreated cells ± SD (n=3)
3.25 Cell migration
CD18/HAPF.luc cells were pretreated with 10 µM gemcitabine for 24 h, trypsinized,
and resuspended with 1 μg/mL PCX in serum-free medium for 15 min. The cell suspension
with PCX was then added to transwell inserts at a final cell density of 200,000 cells in 300
μL medium per insert. DMEM with 10% of FBS was added as the chemoattractant in the
companion plate. After 24 h, the non-invaded cells on the upper surface of the insert
membrane were removed by cotton swabs. The invaded cells on the bottom surface were
fixed in 100% methanol and stained with 0.2% Crystal Violet solution for 10 min at room
temperature. The migrated cells were counted at 10× magnification. The results were
expressed as percentage of migrated cells relative to untreated cells/imaging area ± SD
(n = 4 random imaging areas of triplicate samples).
3.26 Orthotopic implantation of tumor cells and analysis of anticancer activity
Female athymic nude mice (6 weeks old) were purchased from Harlan
Laboratories and housed under controlled humidity, temperature and lighting conditions
in facilities accredited by the American Association for Accreditation of Laboratory Animal
Care, operating in accordance with standards set by the Guide for the Care and Use of
Laboratory Animals (The National Academies Press, 1996). All procedures were approved
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by the University of Nebraska Medical Center Institutional Animal Care and Use
Committee. Orthotopic implantation of pancreatic cancer cells was performed as
described previously [182]. Briefly, CD18/HPAF.luc cells were trypsinized, washed and
resuspended in sterile PBS. Prior to surgery, mice were anesthetized with 350 µL of
intraperitoneal injection of a 4:1 mixture of ketamine (100 mg/mL) and xylazine (20 mg/mL)
diluted 10 times in sterile water. The surgical site was sterilized with 70% ethanol wipe
and a 1-cm incision was made in the peritoneum at the mid-abdomen region below the
sternum by scissors. 2.5 x 105 of CD18/HPAF.luc cells were injected into the head of
pancreas without causing injury and torsion. The abdomen was closed using a 2-layer
suture with 5-0 chromic catgut and soft staple. The skin staples were removed 10 days
after surgery. The animals inoculated with tumor cells were housed in the animal facilities.
After 10 days of growth, the luciferase-expressing tumors were imaged by IVIS and the
mice were randomly assigned into three groups: saline (n=7), negative siRNA control
polyplexes (Chol17-PCXG1/siScr, n=7) and combination polyplexes (Chol17-PCX
G1

/siNCOA3, n=6) group. The PCX/siRNA polyplexes were prepared at w/w 2 and

administered three times per week through tail vein (40 µg siRNA/mouse). The mice were
observed and weighed every other day. Tumor growth and total tumor burden were
monitored by palpation and whole-body IVIS bioluminescence imaging. Magnetic
resonance imaging (MRI), a non–invasive approach, was used to assess tumor perfusion
in the above mouse model of PC before sacrifice. Mice were sacrificed after 39 days of
tumor growth. Changes in tumor growth and sites of metastasis were evaluated in each
experimental group. Pancreatic tumors from different experimental groups were collected
for immunohistochemistry (IHC) analysis.
3.27 Immunohistochemistry analysis (IHC)
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To analyze the histopathology, the tumor tissues were fixed in 10% formalin for 72
h and stored in 75% ethanol. The tissues were embedded in paraffin and 5 µm sections
were cut and stained with haematoxylin & eosin (H&E) as well as requisite antibodies as
described previously [85]. Typically, tissue slides were baked at 58 °C overnight. Next day,
tissues were deparaffinized, hydrated and antigens were recovered by boiling in citrate
buffer. Tissue sections were blocked with 2.5% horse serum and incubated with indicated
primary antibody (8G7) overnight at 4 °C. Tissues were washed and incubated with HRPconjugated secondary antibody. Subsequently, tissues slides were washed and
developed using 3.3’-diaminobenzidine kit (Vector Laboratories, Burlingame, CA) for
colorimetric detection and counterstained with hematoxylin. Tissues were dehydrated,
dried and mounted with Permount and evaluated by a pathologist.
3.28 Tumor perfusion analysis
Mice were evaluated at the end of the treatment before euthanasia by magnetic
resonance imaging (MRI) to assess tumor vascular function using perfusion imaging, after
acquiring a reference T2-weighted image set to visualize the tumor location. For these
procedures, all equipment that direct contacted with animals were treated with disinfectant
and animals were handled as described below. Mice were anesthetized by inhalation
anesthesia (1.5% isoflurane). The anesthetized mice were positioned in a Plexiglas holder
and placed in an RF coil for imaging. The anesthetized animal was secured in place to a
support platform upon which the animal's body rested horizontally for MRI acquisition. The
breathing rate and temperature of the anesthetized animals were monitored continuously
with this holder design using an SA Instruments (Stony Brook, NY) model 1025 small
animal monitoring and gating system. During image acquisition, animals were maintained
on 0.5-1.5% isoflurane, in oxygen with an output of 1 L/min with gases continuously
vacuumed from the opposite side of the chamber using the facility vacuum line regulated
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at a flow rate of 1 L/min. Animals were monitored during the procedure and respiration
rates were maintained at 40-60 bpm by adjusting isoflurane during examinations. The
holder with the mouse was inserted into a birdcage quadrature transmit/receive coil and
mounted at the magnet center. Studies began with a localizer to center the head in the
magnet and coil. After localization and system shimming, T2-weighted high-resolution
anatomical image was obtained for each animal, followed by the acquisition of perfusion
maps. Perfusion maps were acquired and analyzed using Flow Sensitive Alternating
Inversion Recovery (FAIR) [183]. Perfusion maps were generated with a Rapid Acquisition
with Relaxation Enhancement (RARE) readout. Images were acquired with a RARE factor
of 16, 16 inversion recovery times ranging from 30-2300 ms, 1 mm slice thickness,
selective inversion slab thickness of 4 mm, 30 mm x 30 mm field of view, 128 x 128 matrix.
Total imaging time for MRI was 0.5-1 hour per animal.
3.29 Statistical analysis
Statistical analyses were performed using GraphPad InStat 3 software. Student’s
t-test was used to determine the statistical significance between groups and statistical
differences among multiple groups were analyzed using non-parametric ANOVA with
Tukey-Kramer multiple comparisons test. Fisher’s exact test was used to compare the
incidence of metastasis between groups. P<0.05 was considered as significant difference.
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Chapter 4 - Results and Discussion
4.1 Development of Functional Poly(amido amine) CXCR4 Antagonists with
Increased CXCR4 Inhibitory Activity to Deliver Therapeutic Nucleic Acids
Please note that the data of this part was from the paper published in the Advanced
Healthcare Materials [153]. The authors include Dr. Stuart Hazeldine, Dr. Jing Li, Dr. David
Oupický and me. Dr. Hazeldine proposed and developed synthetic strategy for the novel
cyclam monomers and copolymers. As the first author, I performed all the other
experiments to characterize the copolymers in vitro and in vivo. I collected all the data,
participated in their analysis, and wrote early draft of the manuscript. Drs. Li and Oupický
analyzed data, wrote the manuscript, and handled its submission and publication. All the
authors agreed with including their work in this dissertation.

Scientists have undertaken extensive researches to control cancer over half a
century. For early stage cancer patients, surgical intervention is a potential treatment.
However, most of the cancer patients are diagnosed with advanced stage due to scarce
symptoms until the disease has progressed and the treatment is limited to chemotherapy
or radiation [184]. The vast amount of chemodrugs used in clinic are low molecular-weight
compounds, which lack of selectivity and cause high toxicity in vivo. Small molecularweight chemodrugs distribute fast and uniformly into healthy tissues, exhibit a short halflife and a rapid clearance in the systemic circulation. The frequent severe systemic side
effects include neurotoxicity, cardiotoxicity, nephrotoxicity, bone marrow toxicity, mucositis
and gastrointestinal toxicity [185].
Polymer therapeutics are becoming popular in recent years to treat cancer, which
are a class of delivery systems, including polymeric drugs, polymer conjugates of proteins,
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drugs and aptamers, block copolymers micelles, as well as multicomponent non-viral
vectors with covalent linkages [186]. The pathophysiological properties of solid tumor have
been utilized to design polymer therapeutics to improve the drug efficiency in vivo. Tumor
tissues exhibited enhanced extravasation and retention of macromolecules from tumor
blood vessels, which is not observed in normal vasculature and termed as “enhanced
permeability and retention (EPR) effect” [187, 188]. Macromolecular drugs can more easily
extravasate through the leaky tumor endothelium and get trapped in the poorly developed
lymphatic system of the tumor, leading to prolonged circulation time. In comparison with
conventional chemodrugs, polymer therapeutics enhance the selectivity of cancer
targeting, improve the anti-cancer efficiency and diminish the side effects [189, 190].
In contrast to drug delivery systems containing non-covalently therapeutic agents,
the complex and multicomponent constructs of polymer therapeutics work as actual drugs
and macromolecular prodrugs. Polymeric drug Copaxone has been successfully
developed as a treatment for multiple sclerosis and progressed to market, which is a
random copolymer of three amino acids (Glu, Ala and Tyr) [191]. The Oral polymeric
sequestrants Renagel binds phosphate and is used to treat chronic kidney disease [192].
SMANCS is a polymer-protein conjugate consisting of the anticancer protein
neocarcinostatin and a synthetic copolymer of styrene and a maleic acid anhydride drug,
which has been approved for the treatment of hepatocellular cancer in Japan [189].
In tumors, a complex network of chemokines and chemokine receptors controls
cell trafficking into and out of the tumor microenvironment [193]. Cells from different cancer
types have different expression profiles of chemokine receptors. However, CXCR4 is the
most widely expressed chemokine receptor in human cancers, which makes it and its
ligand SDF-1 the most-promising targets within the chemokine network. CXCR4/SDF-1
axis regulates survival, proliferation, migration and invasion of cancer cells by activating
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various intracellular signaling transduction pathways that affect cell survival and migration.
Those pathways include phosphatidylinositol-3-kinase (PI3K) and the mitogen-activated
protein kinase pathways. CXCR4 also activates Erk1/2, which phosphorylates
transcription factors including Elk-1 to promote cancer cell proliferation and survival [117].
CXCR4/SDF-1 is also involved in activating focal adhesion complexes and promoting
adhesion through integrins. All this, combined with increasing secretion of matrix
metalloproteinases that mediate degradation of extracellular matrix, contributes to
invasion of cancer cells [118-120]. Clinical evidence shows that certain anticancer
therapies increase CXCR4 expression and inadvertently enhance the metastatic potential
of tumors [194]. Animal studies of several types of cancer show that CXCR4 antagonists
inhibit macrophage infiltration, induce tumor growth arrest and apoptosis, and prevent
metastatic spread.
Our lab has developed the first generation of polymeric antagonists of the CXCR4
chemokine receptor (PCXG1) based on a commercial CXCR4 antagonist AMD3100
(Plerixafor) (Figure 1a), which was approved by FDA in 2008 for mobilization of
hematopoietic stem cells in bone marrow transplantation procedures [195]. PCXG1 worked
as a dual-function polymeric drug suitable for simultaneous delivery of nucleic acids and
inhibition of cancer metastasis [149, 150, 196]. Based on the proof-of-principle studies, it
is difficult to control the polymerization due to the presence of six reactive secondary
amines in AMD3100, which contributed to the generation of poorly defined highly
branched polymers. The highly branched PCXG1 also showed compromised the CXCR4
antagonistic activity when compared with the original AMD3100. Therefore, we designed
the second generation of polymeric CXCR4 antagonists (PCXG2) based on novel
monocyclam monomers with improved presentation of CXCR4-binding moieties and
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better-controlled polymerization (Figure 1b). The novel linear PCXG2 were able to function
dually as gene delivery vectors and inhibitors of cancer cell invasion (Figure 1c).
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(a)

(b)

(c)

Figure 1. (a) Chemical structure of AMD3100 (Plerixafor). (b) Chemical structure of PCXG2.
(c) Mechanism of action of polymeric CXCR4 antagonists (PCXG2) and PCX G2 polyplexes.
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4.1.1 Synthesis of monocyclam monomers
By sequential replacement or deletion of the amino groups within the azamacrocyclic ring
systems of AMD3100, Bridger et al reported that all eight amino groups are not required
for CXCR4 inhibition. This approach results in the design of several single ring
azamacrocyclic analogues with high potency as AMD3100 [197]. Two novel monocyclam
monomers were developed and synthesized according to the AMD3100 pharmacophore.
The synthesis scheme was summarized in Figure 2. Three of the four secondary amines
in cyclam (1) were protected by Boc to gain compound 2 with yield of 84%. Chlorocompund 3 was achieved by reaction of excess dichloroxylene or dibromoxylene with
unprotected amine in compound 2. Amino-alcohols were added to obtain compound 4 with
secondary amine and terminal hydroxyl group. The secondary amine of 4 was also
protected by Boc and the terminal hydroxyl was converted into primary amine by
Mitsunobu

reaction

using

phthalimide,

triphenylphosphine

(PPh3)

and

diethylazodicarboxylate (DEAD) to obtain protected amine 6. Hydrazine was added to get
the final monocyclam monomers (7a and 7b) with ethylene and propylene spacer
respectively.
4.1.2 Synthesis and characterization of polymeric CXCR4 antagonists (PCXG2)
We hypothesized that when compared with PCXG1, well-defined liner PCXG2 would
improve the CXCR4 antagonism due to better presentation of CXCR4 binding moiety in
the polymer side chain and easier accessibility to CXCR4 receptor. In order to conduct
side-by-side comparison and study the influence of cyclam content and spacer length on
the physicochemical characterizations and pharmacological activity of PCXG2, a series of
PCXG2 were synthesized by Michael-type polyaddition (Figure 1b). The reaction of
equimolar amount of HMBA and Boc-protected monomer 7a or 7b resulted in
homopolymers PCXG2-2 and PCXG2-4. Copolymers PCXG2-1 and PCXG2-3 were obtained
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by polymerization of equimolar amounts of HMBA with a mixture of 4-amino-1-butanol
(ABOL) and 7a or 7b. Negative control polymer (PABOL) without CXCR4 antagonism was
obtained by polymerization of HMBA and ABOL. To achieve desirable molecular weights,
the polymerization conditions of PCXG2 were more rigorous than that of PCXG1. The bulky
Boc-protected monocyclam monomers were polymerized at enhanced temperature (50 °C)
and extended reaction time (2 weeks) to get PCXG2. Excess amount of cyclam was added
and reacted for another two days to consume the unreacted acrylamide residues to
terminate the polymerization. As show in Figure 3, the disappearance of HMBA
acrylamide bonds (5.76 and 6.21 ppm) in 1H-NMR confirmed the completion of the
polymerization. Additional larger amount of cyclam was added to quench all acrylamide
bond residues of PCXG2-2. The content of monocyclam in the PCXG2-1 and PCXG2-3 was
calculated from integral intensities of the phenylene protons (7.3-7.7 ppm) in 7a and 7b
and of the methylene protons (CH2CH2OH) in ABOL (3.65 ppm). Due to the steric
hindrance of the bulky Boc-protected cyclam, the incorporation of the monocyclam
monomers into the copolymers was lower than in feed ratio, suggesting weaker reactivity
of the primary amines in 7a and 7b in comparison with the amine in ABOL. Based on the
analysis of GPC in Table 2, the molecular weight of PCXG2 ranged from 5.2 to 9.0 kDa
with low polydispersity, indicating the linear structure of the polymers.
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Figure 2. Synthesis of monocyclam monomers.
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a)

b)

c)

d)

e)

f)

Figure 3. 1H-NMR of PCXG2 in D2O (a. PABOL, b. PCXG2-1, c. PCXG2-2, d. PCXG2-3, e.
PCXG2-4 and f. PCXG2-2 after consuming all of the acrylamide bonds).
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Table 2. Characterization of polymers

Polymer

ABOL

In polymer
(mol %)a

Mw

Mw/Mn

0

5,250

1.26

--

100

Cyclam
monomer
0

G2

7a

50

50

33

5,910

1.11

G2

7a

0

100

100

9,030

1.11

G2

7b

50

50

45

6,580

1.29

G2

7b

0

100

100

5,230

1.27

PABOL
PCX -1
PCX -2
PCX -3
PCX -4
a

In feed (mol %)

Cyclam
monomer

Content of the cyclam monomer units determined from 1H-NMR.

73
4.1.3 Cytotoxicity of PCXG2
Safety is the major challenge of synthetic polycations to apply nucleic acid
therapeutics to patients. Cytotoxicity study will help with design and selection of safer
polycationic vectors for clinical gene therapy [198]. Hepatocellular carcinoma HepG2 was
widely used for prediction of the potential liver toxicity and human osteosarcoma U2OS
cells was used to define the safe dosing window of PCXG2 for further studies about CXCR4
antagonism and gene transfection [199]. Typically high molecular weight and high charge
density typically related with high cytotoxicity of polycations, which corresponds with the
cytotoxicity result of PCXG2-2 [198]. Figure 4 showed that PCXG2-2 with the highest
molecular weight and highest charge density due to highest contant of cyclam exhibited
the highest cytotoxicity among all PCXG2. However, PCXG2-1 with lowest cyclam content
exhibited the lowest toxicity. Moreover, all of PCXG2 had dramatically less toxic than the
commercial control PEI, indicating the potential usage of PCXG2 in vivo.
4.1.4 CXCR4 antagonism of PCXG2
High content screening (HCS) analysis was used to study the CXCR4 antagonist
activity of monocyclam monomers and PCXG2 polymers by monitoring the degree of
inhibition of SDF-1 triggered internalization of membrane-localized EGFP-CXCR4 fusion
protein to endosomes in human osteosarcoma cell line U2OS. HCS is a phenotypic assay
that in this case uses automatic image analysis to quantify the extent of EGFP-CXCR4
internalization into the cells. As shown in Figure 5a, the untreated cells display punctate
fluorescence documented by EGFP-CXCR4 internalization into endosomes. However, the
control

small-molecule

CXCR4

antagonist

AMD3100

inhibits

EGFP-CXCR4

internalization, as indicated by the diffuse pattern of fluorescence. The usage of propylene
linker in 7b led to 2.6-fold higher activity than that of ethylene linker in 7a (EC50 = 41.2 vs.
105.5 ng/mL ~ 69 vs. 180 nM). After removal of Boc-groups, the CXCR4 antagonism of
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all PCXG2 was calculated and compared with the activity of corresponding monomers
(Figure 5b). Control polymer PABOL exhibited no CXCR4 antagonism. Homopolymer
PCXG2-4 exhibited higher CXCR4 inhibitory activity than PCXG2-2, which corresponded
with less potent of 7a than 7b (EC50 = 21.4 vs. 28.2 ng/mL). Copolymers (PCXG2-1 and
PCXG2-3) showed decreased CXCR4 potency due to less content of the CXCR4 binding
moieties by incorporation of ABOL. Therefore, the polymerization of the monocyclam
monomers improved the CXCR4 antagonism dramatically. To determine the influence of
polymerization on CXCR4 antagonism of the repeating monocyclam unit, the potency was
calculated based on the activity per cyclam in polymers. As shown in Figure 5b,
polymerization increased activity of 7a more than 5-fold and the activity of 7b increased
about 3-fold after incorporation into the polymer chain of PCXG2. Moreover, decreasing
the content of the monocyclam monomers in PCXG2 did not impact the activity of the
repeating units. However, polymerization of AMD3100 caused a significantly decrease in
CXCR4 inhibitory activity per repeating units in the first generation of PCX (PCX G1) (2 vs.
139.1 ng/mL). The activity of PCXG2 was significantly higher than that of PCXG1, indicating
that better presentation of the CXCR4-binding moieties in polymeric CXCR4 antagonists
is important for improving the CXCR4 potent activity. In order to investigate the duration
of CXCR4 inhibition of PCX, U2OS cells were incubated with AMD3100 (0.15 µg/mL) or
the most potent PCXG2 (PCXG2-4, 1.5 µg/mL) respectively for 30 min and the extent of
CXCR4 inhibition was quantified at different time points (Figure 5c). AMD3100 has a high
affinity to CXCR4 receptors and results in long lasting inhibitory effect [200]. In comparison
with AMD3100, there was no significant differences in the duration of CXCR4 inhibition
between AMD3100 and PCXG2-4. We noticed that both treatments maintained CXCR4
inhibition above 80% for at least 36 h and about 50% until 48 h, suggesting the long lasting
antagonist effect and high affinity of PCXG2.
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Figure 4. Cytotoxicity of PCXG2 in U2OS and HepG2 cells. The IC50 curves were
constructed using mean cell viability ± SD (n=3). One-way ANOVA with Tukey-Kramer
multiple comparisons test (a)(P<0.001 vs. PEI); b)(P<0.001 vs. PCXG2-2); c)(P>0.05 vs.
PCXG2-4); d) (P<0.001 vs. PCXG2-4)).

76
(a)

Untreated

AMD3100

(b)

CXCR4 antagonism
EC50 per
EC50
antagonist moiety
[ng/mL]
[ng/mL]

Sample

PCXG2-1

56.8

19.9

PCXG2-2

28.2

19.5

PCXG2-3

29.9

13.3

PCXG2-4

21.3

14.9

7a

105.5

105.5

7b

41.2

41.2

PCXG1
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76.5

AMD3100

2.0

2.0

% CXCR4 Inhibition

(c)
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Figure 5. CXCR4 antagonism of PCXG2. (a) Effect of AMD3100 on redistribution of EGFPCXCR4 receptor in U2OS cells. (b) Effect of monomer type and content on CXCR4
antagonism. EC50 values determined from receptor redistribution assay in U2OS cells
(n=3). (c) Duration of CXCR4 antagonism (n=3).
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4.1.5 Inhibition of cancer cell invasion by PCXG2
The activity of CXCR4 induced by SDF-1 contributes to migration and invasion of
a series of cancers, which can be inhibited by CXCR4 antagonists like AMD3100. To
investigate if the CXCR4 antagonism of the synthesized PCXG2 polymers was also
manifested by inhibition of cancer cell invasion, a Boyden chamber method was used.
Treatment of CXCR4+ U2OS cells with control AMD3100 resulted in maximum 83% of
cancer cells from invading and migrating through the layer of Matrigel (Figure 6). All
PCXG2 exhibited effective inhibition of invasion ranging from 62 to 82% at concentrations
relevant for subsequent transfection experiments. And the ability of PCXG2 to prevent
cancer cell invasion increased with the higher content of the incorporated monocyclam
units. PCXG2-4 was the most potent CXCR4 antagonist and showed the highest inhibition
of cancer cell invasion (82%), which was fully comparable to AMD3100. However, the
negative control PABOL was unable to inhibit cell invasion due to no CXCR4 potency.
4.1.6 Transient mobilization of peripheral blood leukocytes (PBLs)
CXCR4 contributes to tethering leukocytes and hematopoietic stem and progenitor
cells to the bone marrow and the leukocytosis associated with CXCR4 inhibition has been
used as an indicator of the mobilization of hematopoietic stem and progenitor cells. Small
molecule CXCR4 antagonists such as AMD3100 induce a transient leukocytosis in
humans, dogs, mice and rats. An increase in PBL is normally observed within 1 h after
administration of AMD3100 both in humans and animals [201]. We evaluated if the CXCR4
antagonism of PCXG2 observed in vitro will be manifested also by leukocytosis and thus
indirectly assessed the PCXG2 ability to mobilize hematopoietic stem and progenitor cells.
We selected the best performing PCXG2-4 with the highest CXCR4 antagonism in vitro
and administered it intravenously to BALB/c mice.
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Before we started the experiment, the maximum tolerated dose of PCXG2 was
tested in Balb/c mice. PCXG2-4 showed the lowest toxicity in vivo with MTD of 5 mg/Kg by
i.v. injection (Figure 7a). We selected a relatively low dose of PCXG2-4 (1.25 mg/kg) to
avoid any possible side effect related to potential polycation toxicity. Positive control
AMD3100 was given subcutaneously at 5 mg/kg according to a standard protocol. A
widely used polycation PEI was also injected as a negative control, which was with no
known CXCR4 activity. As shown in Figure 7b, the total number of PBL was compared
after administration for 1 h. PCXG2-4 induced 1.6-fold increase in the total number of PBL
when compared with PBS-treated group, which was fully comparable with the effect of
AMD3100 (P>0.05). Different populations of PBL were also analyzed to identify any
possible differences among the tested samples. Administration of both PCXG2-4 and
AMD3100 resulted in a significant increase in the number of lymphocytes and monocytes,
while no significant effect was observed for eosinophils, neutrophils and basophiles. No
statistically significant differences were observed in the ability of PCXG2-4 and AMD3100
to mobilize different PBL populations. We did not observe leukocytosis in the PEI control
group, indicating that the increase in the number of PBL by administration of PCXG2-4 was
indeed due to the inhibition of CXCR4 and not related to any nonspecific polycation-related
toxicity. It is our first time to show that the polymeric CXCR4 antagonists can rapidly and
efficiently mobilize PBL and thus possibly have the potential to mobilize hematopoietic
stem and progenitor cells as AMD3100 used in clinics.
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Figure 6. Inhibition of cancer cell invasion by PCXG2 (2 µg mL-1) and polyplexes (w/w = 5,
total polymer = 2.5 µg mL-1). Statistical comparisons were done using the One-way
ANOVA with Tukey-Kramer Multiple Comparisons Test (***P<0.001 compared with
AMD3100 treated cells).
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4.1.7 DNA condensation and transfection activity by PCXG2
After evaluation of PCXG2 CXCR4 antagonism and ability to inhibit cancer cell
invasion, we have investigated the capability of PCXG2 to function as gene delivery vectors.
First, the ability of all PCXG2 to condense DNA and form polyplexes was confirmed using
ethidium bromide (EtBr) exclusion assay. Figure 8 showed that the DNA condensation
ability increased with increasing content of the cyclam monomers in PCXG2. In agreement
with previous reports [202, 203], the ability of PABOL to condense DNA was poor in the
studied range of polymer/DNA w/w ratios. The length of spacer in the cyclam monomers
had no discernible effect on DNA condensation ability. Hydrodynamic size and zeta
potential of PCX/DNA polyplexes were determined by dynamic light scattering at
polymer/DNA w/w ratio of 5, which corresponded to about 3-fold excess of PCXG2 relative
to the minimum amount required to fully condense DNA. The sizes of PCX G2/DNA
polyplexes ranged from 56 to 122 nm and the polyplexes were all positively charged with
zeta potential 17 to 31 mV (Table 3). Control PABOL cannot condense full condense DNA
at w/w ratio of 5, which was reflected by a large hydrodynamic size and slightly negative
zeta potential. Moreover, PCXG2/DNA polyplexes prepared at w/w 5 were also evaluated
for their ability to inhibit CXCR4-mediated cancer cell invasion. All the PCXG2 polyplexes
(polymer concentration 2.5 μg/mL) showed effective inhibition of cancer cell invasion that
was fully comparable to AMD3100 (Figure 6).
In vitro transfection activity of PCXG2/DNA polyplexes at varying polycation/DNA
(w/w) ratios was evaluated in U2OS and B16F10 cells both in the presence and absence
of 10% FBS (Figure 8). PEI/DNA polyplexes at w/w ratio of 1.2 was used as a control. A
single DNA dose of 2.35 µg/mL was used in all transfection experiments. The transfection
activity of PCX/DNA polyplexes in U2OS was almost independent of the type and content
of cyclam monomer at the lowest tested w/w ratio of 5. There was a marked decrease in
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serum-free transfection with increased cyclam content at higher w/w ratios because of the
polymer toxicity. In contrast, no such effect was observed in the presence of 10% serum
as the transfection increased 7-fold when increasing the cyclam content (PCXG2-2 vs.
PCXG2-1). Transfection in B16F10 was much less sensitive to PCXG2 toxicity and cyclam
content, although weak tendency for transfection to increase with increasing cyclam
content was observed. The type of cyclam monomer had no discernible effect on
transfection. Overall, transfection of PCXG2 polyplexes was several orders of magnitude
higher than transfection of PABOL polyplexes and comparable to transfection of PEI
polyplexes. The low dependence of transfection on cyclam content suggests that using
PCXG2 with lower cyclam content could be beneficial because of the lower toxicity.
4.1.8 Cell uptake of PCXG2/DNA polyplexes
We developed PCXG2 with the goal of combining CXCR4 antagonism with the
ability to deliver therapeutic nucleic acids. Successful nucleic acid therapies require
efficient internalization into cells and delivery to the appropriate intracellular organelles.
Since PCXG2 inhibit internalization of CXCR4 receptor, it was important to determine if the
PCXG2 antagonism negatively impacts the intracellular uptake of DNA polyplexes, which
could compromise transfection activity. DNA was labeled with CX-Rhodamine and used
to prepare PCX/DNA polyplexes. We first measured cell uptake of the fluorescently
labeled PCXG2/DNA polyplexes in two cancer cell lines (U2OS and B16F10) by using flow
cytometry (Figure 10). Based on the results, the cell uptake properties of PCXG2/DNA
polyplexes were highly cell line dependent. In U2OS cells, higher cyclam led to lower
uptake. The cellular uptake of PCXG2/DNA polyplexes in U2OS cells was much higher
than PEI control. PCXG2-1 complex with lower content of cyclam monomer had higher
fluorescence than PCXG2-2, and PCXG2-3 complex showed a little higher cellular uptake
than PCXG2-4. However, the opposite behavior was observed in B16F10 cells with lower
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CXCR4 levels, there was no so much difference between PCXG2 and control PEI.
Moreover, PCXG2-3 and PCXG2-4 showed a little better cellular uptake than PCX-1 and
PCX-2 in serum free conditions. The overall cellular uptake of PCXG2 polyplexes was
several folds higher than that of PABOL polyplexes. Under the consideration that higher
CXCR4 expression in U2OS cells compared with B16F10 cells, we investigated whether
CXCR4 receptors was involved in the process of cellular uptake of PCX polyplexes. U2OS
cells were pretreated with CXCR4 antagonism AMD3100 for 1 h before adding PCXG2
polyplex (Figure 10c). The relative fluorescence intensity of PCXG2 polyplexes did not
show decrease in U2OS cells pretreated with AMD3100 in comparison with untreated one,
suggesting that CXCR4 receptor did not affect the cellular uptake of the CXCR4-inhibiting
polyplexes.
4.1.9 Summary
The above studies described the successful design and development of polymeric
drugs PCXG2 with a dual function to simultaneously inhibit CXCR4 chemokine receptor
and deliver genes. Polymerization improved the CXCR4 inhibitory activity of the
synthesized monocyclam monomers significantly after incorporation into the polymer
chains. And CXCR4 antagonism of the second generation of PCX was much higher when
compared with the first generation, confirming the importance of a proper presentation of
the ligands within synthetic polymers. We first reported that intravenous administration of
PCXG2 resulted in mobilization of leukocytes from bone marrow into peripheral blood,
which might work as synthetic polymeric mobilizers for blood stem cells or progenitor cells.
Furthermore, PCXG2 inhibited cancer cell invasion in either formation of free polymers or
polyplexes to a level fully comparable with AMD3100. And the gene transfection results
indicated the ability of PCXG2 to efficiently deliver genes to cancer cells. Therefore, PCXG2
have the potential to become a new class of polymeric drugs for cancer treatment with a
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promising dual functionality that synergistically combine CXCR4 antagonism to inhibit
cancer metastasis with anti-cancer therapeutic effect of the delivered nucleic acids [204].
Polypelxes have received significant attention as promising gene delivery vectors
due to multiple potential advantages when compared with viral vectors, including minimal
immunogenicity, lower toxicity, and easier manufacturing and functional modifications
[205, 206]. Safety and stability are still the major concerns to apply dual-functional
polycationic nanoparticles in vivo. Positively charged polyplexes attached to negatively
charged heparan sulfate proteoglycans on the cell surface to facilitate uptake into cells via
adsorptive endocytosis [207]. During endocytosis, the decreasing pH confers "proton
sponge effect", which causes enhanced protonation of polycations, influx of anions and
high internal osmotic pressure, leading to burst of endosome membrane, escape of
complexes from endosomes and high transfection efficiency in vitro [208]. However, high
density of positive charges damages negatively charged cell membranes and contributes
to cytotoxicity of polyplexes [209]. Positively charged polyplexes are colloidally stabilized
by electrostatic repulsion and frequently aggregate under physiological salt conditions.
The positive aggregation was rapidly eliminated from circulation by reticulo-endothelial
systems (RES) [210-212].
In the next part of 4.2, the goal is to improve the in vivo applicability of PCX
polyplexes by chemical modification. PCXG1 was used as the model cationic polymer.
Nonionic polymer poly(ethylene glycol) (PEG) was applied to modify PCXG1 to shield the
surface charges and improve colloidal stability by steric stabilization [213-216]. PEGylation
typically prolongs circulation by increasing stability of polyplexes in physiological fluid and
reduces the interaction of polyplexes with extracellular membrane surface to decrease iv
vivo toxicity [217, 218].
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Table 3. Hydrodynamic size and zeta potential of DNA polyplexes
w/w 5

w/w 10

w/w 15

Polyplex

Size (nm)

δ potential
(mV)

Size (nm)

δ potential
(mV)

Size (nm)

δ potential
(mV)

PABOL

870.9 ± 7.5

-2.3 ± 0.9

796.9 ± 5.9

4.0 ± 0.2

650.1 ± 8.6

6.7 ± 0.1

PCXG2-1

121.7 ± 2.5

24.4 ± 0.5

90.4 ± 2.0

29.6 ± 0.4

87.1 ± 2.1

30.5 ± 0.7

PCXG2-2

59.9 ± 1.1

22.0 ± 0.9

56.3 ± 2.6

17.3 ± 0.5

64.9 ± 0.9

20.6 ± 1.0

PCXG2-3

84.6 ± 2.5

29.9 ± 0.9

70.3 ± 0.1

29.1 ± 0.8

65.1 ± 0.3

27.8 ± 1.5

PCXG2-4

75.0 ± 0.8

30.5 ± 0.5

65.1 ± 0.4

28.6 ± 1.0

64.0 ± 1.6

25.6 ± 0.3

PEI (N/P 10) 52.4 ± 5.5

20.8 ± 1.2
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4.2 PEGylation of Poly(amido amine) CXCR4 Antagonists to Enhance Safety and
Colloidal Stability for Gene Therapy in Cancer
Please note that the data of this part was from the paper published in the
Pharmaceutical Research [151]. The authors include Dr. Jing Li, Dr. David Oupický and
me. As the first author, I performed all the experiments, analyzed data and wrote the draft
of manuscript. Dr. Jing Li and Dr. Oupický helped to revise it and made it publishable. All
the authors agreed with including their work in this dissertation.

The goal of PEGylation was to improve physical properties and safety of
polycationic PCXG1. However, it would decrease the transfection activity due to minimizing
cellular association, cell uptake, endosomal escape, and gene release [219, 220]. To
optimize the physicochemical characteristics and biological activities, proper PEG content
should be carefully balanced. In the following studies, how the presence of PEG affects
colloidal stability, safety, CXCR4 antagonism, inhibition of cancer cell invasion, and
transfection activity of the polymers and their polyplexes would be evaluated. We would
develop proper polyplex formulations that retain CXCR4 antagonism of PCXG1, while
exhibiting enhanced colloidal stability, decreased cytotoxicity, but improved transfection
activity under physiologic conditions (Scheme 4).
4.2.1 Synthesis and characterization of PEG-PCXG1
PCXG1 was synthesized in the form of a poly(amido amine) by Michael polyadditon
of secondary amines present in AMD3100 with bisacrylamide monomer HMBA (Figure
11). Plerixafor functions as a hexafunctional monomer in the Michael polyaddition and
leads to insoluble crosslinked PCXG1 at high temperature and high monomer
concentrations [221, 222]. A more gentle condition resulted in a soluble PCXG1 with
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weight-average molecular weight (Mw) of 10.6 kDa and unimodal distribution of molecular
weights (Figure 12). Owing to excess and high reactive secondary amines in the
AMD3100 structure, PEG chain could be introduced into the polymer by the reaction of
mPEG-acrylamide with the secondary amines of PCXG1 (Figure 11). In contrast to
common amide coupling, using Michael addition for the PEGylation allowed us to
conserve the overall number of protonizable amines in PCXG1. Three copolymers with
increasing content of PEG were synthesized and named according to their PEG content
as described in Table 4. The copolymers were isolated by precipitation in diethyl ether
and collected as hydrochloride salts after extensive dialysis. The content of PEG in the
copolymers was calculated from 1H-NMR integral intensity of the PEG methylene protons
at 3.7 ppm and aromatic protons of AMD3100 at 7.4-7.8 ppm (Figure 13). As shown in
Table 4, a slight higher content of PEG was gained in comparison with original feed
composition, which could be explained by the preferential removal of lower molecular
weight polymer fraction by precipitation process in organic solvent and removal of the low
molecular weight polymer fractions rich in PCXG1 during dialysis. The successful synthesis
of PEGylated polymer and absence of unreacted mPEG-acrylamide can also reflect from
GPC trace (Figure 13) of starting material PEG-acrylamide and those polymers. The
PEGylated polymers with higher PEG composition showed earlier elution time, suggesting
higher molecular weight. The polydispersity index (PDI) of the polymers ranged from 1.1
to 1.4, suggesting a good control of the polymerization. Therefore, the direct PEG
modification of PCXG1 with a range of conformed substitution was developed, and the
effects of PEGylation on PCXG1 in respect to DNA condensation, polyplexes stability,
toxicity, transfection as well as CXCR4 antagonism would be studied comprehensively.
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Scheme 4. Mechanism of dual-function PEG-PCXG1 as gene delivery vector and CXCR4
antagonist inhibiting cancer cell invasion.
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Figure 11. Synthesis of PCXG1 and PEG-PCXG1.
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Table 4. PEG content in PEG-PCXG1 determined by 1H-NMR.
PEG content (wt %)
Polymer
in feed

in
copolymer

PCXG1

0

0

PEG12-PCXG1

10

12

PEG41-PCXG1

35

41

PEG52-PCXG1

50

52

Detector signal (a.u.)
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Figure 12. Gel permeation chromatograms of PCXG1 and PEG-PCXG1.
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Figure 13. Typical 1H-NMR spectrum of PEG-PCXG1 (PEG12-PCXG1 in D2O) used in the
determination of the PEG content (a – aromatic phenylene protons of AMD3100, b –
methylene protons of PEG).
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4.2.2 Preparation and characterization of PEG- PCXG1 polyplexes
The effect of PEGylation on DNA condensation ability of PCXG1 was investigated
by EtBr exclusion assay as shown in Figure 14. All the PEG-PCXG1 exhibited similar
condensation curves with a typical sigmoidal shape and were able to condense plasmid
DNA to the same extent as PCXG1 as indicated by the same residual fluorescence at the
highest polymer/DNA ratios. With increasing PEG content, the DNA condensation curves
shifted to higher w/w ratios. However, if we only considered the polycation part and
transformed PEG-PCXG1 into equivalent content of PCXG1, the DNA condensation curves
almost overlaid, suggesting that DNA binding properties of PCXG1 part in the copolymer
are not affected by the presence of PEG chain. A similar finding was recently reported by
Fitzsimmons and Uludağ [223].
One of the key motivations for PEGylation is to shield the positive surface charge
of polyplexes by neutral PEG chains. The influence of PEGylation on polyplex surface
charge was investigated. Our results confirmed that the use of PEG-PCXG1 significantly
decreases surface charge of the polyplexes as documented by the decrease in the
measured zeta potential (Figure 15). The PEGylated polyplexes showed almost neutral
surface charge (3.3-5 mV) in 10 mM HEPES buffer, pH 7.4. However, unPEGylated
PCXG1/DNA showed zeta potential of + 20 mV. PEGylation significantly reduced polyplex
surface charge, which is consistent with other researches on influence of PEGylated
polyplexes [224-226].
The positive surface charge provides electrostatic stabilization to the polyplex
nanoparticles at low concentration buffers. However, physiological ionic conditions would
cause aggregation and destabilization of polyplexes by non-specific interactions [227,
228]. Steric stabilization by PEG can typically overcome the problem of low colloidal
stability of polyplexes [229]. We have prepared PEG-PCXG1 and PCXG1 polyplexes in 10
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mM HEPES buffer (pH 7.4) at polymer/DNA (w/w) ratio of 5 and measured their
hydrodynamic diameter. Then polyplexes were incubated in phosphate-buffered saline
(PBS) (pH 7.4) to mimic the physiologic ionic conditions and observed changes in polyplex
size during the following period of 12 h were monitored by DLS (Figure 16). The results
showed that PCXG1 polyplexes displayed an immediate aggregation after PBS addition as
documented by the increase of their size from ~60 nm to ~430 nm in the span of only 15
min. The size of PCXG1 polyplexes increased to nearly 1 µm within 1 h of PBS addition. In
contrast, polyplexes prepared with PEG-PCXG1 exhibited markedly improved colloidal
stability. Polyplex containing 12% PEG showed an improved stability up to 1 h in PBS, but
it was ineffective in long-term evaluation as documented by the increase in size from 58
nm to 690 nm within 12 h of PBS addition. In contrast, polyplexes containing 41% and 52%
PEG totally prevented aggregation up to 12 h with stable size lower than 200 nm.
Modification with PEG chain is an efficient method to stabilize particles against
physiological salts. PEG chains formed a hydrophilic corona surrounding the particle core
and protected them from aggregation through electrostatic interaction between polyplexes
and physiological ionic components [225, 230].
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Figure 14. DNA condensation ability of PCXG1 and PEG-PCXG1 determined by ethidium
bromide exclusion assay.
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4.2.3 Cytotoxicity of PEG-PCXG1
Usually, cationic polymers display cytotoxicity by disturbing cell membrane such
as high density of positive charge mediated membrane damage and phospholipids
reshuffling [209]. PEGylation could produce a hydrophilic shell on the particle surface to
efficiently decrease the charge density and block intermolecular interaction, avoiding
extracellular mechanism of cytotoxicity. Cytotoxicity of PEGylated polymers and control
PEI was evaluated by MTS assay in HepG2 and U2OS cells (Figure 17). HepG cells are
widely used for prediction of liver toxicity [199]. The PEGylated polymers showed lower
toxicity than the unPEGylated polymer as expected [219, 231, 232]. Importantly, similar
trend was observed also when only the polycation part of the copolymers was considered
in calculating IC50. The measured IC50 value for PCXG1 was 72 µg/mL. The IC50 values of
PEG-PCXG1 were calculated considering only the PCXG1 polycation content. In such case,
the cytotoxicity of PEG12-PCXG1 was similar to that of PCXG1 (77 µg/mL). The two
copolymers with higher PEG content exhibited significantly decreased cytotoxicity with
their IC50 values above the maximum tested polycation concentration of 100 µg/mL. In
order to establish a safe, nontoxic working concentration range of PCXG1, we tested U2OS
cells which were then used throughout this study in evaluating CXCR4 antagonism, cell
invasion inhibition, and transfection of PCXG1. IC50 values for PCXG1 and PEG12-PCXG1
were indistinguishable at ~17 µg/mL but they increased to 25 µg/mL and 41 µg/mL in case
of PEG41-PCXG1 and PEG52-PCXG1 respectively, which were all higher than control PEI
(22.0 µg/mL). In conclusion, the cell viability study proved that PEGylation effectively
decreased the cytotoxicity profile of polycations not only by simply reducing the cationic
content in polymers but also by decreasing the interactions of the toxic part with cellular
membranes and vital intracellular proteins, which are unlike existing reports [223, 232].
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Figure 17. Effect of PEG on cytotoxicity of PCXG1 in HepG2 and U2OS cells. Cell viability
was measured by MTS assay after 24 h incubation with increasing concentrations of
polymers. Polymer concentration for PEG-PCXG1 copolymers is expressed as PCXG1
concentration only (i.e., excluding PEG). Results are expressed as mean ± SD (n=3).
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4.2.4 CXCR4 antagonism of PEG-PCXG1
Binding of PCXG1 to CXCR4 receptor is required for the copolymers to exhibit
CXCR4 inhibitory activity. However, steric barrier created by PEGylation might cause the
negative effect on binding of polymers to receptors. Therefore, CXCR4 redistribution
assay was used to evaluate the influence of PEGylation on CXCR4 antagonism of PCXG1
polymer and PCXG1/DNA polyplexes. This assay is based on monitoring the degree of
inhibition of SDF-1 triggered endocytosis of membrane-localized EGFP-tagged CXCR4
receptor using HCS analysis. Figure 18a showed the difference in the fluorescence
pattern of EGFP-CXCR4 between untreated cells (punctate fluorescence) and cells
treated with CXCR4 inhibitor (diffuse pattern of fluorescence). The CXCR4 inhibitory
activity of PEG-PCXG1 was tested at equal concentrations of the polycationic (PCXG1)
content and expressed as % CXCR4 antagonism relative to the control AMD3100 (Figure
18b). The CXCR4 antagonism of PEG-PCXG1 at the lowest tested concentration (0.05
µg/mL) ranged from 57-77% of AMD3100 activity, which had no statistically significant in
a one-way ANOVA analysis in comparison with PCXG1. At two higher tested
concentrations of 0.15 μg/mL and 0.5 μg/mL, all PEG-PCXG1 and PCXG1 exhibited
comparable CXCR4 inhibitory activity to the control AMD3100, indicating that PEG did not
affect the binding properties of polymers with CXCR4 receptors. We also tested whether
PEG-PCXG1 polyplexes prepared at two different w/w ratios (1.5 and 5) retained the
CXCR4 inhibitory functionality of the free polymers under practically relevant experimental
conditions employed in transfection assays (Figure 18c). Both polyplex formulations
achieved nearly 100% CXCR4 inhibition According to the EtBr exclusion assay, polymers
were just used to fully condense DNA and little amount of free polymers were present in
polyplexes at w/w of 1.5, indicating the ability of polyplexes to inhibit CXCR4. At w/w of 5,
the observed CXCR4 antagonism came from the free polymer in the formulation. The
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cyclam ring of AMD3100 was totally 2+ charged at physiological pH and formed a stable
trans-III R,R,S,S-type conformation regarding to the four nitrogen atoms, which permitted
AMD3100 to bind tightly with CXCR4 receptor by hydrogen bond interactions with
carboxylic acid group [233]. PEGylation does not negatively affect pharmacologic activity
of PCXG1 to fully inhibit CXCR4 even in polyplex formulations. The possible reason might
be that PEG chain did not decrease the overall charge profiles of cyclam rings and
maintained their binding ability with Asp262, Glu318 or Asp 171 to fit into the main ligandbinding pocket of CXCR4 receptors [234].
4.2.5 Inhibition of cancer cell invasion by PEG-PCXG1
As we know, CXCR4/SDF-1 axis plays a significant role in regulation of stem cell
trafficking, neovascularization as well as cancer migration [235-241]. However, CXCR4
antagonists like AMD3100 can inhibit invasion of those cancer cells towards SDF-1
concentration gradient. In this study, Boyden chamber method was used to evaluate the
effect of PEGylation on the ability of PCXG1 polyplexes to inhibit invasion of cancer cells.
As shown in Figure 19, all PEG-PCXG1 polyplexes prepared at equivalent PCXG1/DNA
w/w ratio 5 effectively prevented 77.1-79.8% cancer cells from invading and migrating
through Matrigel, which was comparable to that of AMD3100 (81.3%). Therefore, the
ability of PCXG1 polyplexes to inhibit cancer cell invasion was not negatively impacted by
PEGylation, suggesting that PEG-PCXG1 could be well-suited for applications in the
treatment that aim at preventing or delaying metastasis. To apply the PEG-PCXG1 for gene
therapy, the gene transfection efficiency would be tested and formulation studied would
be discussed.
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Figure 18. CXCR4 antagonism of PEG-PCXG1 polycations and polyplexes. (a) Effect of
AMD3100 on redistribution of EGFP-CXCR4 receptor in U2OS cells. CXCR4 antagonism
of PCXG1 and PEG-PCXG1 (b) and their polyplexes (c). The results are shown as mean %
CXCR4 inhibition relative to AMD3100 ± SD (n=3).
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Figure 19. Inhibition of cancer cell invasion by PEG-PCXG1 polyplexes. Polyplexes were
prepared at w/w ratio of 5 (total PCXG1 concentration 2.5 µg/mL). Cells were allowed to
invade through a layer of Matrigel toward SDF-1 concentration gradient for 19 h before
fixation and imaging. Average numbers of invaded cells were counted in randomly
selected 5-10 imaging areas at 20x magnification (Scale bar = 200 µm).
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4.2.6 Transfection activity of PEG-PCXG1 polyplexes
To study the effect of PEGylation on gene transfection activity, B16F10 and U2OS
cell lines were incubated for 4 h with PEG-PCXG1 polyplexes formed with luciferase
reporter plasmid in the absence or presence of 10% of FBS and continuously cultured in
fresh medium for another 24 h (Figure 20). PCXG1 and PEG12-PCXG1 polyplexes
displayed fully comparable transfection efficiency, however, the transfection decreased
dramatically for polyplexes containing higher amount of PEG in either absence or
presence of FBS. The possible reasons of reduced gene transfection of PEGylated
polyplexes are that decreasing surface charge decreased cellular association and
internalization, leading to a low transfection activity [219, 230]. DNA unpackaging from
PEGylated polyplexes decreased, which might be another reason for poor luciferase
expression. Unmodified polyplexes may escape more easily from endosome because
aggregated particles filled intracellular vesicles and distort the membrane, however, the
vesicles with PEGylated particles had more smooth appearance and would restrict the
endosome escape [230]. In conclusion, the effect of PEGylation on transfection activity of
polyplexes are due to restricted interaction with cellular membranes, resulting in
decreased cellular uptake and compromised endosomal escape of polyplexes [219, 229].
4.2.7 Mixture formulation of PCXG1 and PEG-PCXG1
With the increasing content of PEG in the polyplexes, the colloidal stability
enhanced but transfection activity reduced correspondingly. As discussed above, several
strategies have been developed to overcome the negative effect of PEGylation on
transfection activity. In an attempt to solve the problems and easily control the amount of
PEG, we have utilized a mixed polyplex strategy to prepare polyplexes with acceptable
colloidal stability, near-neutral zeta potential, and high transfection activity. The mixed
polyplex strategy depends on using a mixture of non-PEGylated and PEGylated
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polycations. The mechanism is that the non-PEGylated polycation provides effective DNA
condensation and facilitates endosomal escape of the polyplexes, while the PEGylated
polycation equips the polyplexes with favorable surface properties and colloidal stability.
This strategy has been successfully utilized with several different types of polycations
[242-244]. We optimized PEG/polycation amounts by mixing PCXG1 and its PEGylated
counterpart PEG52-PCXG1 to obtain largest range of PEG composition (Figure 21).
As shown in Figure 21a, with increasing PEG content, the DNA condensation
curves of the mixed formulations shifted to higher w/w ratios. However, the condensation
efficiency of PCXG1 part in the formulation was not affected because the curves overlaid
when re-plotted as relative fluorescence vs. PCXG1/DNA ratio (not shown). Using a
mixture consisting of 80% PCXG1 and 20% PEG52-PCXG1 leads to positively charged
polyplexes and rapid increase in size and aggregation in PBS (Figure 21b). However,
increasing the content of PEG52-PCXG1 in the mixture to 40 and 70% resulted in
decreased zeta potential and formulation of colloidally stable polyplexes.
In order to investigate the influence of mixture formulation on gene transfection,
we tested the polyplexes above in both U2OS and B16F10 cells in the absence or
presence of 10% FBS (Figure 21c). The transfection results showed that even polyplexes
formed with 70% PEG52-PCXG1 retained transfection activity that was similar to that of
non-PEGylated PCXG1 polyplexe, confirming that the mixed polyplex strategy is a suitable
approach to prepare polyplexes with low surface charge, good colloidal stability as well as
high transfection activity.
CXCR4 antagonism and the ability to inhibit cancer cell invasion are required for
the mixed polyplexes. We also confirmed them in the CXCR4+ U2OS cells as displayed
in Figure 22 and 23. All of the mixed polymers and polyplexes exhibited comparable
CXCR4 inhibitory activity at all tested concentrations and w/w ratios. Similarly, mixed
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formulation retained the ability to prevent cancer cell invasion, which was fully comparable
with AMD3100. Those results indicated that mixed PCXG1 and PEG52-PCXG1 can be wellsuited for applications in treatment that aim at combining gene therapy with preventing
cancer metastasis.
4.2.8 DNA biodistribution in vivo
The ability of mixed PCXG1 and PEG-PCXG1 to deliver intact DNA in vivo was
detected in 4T1 mice model. Linear PEI was used as positive control. Before the
experiment, the size and zeta potential of DNA polyplexes prepared in HBG buffer were
investigated. As shown in Figure 24, using a mixture consisting of 60% PCXG1 and 40%
PEG52-PCXG1 leads to the smallest size with near-neutral zeta potential. This formulation
was administrated in 4T1 mice and RT-PCR was used to study the biodistribution of intact
DNA delivered to different organs. Figure 25 revealed that the large amount of DNA was
delivered to liver and spleen, which caused the sever off-target effect. However, in
comparison with positive control PEI, PCXG1 and the mixed PEGylated formulation
reduced the off-target effect as well as improved the ability to deliver DNA to tumors with
5.8-fold and 10.8-fold increase, respectively. Therefore, mixed PCXG1 and PEG52-PCXG1
would be a good option to target tumors and deliver nucleic acid for gene therapy.
4.2.9 Conclusion
To conclude, polymeric CXCR4 antagonism is a potential dual-fucntion vector,
which are capable to inhibit cancer cell invasion and deliver efficient gene transfection. In
order to perform colloidal stability, retain CXCR4 antagonism and exhibit high transfection
activity, combination of PEGylation of PCXG1 with using a mixed polyplex approach is a
viable strategy. The ability of PCXG1 to deliver DNA has been comprehensively studied,
however, the siRNA delivery by the dual-funtional PCX still need to be further investigated.
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Figure 20. Transfection activity of PEG-PCXG1 polyplexes in B16F10 and U2OS cells.
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Figure 21. Properties of mixed PCXG1/PEG-PCXG1 polyplexes. (a) DNA condensation
ability of the PCXG1/PEG-PCXG1 mixture determined by ethidium bromide exclusion assay.
(b) Colloidal stability (left) and zeta potential (right) of polyplexes (w/w 5) prepared with
increasing content of PEG52-PCXG1 in a mixture with PCXG1. (c) Transfection activity of
the mixed polyplexes.
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Figure 22. CXCR4 antagonism of mixed PCXG1/PEG-PCXG1 polymer and polyplexes in
U2OS cells. The results are shown as mean % CXCR4 inhibition relative to AMD3100 ±
SD (n=3).
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Figure 23. Inhibition of cancer cell invasion by mixed PCXG1/PEG-PCXG1 polyplexes.
Polyplexes were prepared at equivalent PCXG1/DNA w/w ratio of 5 (total equivalent PCXG1
concentration 2.5 µg/mL). Cells were allowed to invade through a layer of Matrigel toward
SDF-1 concentration gradient for 19 h before fixation and imaging. Average numbers of
invaded cells were counted in randomly selected 5-10 imaging areas at 20x magnification
(Scale bar = 200 µm).
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Figure 24. Size (left) and zeta potential (right) of mixed PCXG1/PEG-PCXG1 polyplexes at
equivalent PCXG1/DNA w/w 3 in HBG buffer. Results are shown as mean ± SD (n=3).
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Figure 25. DNA biodistribution by polyplexes in BALB/c mice. Results are expressed as
luciferase DNA ng/g tissue ± SD (duplicate of two mice). Statistical comparisons were
done using the One-way ANOVA with Tukey-Kramer Multiple Comparisons Test (*P<0.05
and **P<0.01).
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4.3 Cholesterol Modification of Poly(amido amine) CXCR4 Antagonists to Improve
siRNA Delivery for Combined Anticancer Therapies
Please note that the data of this part was from the paper published in the
Biomaterials Science with permission from The Royal Society of Chemistry [152]. The
authors include Dr. Jing Li, Yi Chen and Dr. David Oupický and me. As the first author, I
performed all the experiments, analyzed data and wrote the draft of manuscript. Dr. Jing
Li and Dr. Oupickýrevised it and made it publishable. All the authors agreed with including
their work in this dissertation.

Therapy with nucleic acids has potential in a broad range of disease. For
instance, small interfering RNA (siRNA) was capable to achieve sequence-specific
gene silencing effect in mammalian cells, and emerging as one of the most potential
agents for the treatment of various diseases, such as viral infections, gene
disorders as well as cancers [245-247]. Polyelectrolyte complexes of nucleic acids
with polycations have been under development as delivery vectors for over two
decades and received significant attention for multiple potential advantages,
including lower toxicity, minimal immunogenicity, easier manufacturing and
functional modifications [205, 206]. However, low bioavailability of siRNA has
hampered

its

accumulation

therapeutic
in

application

non-targeted

in

tissues,

clinical.

Enzymatic

insufficient

degradation,

cellular

uptake,

endosomal/lysosomal escape, and dissociation of siRNA from gene carriers must
be circumvented when developing safe and efficient siRNA delivery vectors [248250].
In comparison with lipid based delivery methods, the use of siRNA polyplexes
remains hindered by a relatively low efficacy [249, 250]. And polyplex formulations
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optimized for delivery of large DNA often perform poorly when delivering siRNA [251].
Many efforts have been made to develop various types of siRNA-loaded
nanoparticles to overcome biological hurdles of siRNA delivery in recent years [252,
253]. Modification of polycations with hydrophobic moieties (e.g., cholesterol) have been
among the most successful approaches [254, 255]. Cholesterol is a naturally occurring
lipid and metabolized in the body. It also plays an important role in self-assembly of
lipopolymer into miclelles or nanoparticles in biological environment, reducing
cytotoxicity and facilitating endocytosis [256-258].

For example, water-soluble

lipopolymers based on polyethylenimine and cholesterol exhibited high serum
compatibility, enhanced cellular uptake, and

better gene delivery than

commercially available PEI, which were due to favourable interactions between
cholesterol moiety and cell membrane [259]. In another example, a series of bioreducible cholesterol-grafted poly(amidoamines) were synthesized and able to selfassemble into cationic nanoparticles in aqueous solution, which possessed high
cell uptake, offered effective VEGF gene silencing in vitro as well as exhibited
effective inhibition of tumor growth in vivo [260].
In this section of study, we focus on further development of PCX G1 as siRNA
delivery vectors to achieve combined antimetastatic and antitumor effect by inhibiting
CXCR4 activity. Based on available evidence, we proposed that modification of PCXG1
with cholesterol will improve overall stability and improve cell uptake and intracellular
trafficking of siRNA polyplexes. We would synthesize a series of copolymers with different
cholesterol grafting degress. The influence of cholesterol modification on siRNA
complexation, colloidal and enzymatic stability of polyplexes, and the ability to inhibit
CXCR4 and deliver anticancer siRNA against PLK1 will be investigated (Scheme 5).
4.3.1. Synthesis and characterization of Chol-PCXG1
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The synthesized PCXG1 was described before by Michael-type polyaddition of
sencondary amines present in AMD3100 and acryloyl group of bisacrylamide HMBA at
equal molar ratio. AMD3100 functions as a hexafunctional monomers and HMBA reacted
randomly with one of the six amines, resulting in a branched water-soluble polymer when
the reaction was performed at relatively low temperature and monomer conentrations [221,
222]. The weight-average molecular weight of PCXG1 was 13.9 kg/mol with a
polydispersity of 1.9 as determined by gel permeation chromatography. As shown in
Figure 26, the Chol-PCXG1 copolymers were synthesized by amidation reaction between
the cholesteryl chloroformate and the remaining secondary amines in PCXG1. The content
of cholesterol moiety in the copolymers could be tuned by changing the feed ratio of
cholesteryl chloroformate to PCXG1 in the reaction. Three copolymers with increasing
content of cholesterol were synthesized and named according to their cholesterol content
(Table 5). The content of cholesterol in the copolymers was determined from 1H-NMR
integral intensity of the methyl group b directly linked to the cyclic hydrocarbon at chemical
shift of 0.65 ppm in cholesterol and aromatic protons a of AMD3100 at 7.1-7.5 ppm (Figure
27). The weight-average molecular weight of each synthesized Chol-PCXG1 was
calculated based on the Mw of PCXG1 and the cholesterol grafting degree as estimated by
1

H-NMR.

4.3.2 Critical Micelle Concentration of Chol-PCXG1
Hydrophobic cholesterol moieties were linked to the hydrophilic PCXG1, which
made copolymers amphiphilic and be possible to self-assemble into micelles in aqueous
media. This potential self-assembly into micelles could change the nature and dynamic of
the complexation with siRNA, which depended on whether the copolymers bind the nucleic
acid as a unimer or as assembled micelles. Fluorescence spectroscopy was used to
estimate the CMC values of these copolymers in distilled water with pyrene as a
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hydrophobic fluorescent probe [179, 260-262]. Above CMC (in the presence of micelles),
pyrene could be incorporated into the hydrophobic core in the micelles, leading to the
increase in the ratio of two fluorescence intensity peaks (I3/I1). CMC of each Chol-PCXG1
could be determined by plotting the ratio of I3/I1 against the polymer concentration. The
CMC values decreased from 63.1 µg/mL for Chol17-PCXG1 to 89.1 µg/mL for Chol25PCXG1 (Figure 28), indicating that the increasing cholesterol modification could reduce
CMC values of those copolymers.
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Scheme 5. Proposed mechanism of action of the dual-function Chol-PCXG1 as polymeric
CXCR4 antagonists and siRNA (PLK1) delivery vectors.

121

Figure 26. Synthesis of Chol-PCXG1.
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b

a

a

b
a

Figure 27 Typical 1H-NMR spectrum of Chol-PCXG1 used in the determination of the
cholesterol content (spectrum of Chol25-PCXG1 in DMSO shown).
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Table 5. Characterization of Chol-PCXG1 copolymers.

Cholesterol content (wt %)
Polymer
PCXG1
Chol17-PCXG1
Chol25-PCXG1
Chol34-PCXG1
a

In Feed

In copolymera

Mw
(kg/mol)

0
15
25
36

0
17
25
34

13.9b
16.7c
18.5c
21.1c

From 1H-NMR.
From GPC.
c
Calculated from the Mw of PCXG1 and cholesterol content.
b
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Figure 28. Critical micelle concentration (CMC) of Chol-PCXG1 determined by
fluorescence spectroscopy. CMC was determined as the concentration at the inflection
point of the curve where I3/I1 was plotted against Chol-PCXG1 concentration (n=3).
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4.3.3 Preparation and characterization of Chol-PCXG1/siRNA polyplexes
Agarose gel electrophoresis assay was used to investigate the influence of
cholesterol grafting on the ability of PCXG1 to complex siRNA into polyplexes (Figure 29a).
The complete retardation of siRNA mobility was achieved for all complexes at equivalent
PCXG1/siRNA w/w ratio of 1. The siRNA binding ability of the parent PCXG1was slightly
better than that of cholesterol modified copolymers as shown by the minimum siRNA
releasing from complexes at w/w ratio 0.5. The better complexation ability of PCXG1 is
likely due to that cholesterol conjugation caused a decreased number of protonated
amines in Chol-PCXG1. The w/w ratios in this study were expressed as equivalent
PCXG1/siRNA ratios, not taking cholesterol content into account. In all of the following
studies, all siRNA polyplexes were prepared above w/w of 1 to maintain complete siRNA
complexation.
The hydrodynamic size and zeta potential of Chol-PCXG1/siRNA polyplexes
prepared in 10 mM HEPES buffer (pH 7.4) at various equivalent PCXG1/siRNA w/w ratios
were measured by dynamic light scattering (Figure 29b). The polyplexes were stabilized
for 20 min at room temperature before measurement. Except for Chol34-PCXG1/siRNA
prepared at lower w/w ratios, all the other polyplexes displayed small particle size ranging
from 56 to 121 nm. All the Chol-PCXG1/siRNA polyplexes prepared at higher w/w ratios
showed significantly smaller sizes than polyplexes prepared at lower w/w ratios, perhaps
suggesting tighter binding. At w/w ratios above 2, Chol17-PCXG1 with the lowest
cholesterol content exhibited the smallest sizes compared with other Chol-PCXG1/siRNA
polyplexes, which is possibly due to that the proper content of cholesterol in copolymers
allowed tighter hydrophobic interaction between cholesterol molecules. All CholPCXG1/siRNA polyplexes exhibited positive surface charge indicated by zeta potentials
ranging from 18 to 31 mV.
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Figure 29. siRNA complexation and physicochemical characterization of siRNA
polyplexes. (a) siRNA binding ability of the Chol-PCXG1 copolymers. (b) Hydrodynamic
size and zeta potential of Chol-PCXG1/siRNA polyplexes at various w/w ratios (equivalent
PCXG1/siRNA). Results are shown as mean ± SD of three measurements.
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4.3.4 Colloidal and enzymatic stability of Chol-PCXG1/siRNA polyplexes
For simulating physiologic conditions, the Chol-PCXG1/siRNA polyplexes were
analysed for their colloidal and enzymatic stability, which are important prerequisites for
successful application. In low concentration buffers (e.g., 10 mM HEPES, pH 7.4),
PCXG1/siRNA polyplexes retained stable size like other polycation/siRNA polyplexes.
However, addition of salts to reach physiologically relevant levels, polyplexes would
aggregate into large molecules (Figure 29b vs. 30). Aggregation of polyplexes depends
on various parameters, including the chemical structure, molar mass and hydrophobicity
of the used polycations [263]. We prepared Chol-PCXG1/siRNA polyplexes at two different
equivalent w/w ratios (2 and 5) and incubated them in PBS. And the changes in polyplex
size during the following period of 12 h incubation were monitored by DLS (Figure 30). At
w/w ratio of 2, all the Chol-PCXG1/siRNA polyplexes aggregated and reached sizes
ranging from ~690 nm to ~2 µm within 15 min of incubation in PBS. siRNA polyplexes with
higher cholesterol content (Chol25-PCXG1 and 34) showed significantly faster rate of
aggregation than that of Chol-PCXG1 with low (Chol17-PCXG1) or no (PCXG1) cholesterol.
However, all of the siRNA polyplexes prepared with Chol-PCXG1 copolymers at w/w ratio
5 exhibited markedly improved colloidal stability with nearly constant size (< 150 nm)
displayed for the duration of the experiment (12 h). In contrast, siRNA polyplexes prepared
with the parent PCXG1 showed similar aggregation behavior as polyplexes prepared at
w/w ratio of 2 and rapidly formed large aggregates. This similar findings were also reported
in DNA polyplexes where increasing the amount of cholesterol resulted in polyplexes with
enhanced colloidal stability [264]. For the reasons of maintaining good colloidal stability at
w/w 5, we propose that as the surface positive charge of polyplexes is reduced at
physiological salt concentrations, more Chol-PCXG1 can bind to the particle surface via
hydrophobic interactions and increase colloidal stability by forming an additional shell of a
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polycation. Moreover, even the Chol-PCXG1 concentrations were below their CMC in all of
the above experiments. The concentration of the local copolymer within each polyplex
particle was possibly significantly higher than CMC, which provided another contribution
to improve the stability.
Enzymatic degradation is one of the main factors, which hampered effective siRNA
delivery in vivo. Therefore, we evaluated the stability of those Chol-PCXG1/siRNA
polyplexes against RNase I degradatin. siRNA polyplexes were formed at at various
equivalent w/w ratios ranging from 1 to 5, and followed by the incubation with 0.5 U RNase
I for 30 min. In order to evaluate siRNA integrity, the samples were incubated with 200
µg/mL of heparin for another 30 min to dissociate polyplexes. Gel electrophoresis was
used to examine the siRNA integrity and the intensity of each band was quantified and
normalized to free siRNA. As shown in Figure 31, naked siRNA was not stable and
completely degraded after half hour in the presence of RNase I. All the polymers, including
parent PCXG1, were able to provide protection of the siRNA against RNase I. PCXG1 with
lower cholesterol modification (Chol17-PCXG1 and 25) displayed improved ability to
protect siRNA when compared with the parent PCXG1 at the same equivalent w/w ratio,
which might be due to the proper hydrophobic interaction of cholesterol molecules. Similar
to PCXG1, Chol17-PCXG1 and Chol25-PCXG1 also exhibited improved resistance to RNase
I with increasing w/w ratios, indicating important role of excess polycations in properties
of polyplexes. At w/w of 4, Chol25-PCXG1/siRNA polyplexes prepared demonstrated the
best protection against RNase I degradation with ~80% siRNA remaining intact after
exposure. However, Chol34-PCXG1 with the highest cholesterol content remained only 50%
siRNA intact when the polyplexes were prepared at w/w 1.5 and displayed decreasing
ability to protect siRNA above w/w 2, indicating that proper content of cholesterol were
needed to take into consideration.
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Figure 30 Colloidal stability of Chol-PCXG1/siRNA polyplexes in PBS up to 12 h. Results
are shown as mean ± SD of three measurements.
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Figure 31. Stability of Chol-PCXG1/siRNA polyplexes against RNase I. Polyplexes
prepared at various w/w were exposed to RNase I, followed by incubation with heparin to
release the siRNA for agarose gel electrophoresis. siRNA band intensity was quantified
to calculate % siRNA remaining compared with untreated free siRNA.
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4.3.5 Cytotoxicity of Chol-PCXG1
Cytotoxicity is a major concern for application of polycations in clinical. Several key
factors relate with cytotoxicity of polycation-based gene delivery systems, such as molar
mass of the polycations, polymer structure, charge density and biodegradability [265-267].
The influence of hydrophobic modification on polycations has been reported with both
positive and negative effects [255]. For instance, some hydrophobic moieties are common
endogenous physiological molecules, so that the conjugated polycation should be noncytotoxic. However, in some cases, high content of hydrophobic chains could cause cell
membrane disruption and result in cell death [268]. Thus it was important to evaluate how
cholesterol affects toxicity of PCXG1 to avoid or minimize any undesired toxic side effects.
Cytotoxicity of Chol-PCXG1 was investigated in human osteosarcoma U2OS cell line by
MTS assay (Figure 32). U2OS cells would be used to determine the safe dosing window
to study the biological activity of the Chol-PCXG1/siRNA polyplexes. The cute 24 h toxicity
of those polymers was assessed, which could be mostly attributed by the polycation
character of the polymers. In order to directly evaluate the effect of cholesterol modification
on the toxicity of the polycation, Chol-PCXG1 concentrations were expressed as PCXG1
concentration only and the IC50 values were calculated based on the PCXG1 content. The
benchmark 25 kDa branched PEI was used here as a control with IC50 of 4.2 µg/mL. Parent
PCXG1 showed IC50 12.8 µg/mL, which was significantly higher than PEI control. CholPCXG1 was slightly more toxic than PCXG1 with IC50 10.3 µg/mL. However, for the
polycations with higher content of cholesterol (Chol25-PCXG1 and Chol34-PCXG1), the IC50
values increased to 16.7 µg/mL and 33.4 µg/mL, respectively. The formation of amido
bonds after cholesterol modification decreased the protonable amine group in PCXG1
available for interaction with cell membranes, which possibly induced the decreased
cytotoxicity in polycations with higher content of cholesterol.
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Figure 32. Cytotoxicity of Chol-PCXG1. Cell viability was measured by MTS assay after 24
h incubation with increasing concentrations of polymers. Chol-PCXG1 concentrations are
expressed as PCXG1 concentration only (i.e., excluding cholesterol). Results are
expressed as mean cell viability ± SD (n=3).
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4.3.6 CXCR4 antagonism of Chol-PCXG1 and Chol-PCXG1/siRNA
Binding of PCXG1 to CXCR4 receptor is required for the pharmacologic activity of
the polymers and polyplexes. The accessibility of the receptor-binding cyclam moieties in
the polycation structure is necessary for PCXG1 binding with CXCR4 to exhibit inhibitory
activity. Not all of the eight amino groups in the AMD3100 are required for CXCR4 binding
and inhibition [197]. However, binding of polymers to receptors on the cell surface can be
negatively affected by the configuration alternation created by cholesterol. Therefore, it is
important to investigate the influence of cholesterol on CXCR4 antagonism and confirm
that the proposed dual functionality of the vector is preserved. We evaluated the CXCR4
inhibition of SDF1-triggered endocytosis of EGFP-CXCR4 receptors in U2OS
osteosarcoma cells by CXCR4 receptor redistribution assay, as described before. The
different fluorescence patterns of EGFP-CXCR4 between untreated and AMD3100
treated cells are illustrated in Figure 33a.
In order to permit direct evaluation of the effect of cholesterol moieties on CXCR4
antagonism of PCXG1, we have tested activity of the synthesized copolymers at equal
concentrations of the polycationic (PCXG1) part of the copolymers. Activity of PAMD-Ch
was analyzed and expressed as % CXCR4 antagonism relative to the control AMD3100
(300 nM) (Figure 33b). We tested Chol-PCXG1 at two different concentrations (0.6 and 2
µg/mL) and evaluated Chol-PCXG1/siRNA polyplexes prepared at w/w ratios (1.5 and 5).
The selected w/w ratios allowed us to achieve the same polymer concentrations as in the
experiment with free copolymers. CXCR4 antagonism of Chol-PCXG1 copolymers and
their siRNA polyplexes exhibited similar concentration-dependent behavior. When
compared with the free polymer at the same concentration, Chol-PCXG1 polyplexes
showed slightly decreased CXCR4 inhibition, which might be due to a result of
sequestration of a portion of the copolymers in the core of the siRNA polyplexes. A
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decrease in CXCR4 antagonism showed up with the increasing content of cholesterol
grafting degree. Chol34-PCXG1 with the highest cholesterol content displayed the lowest
CXCR4 antagonism among all the tested polymers. However, at a low w/w ratio of 1.5,
Chol17-PCXG1/siRNA polyplexes achieved nearly 100% CXCR4 inhibition. And Chol25PCXG1/siRNA polyplexes achieve similar levels of CXCR4 antagonism at w/w 5. Those
results indicated that there is a fine balance between the hydrophobicity caused by
cholesterol moiety and CXCR4 binding.
4.3.7 Delivery of anti-PLK1 siRNA (siPLK1) by Chol-PCXG1
PLK1 expression is elevated in multiple types of human cancers, which is a key
mitotic regulator in mammalian cells, has prognostic value for predicting aggressiveness
of cancer as well as target values for cancer treatment [269-271]. Inhibition of PLK1 could
be achieved by small molecule inhibitors or using PLK1 gene silencing with siRNA. Both
of them caused cell apoptosis and inhibition of tumor growth in vivo [272-274].
We proposed that combination of antimetastatic effect by Chol-PCXG1 and
antitumor activity by PLK1 silencing would be promising for cancer treatment. Therefore,
the investigated the ability of Chol-PCXG1 to deliver siPLK1 in U2OS osteosarcoma cells.
PEI/siPLK1 polyplexes prepared at w/w 1.5 were used as a positive control. Scrambled
siRNA (siScr) was used in control experiments to assess toxicity of the studied polyplexes.
As shown in Figure 34a (left), in serum-free conditions, the safety of the selected polyplex
formulations were evaluated with acceptable cell viability above 85%. The anticancer
activity of Chol-PCXG1/siPLK1 polyplexes was determined from their ability to induce
cancer cell death as a result of PLK1 gene silencing. Different anticancer activities were
shown with different grafting degrees of cholesterol in PCXG1 polymers. Chol17-PCXG1
and Chol25-PCXG1 polyplexes polyplexes exhibited better anticancer activity than
unmodified PCXG1 at equivalent PCXG1/siRNA w/w ratios. The best performing Chol17-
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PCXG1/siPLK1 polyplexes showed cell killing activity (48-62%) fully comparable to the
PEI/siPLK1 control. Although grafting degree of cholesterol reached 34% in Chol-PCXG1
polymer, the siPLK1 induced cell killing was not further improved, indicating that it was
necessary to optimize cholesterol content in the preparation of copolymers and
investigated the best percentage.
In order to investigate the practical application of Chol-PCXG1/siRNA polyplexes,
we also evaluated the anticancer activity in the presence of 10% serum (Figure 34b). In
the presence of serum, the safety of the tested polyplex formulations was improved, as
indicated by the negligible effect on cell viability by Chol-PCXG1/siScr polyplexes. Serum
compromised the the ability of most of the tested polyplexes to deliver siPLK1 as indicated
by nearly-background levels of cell killing. For instance, both PCXG1/siPLK1 and
PEI/siPLK1 lost nearly all their anticancer activity when compared with the serum-free
conditions. However, Chol17-PCXG1 and Chol25-PCXG1 achieved optimal activity at w/w
1.5 and 2. Especially, Chol17-PCXG1/siPLK1 polyplexes maintained the significant cell
killing activity at w/w 2, which was comparable to the activity in serum-free conditions.
While in the case of Chol34-PCXG1, the highest activity was obtained at w/w 2.5. These
findings suggest that cholesterol modified copolymers can protect siRNA from degradation
in serum and facilitate efficient siRNA delivery, but the content of cholesterol and proper
ratio of polymer/siRNA have to be optimized to achieve maximum anticancer activity.
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Figure 33. CXCR4 antagonism of Chol-PCXG1 and Chol-PCXG1/siRNA polyplexes. (a)
Illustration of EGFP-CXCR4 receptor redistribution assay: untreated cells (0% CXCR4
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Figure 34. siRNA delivery by Chol-PCXG1 in U2OS cells. Transfections were conducted
either in the absence (a) or the presence of 10% serum (b). Polyplexes were prepared
with control siScr (left) or siPLK1 (right) at various equivalent PCXG1/siRNA w/w ratios and
cell killing mediated by PLK1 knockdown was measured (n=4).
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4.3.8 Intracellular distribution of Chol-PCXG1/siRNA polyplexes
To gain the expected therapeutic effect, siRNA has to be protected in the
polyplexes, internalized by the cells and released in the cytoplasm. Proper intracellular
trafficking is significant for successful delivery of functional siRNA by polyplexes. It was
reported that introducing hydrophobic moiety like cholesterol into polycations showed
positive effects on enhancing nucleic acid delivery [255, 260]. Hydrophobic moiety can
promote cell membrane adsorption, alleviate serum inhibition and facilitate nucleic acid
dissociation from polycations. In order to visualize both components of the polyplexes,
copolymers were lablelled with AlexaFluor 647 and form polyplexes with commercially
available siRNA labelled with AlexaFluor 555. Side-by-side comparison was conducted
between the best performing Chol17-PCXG1/siRNA polyplexes and parent PCXG1/siRNA
polyplexes (Figure 35). Confocal microscopy was used to investigate the influence of
cholesterol modification on the cellular uptake and intracellular distribution of the CholPCXG1/siRNA polyplexes.
Cellular uptake is one of the main factors determining the success of siRNA
delivery by the dual-function PCXG1 polyplexes. As shown in Figure 35, polyplexes that
exhibited high transfection activity also exhibited high levels of cellular internalization.
Serum contains large amount of anionic proteins that can bind to cationic polyplexes and
impact the extent and mechanism of cell uptake and intracellular trafficking [275]. The
effect of serum on the polyplex uptake and intracellular distribution was evaluated. The
severe adverse effect of serum on the cellular uptake of PCXG1/siRNA polyplexes was
observed. PCXG1/siRNA polyplexes prepared at w/w 2 exhibited considerably much lower
cellular uptake and distribution to the cytoplasm than that of Chol17-PCXG1/siRNA
polyplexes, which correlated to the previous reports that hydrophobic modification of
polycations can enhance serum compatibility [276, 277]. Moreover, less co-localization of
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the Chol17-PCXG1 and siRNA signal (bright pink) were shown when compared with
PCXG1/siRNA where nearly all siRNA was associated with the polycation. The reduced
co-localized points were due to enhanced intracellular dissociation of the polyplexes and
release of free siRNA. Incorporating hydrophobic moieties have been reported to facilitate
intracellular polyplex dissociation [278, 279].
We have demonstrated that the internalization of PCXG1/DNA polyplexes was
independent of the CXCR4 trafficking pathway. However, the interaction mechanism of
polyplexes with cell membranes and membrane receptors might be altered by cholesterol
modification. Therefore, it was necessary to investigate if the CXCR4 trafficking was
involved in the intracellular distribution of siRNA polyplexes. EGFP-CXCR4 expressing
U2OS cells were treated with fluorescently labelled Chol17-PCXG1/siRNA polyplexes (w/w
5) and 10 nM SDF-1 for 1 h, which allowed Chol17-PCXG1 polyplexes to directly compete
with the chemokine ligand for binding with CXCR4. As shown in the confocal microscopy
pictures (Figure 36), Chol17-PCXG1/siRNA polyplexes can efficiently inhibit CXCR4 as
indicated by the diffuse pattern of EGFP-CXCR4 fluorescence. And there were only a
small amount of internalized receptors as shown by the discrete green puncta. A fraction
of the Chol-PCXG1/siRNA polyplexes overlapped with the CXCR4 trafficking as
demonstrated by the colocalization of siRNA and CXCR4 (yellow) as well as the Chol17PCXG1 and CXCR4 (bright blue), indicating that cholesterol modification might change the
interaction of polyplexes with CXCR4 and facilitate siRNA internalization. However, more
details of this mechanism have to be further studied.
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Figure 35. Intracellular distribution of PCXG1/siRNA and Chol17-PCXG1/siRNA polyplexes
in U2OS cells using siRNA labelled with AlexaFluor 555 (red) and polymers labelled with
AlexaFluor 647 (blue) (cell nuclei stained with Hoechst 33258 (shown as white)).

141

Chol17-PCXG1

siRNA

CXCR4

Chol17-PCXG1+siRNA

siRNA+CXCR4

Chol17-PCXG1+CXCR4

Figure 36. Intracellular distribution of fluorescently labelled Chol17-PCXG1/siRNA
polyplexes in U2OS cells expressing EGFP-CXCR4 receptors. Cells were incubated with
polyplexes and 10 nM SDF-1 for 1 h and imaged using a confocal microscope: siRNA
(red), Chol17-PCXG1 (blue), EGFP-CXCR4 (green), cell nuclei (white).
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4.3.9 Conclusion
PCXG1 was modified with different contents of cholesterol and developed for siRNA
delivery vector. The above findings showed that proper cholesterol modification provided
the Chol-PCXG1/siRNA polyplexes with increased colloidal stability, improved enzymatic
stability against RNase, and greatly enhanced siRNA transfection in the presence of
serum, while retaining strong CXCR4 antagonism. Furthermore, investigation of
combining Chol-PCXG1 with therapeutic siPLK1 showed promising cell killing effects in
cancer cells. Therefore, Chol-PCXG1/siRNA polyplexes would be a novel and potential
dual-functional strategy to treat metastatic cancer.
As we know, cancer metastasis caused nearly 90% death of cancer patients, which
is the main reason for the failure of cancer treatment [2]. For instance, less than 20% of
PC patients are candidates for surgery because it has spread beyond the pancreas at the
time of diagnosis. Late diagnosis, complex microenvironment and early metastasis in PC
contributes to the extremely low five-year survival rate (~7%) [30-32]. Better therapeutic
strategies are needed to be designed to treat PC. Dual-functional PCX nanoparticles will
be further investigated for PC treatment by combining prevention of cancer metastasis by
inhibiting CXCR4/SDF-1 axis and ability to deliver therapeutic nucleic acids to tumors.
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4.4 Polyplex-Mediated Inhibition of CXCR4 and NCOA3 Impedes Pancreatic Cancer
Progression and Metastasis
Please note that the data presented in this chapter were published in Biomaterials
[280]. The authors include Dr. Sushil Kumar, Dr. Satyanarayana Rachagani, Dr.
Balasrinivasa R. Sajja, Ying Xie, Yu Hang, Dr. Maneesh Jain, Dr. Jing Li, Dr. Michael D.
Boska, Dr. Surinder K. Batra, Dr. David Oupický and me. I contributed equally with Dr.
Sushil Kumar to this paper. I prepared polyplexes, characterized their physicochemical
properties, toxicity, and in vitro activity. I helped to analyze data and wrote early draft of
the manuscript. Dr. Sushil Kumar designed the in vivo experimental plan and analyzed
NCOA3 expression in primary tumors by RT-PCR, analyzed primary tumor necrotic area
and Muc4 expression by immnuohistochemistry staining. Ying Xie helped me with the
operation of flow cytometry to measure CXCR4 expression. The animal surgery, tumor
implantation, and IVIS measurements were done by Dr. Satyanarayana Rachagani with
my help. Perfusion measurement by MRI and data analysis were performed by Dr. Boska
and Dr. Sajja. Drs. Li, Kumar, Jain, Batra, and Oupicky wrote and revised the manuscript
and made it published. All the authors agreed with including their work in this dissertation.

PC is one of the worst prognoses of all cancer with a prediction of 53,070 new
cases and 41,780 deaths in US of 2016 [281]. By 2030, PC might become the second
leading cause of cancer-related mortalities [29]. PC is unique among solid tumors due to
the extremely dense desmoplstic reaction, which presents substantial barriers to
perfusion, diffusion, and convection of antitumor therapeutics into the PC tissues, resulting
in acquired resistance [34]. Desmoplasia contains extracellular matrix (ECM) proteins,
myofibroblastic pancreatic stellate cells, and immune cells, which provide growth factors
and immune modulators to support PC growth [35]. The proliferation of fibroblasts and
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increased stromal fibrosis induces desmoplastic PC microenvironment with high interstitial
pressure, dense stroma and vascular dysfuction [39, 40]. Aberrant expression of mucins
has been found as one of the characteristic features of PC and increases with PC
progression [93, 94, 282-284]. Mucins induce PC progression, metastasis and
chemoresistance by interaction with receptor tyrosine kinase, extracellular matrix and
signal via the cytoplasmic tails [85, 285]. NCOA3 is a crucial regulator of mucin expression
at both transcriptional and post-translational levels [85]. Furthermore, NCOA3 also
promote the expression of chemokines in PC microenvironment, which involve in the
recruitment of immune cells, activation of pancreatic stellate cells and maintenance of
proinflammatory conditions [286]. Chemokine pathway CXCR4/SDF-1 axis has been
significantly studied for its role in PC invasion, angiogenesis and proliferation [123, 124].
Abundant SDF-1 is produced by PC stromal cells and activates CXCR4 expression in PC
cells, which also augments Shh pathway to elevate desmoplasia, enhance
chemoresistance as well as promote invasion in PC [125, 126]. Multiple retrospective
clinical studies have directly linked the expression of CXCR4 with poor survival and
metastasis in PC patients [127, 128]. Given the critical role of NCOA3 and CXCR4 in the
progress of PC, we can develop novel treatment by delivery of NCOA3-silencing siRNA
using PCX. Our hypothesis is that combination of NCOA3 gene silencing and CXCR4
inhibition will reduce mucin expression, regulate tumor microenvironment, decrease
desmoplasia, prevent metastasis, chemosensitize tumor cells and improve the overall
anticancer activity in PC treatment (Scheme 6).
4.4.1 PCX selection
All of the PCX polymers were obtained by Michael-type polyaddition of cyclambased CXCR4 antagonists as described in 4.1-4.3 [149, 152, 287]. However, the ability of
the polymers to condense and deliver siRNA in PC cells was never compared
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simultaneously. In order to select PCX polymers with the most optimized properties, we
chose two unmodified PCX as shown in Figure 37: branched PCXG1 synthesized from a
commercial CXCR4 antagonist AMD3100 and linear PCXG2 synthesized from a
monocyclam monomers with CXCR4 antagonism. We also chose cholesterol modified
PCXG1 (Chol17-PCXG1 and Chol25-PCXG1) with high enzymatic stability again RNase and
improved siRNA delivery. Then, PEGylated PCXG1 in the mixed formation was selected to
prepared polyplexes with decreased positive surface charge and acceptable colloidal
stability. All of the above PCX polymers would be screened simultaneously in a series of
experiments, such as cytotoxicity, siRNA condensation, CXCR4 antagonism, NCOA3
gene silencing and inhibition of PC cell migration to obtain the most favorable formulation
for in vivo studies.
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Scheme 6. Proposed mechanism of action of PCX/siNCOA3 polyplexes.
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Figure 37. Chemical structures of polymeric CXCR4 inhibitors PCXG1 and PCXG2.
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4.4.2 Cytotoxicity
Before the in vitro experiments, toxicity of polycations have to be investigated to
predict their application for delivery nucleic acid. HepG2 cells were utilized to evaluate the
possible toxicity of novel compounds in liver. A shown in Figure 38a, all PCX exhibited
significantly less toxic in comparison with benchmark commercial control PEI. Linear
PCXG2 had lower molecular weight as well as charge density than the branched PCXG1
and displayed the least toxic of all the tested polymers. PEG-PCXG1 showed the lowest
toxicity of the polymers on the basis of PCXG1 due to the steric hindrance of PEG that
prevents interaction of the polycations with cell membranes and vital intracellular proteins
[198, 288]. Cholesterol modification of PCXG1 did not impact the cytotoxicity in HepG2
cells, indicating that proper content of hydrophobic moieties would not cause cell death
induced by cell membrane disruption. PC cell line CD18/HPAF.luc was used to determine
the cytotoxicity of PCX and establish safe concentration for the subsequent optimization
studies in vitro. As shown in the table of Figure 38, all of the PCX polymers displayed less
toxicity than control PEI. However, the sensitivity of PC cells to PCX increased and the
differences of IC50 values between PCX and PEI reduced. The preferred cytotoxicity and
sensitivity of PC cells to PCX may have the potential to improve anticancer activity of PCX
delivery system. More studies need to conduct to explain the phenomenon.
4.4.3 Preparation of PCX/siNCOA3 polyplexes
The ability of PCX to form polyplexes with siNCOA3 was first investigated by
agarose gel electrophoresis (Figure 38b). All w/w ratios in this study are expressed as
equivalent PCX/siRNA ratios without taking cholesterol or PEG content into consideration.
The polyplexes were prepared at increasing PCX-to-siNCOA3 w/w ratios and incubated
at room temperature for 20 min before use. All PCX were able to fully complex siNCOA3
at or above w/w ratio 2. The siNCOA3 binding ability of PEG-PCX was slightly weaker
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than the other PCX at w/w 1, as suggested by a stronger smear of siNCOA3 releasing
from loading well. The weaker complexation ability of PEG-PCX is likely due to
interference of the interaction between polymer and siRNA by the long PEG chains.
Therefore, all siNCOA3 polyplexes used in the following studies were prepared at w/w 2
to assure complete siRNA complexation.
4.4.4 Characterization of PCX/siNCOA3 polyplexes
Hydrodynamic size and zeta potential of PCX/siNCOA3 polyplexes were evaluated
by dynamic light scattering (Figure 38c). Polyplexes were prepared in HBG buffer at
equivalent w/w ratio of 2 and were allowed to stabilize for 20 min at room temperature
before measurement. Except for PCXG2/siNCOA3, all the other polyplexes displayed small
particle ranging from 88 to 125 nm. All PCX/siNCOA3 polyplexes exhibited positive
surface charge indicated by zeta potentials ranging from 5 to 23 mV. Cholesterol or PEG
modified siNCOA3 polyplexes showed smaller sizes than PCXG1/siNCOA3, perhaps
suggesting tighter binding at w/w ratio of 2. However, PEGylated PCX exhibited nearly
neutral zeta potential because that PEGylation shielded the positive surface charge of
polyplexes [288].
4.4.5 CXCR4 antagonism of PCX/siRNA polyplexes
The CXCR4 inhibitory activity is significant for the proposed mechanism of
polyplexes to inhibit cancer metastasis. CXCR4 redistribution assay was used to conduct
this experiment and HCS analysis was used to quantify the extent of EGFP-CXCR4
internalization into the cells as described before [287]. In order to avoid any potential
confounding effects from NCOA3 silencing, negative control siRNA (siScr) was utilized to
prepare polyplexes with PCX. As shown in Figure 39, all PCX polyplexes displayed nearly
complete CXCR4 inhibition at w/w ratio of 2, which were comparable to positive control
AMD3100. Cholesterol modification induced a slight decrease in CXCR4 inhibitory activity
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of the polyplexes. Chol17-PCXG1/siScr and Chol25-PCXG1/siScr showed 96% and 91%
CXCR4 inhibition, respectively. PCXG1, PCXG2 and PEG-PCXG1 were more effective than
Chol17-PCXG1. Polycation PEI worked as a negative control and did not display CXCR4
antagonism, indicating that the observed effect is due to the specific binding of PCX to the
CXCR4 receptor, but not due to the polycationic character. After confirming the complete
CXCR4 inhibitory activity of PCX, the ability of PCX to inhibit PC cell metastasis would be
evaluated.
4.4.6 CXCR4 expression in PC cell line
CXCR4 overexpression increases PC cell motility and invasion, leading to
enhanced metastasis [122, 289, 290]. And a growing experimental and clinical evidence
shows that anticancer therapies can promote hypoxic environment and increase CXCR4
expression, which may inadvertently enhance the metastatic potential of the tumors [291293]. It is also reported that CXCR4/SDF-1 signaling plays an important role in
gemcitabine resistance of PC cells. Gemcitabine up-regulates CXCR4 expression in PC
cells (Colo357 and MiaPaCa) and promotes their invasiveness, indicating that some
current chemodrug administration may cause aggressive phenoty of PC [294]. Here, we
used CD18/HPAF.luc cells as PC model in the study. To detect the CXCR4 expression
after gemcitabine treatment in CD18/HPAF.luc cells, the changes of CXCR4 expression
on cell membrane were determined by flow cytometry and changers at total protein level
were analyzed by western blot. As shown in Figure 40, the population of CXCR4-positive
CD18/HAPF.luc cells enhanced from 11.3% to 18% after treatment with 10 µM
gemcitabine for 24 h. Similarly, western blot analysis corroborated this finding, as there
was a noticeable increase in CXCR4 expression in CD18/HPAF.luc cells (1.75-fold and
1.7-fold) at both 1 and 10 μM gemcitabine concentrations. Therefore, we will test the ability
of PCX to prevent CXCR4-mediated migration of PC cells in the following study.
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Figure 38. Characterization of PCX and PCX/siNCOA3 polyplexes. (a) Cytotoxicity of
PCX in HepG2 and CD18/HPAF.luc cells. IC50 (in μg/mL) were calculated as the polymer
concentration that achieves 50% decrease in cell viability relative to untreated cells (n =
3). (b) Ability of PCX to form polyplexes with siNCOA3 evaluated by agarose gel
retardation assay at increasing PCX/siNCOA3 w/w ratios. (c) Hydrodynamic size and zeta
potential of PCX/siNCOA3 polyplexes prepared at w/w 2 (mean ± SD, n = 3). All
polyplexes were prepared in HBG at siNCOA3 concentration of 20 µg/mL.
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Figure 39. CXCR4 antagonism of PCX/siScr polyplexes (polymer = 1 µg/mL, w/w 2) in
U2OS cells. (a) The results are shown as mean % CXCR4 inhibition relative to AMD3100
± SD (n=4). One-way ANOVA with Tukey-Kramer multiple comparisons test (***P<0.001
vs. PEI). (b) Representative images of EGFP-CXCR4 distribution in cells treated with
different polymers. The scale bar = 200 µm.
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Figure 40 Effect of gemcitabine (Gem) on the CXCR4 expression in CD18/HPAF.luc PC
cells. (a) Cell surface CXCR4 expression in CD18/HPAF.luc cells by flow cytometry before
and after gemcitabine treatment. (b) Total cellular CXCR4 expression by Western blot
(n=2). Results are expressed as ratio of a mean relative CXCR4 expression vs. cells not
treated with gemcitabine (n=2).
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4.4.7 Inhibition of PC cell migration by PCX
As we confirmed, CXCR4 expression was enhanced by gemcitabine treatment in
CD18/HPAF.luc cells. We studied the migration of gemcitabine-treated CD18/HPAF.luc
cells in a Boyden chamber using 10% serum as the chemotactic signal. PC cells were
pretreated with 10 µM gemcitabine for 24 h and 105 cells were loaded into each insert on
the next day. As shown in Figure 41, without gemcitabine treatment, seldom cells
migrated through the membrane. However, gemcitabine promoted the aggressiveness of
PC cells and increased their metastasis. CXCR4 antagonists can inhibit migration of
cancer cells that are based on the CXCR4/SDF1 axis. We have shown that PCX and their
polyplexes inhibited CXCR4-mediated migration and invasion in human osteosarcoma
and cholangiocarcinoma cells [152, 287, 295]. Here, we would like to investigate the ability
of PCX to prevent CXCR4-medicated migration in CD18/HPAF.luc cells (Figure 42). After
pretreated with 10 µM gemcitabine for 24 h, 2x105 cells were loaded into each insert.
Untreated cells migrated significantly toward the chemotactic gradient. Small-molecule
CXCR4 antagonist AMD3100 was able to reduce the number of migrated cells by 29.5%.
However, all tested PCX PCX were capable to effectively inhibit cell migration at 1 μg/mL,
ranging from 38% for Chol25-PCXG1 to 43% for PCXG2, which was more efficient than
conventional CXCR4 inhibitors. In contrast, polycation control PEI was not observed any
inhibitory effect on cell migration, suggesting that PCX would be well-suited for
applications in treatment of PC that aim at preventing or delaying metastasis.
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Figure 41. Migration of PC cell enhanced after gemcitabine treatment. CD18/HPAF.luc
were pretreated with or without 10 µM gemcitabine for 24 h. 105 cells were loaded into
the insert and culture medium containing 10% FBS was used as chemoattractant. Images
were taken at 10x magnification (scale bar = 400 µm).

156

Figure 42. Inhibition of PC cell migration by PCX (1 µg/µL). CD18/HPAF.luc cells were
treated with 10 μM gemcitabine for 24 h before the migration study. 2x105 cells were
loaded into the insert. Migrated cells were counted in 4 randomly selected imaging areas
at 10x magnification of triplicate samples (scale bar = 400 µm). One-way ANOVA with
Tukey-Kramer multiple comparisons test (***P<0.001, vs. untreated cells).
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4.4.8 NCOA3 silencing by PCX/siNCOA3 polyplexes
After evaluating the ability of PCXs to form polyplexes with NCOA3 siRNA and
inhibit the migration of PC cells, we have studied the capacity to deliver siNCOA3 and
downregulate NCOA3 in PC cells. The NCOA3 silencing by PCX polyplexes at protein
level was analysed by western blot. PCX polyplexes were formulated at w/w of 2 using
either siNCOA3 or a negative control siRNA (siScr). PEI/siRNA (w/w 1.5) polyplexes were
used as controls.
As shown in Figure 43, Chol17-PCX and Chol25-PCX exhibited significantly
higher NCOA3 knock-down (78% and 52% respectively) than other PCX polyplexes (PCX1 = 21%, PCX-2 = 9.6%, PEG-PCX = 3.5%). PEI displayed second high NCOA3 gene
silencing with 59%, however, it caused significant off-target effects as indicated by
decreased NCOA3 levels observed with PEI/siScr [296]. Chol17-PCX was chosen to form
dual-function polyplexes with siNCOA3 to treat PC in vivo, due to the highest NCOA3 gene
silencing and effective inhibition of cell migration.
4.4.9 Inhibition of primary pancreatic tumor growth by PCX/siNCOA3 polyplexes
CXCR4 and its ligand CXCL12 promote metastatic and invasive process of PC,
fostered by the expression of matrix-metalloproteinase including MMP-2 and MMP-9 [297300]. Except the role of CXCR4/SDF-1 axis in PC metastasis, it also extensively involved
in tumor proliferation [122, 289, 290]. NCOA3 is a chromatin remodelling enzyme, which
plays a vital role in mucins regulation, creates pro-inflammatory conditions and modulates
tumor microenvironment to promote growth and dissemination of PC cells [85]. Therefore,
both CXCR4 and NCOA3 are involved in the proliferation of PC cells and in maintenance
of tumor microenvironment that promotes metastatic spread.
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First, we tested whether combining inhibition of CXCR4 and NCOA3 affects the
growth of the primary PC tumors. The antitumor activity of Chol17-PCXG1/siNCOA3
polyplexes was evaluated in orthotopic pancreatic cancer animal model. CD18/HPAF.luc
cells were implanted into the pancreas of female nude mice and allowed to grow for 10
days. As shown in Figure 44, the body weight of mice decreased less than 10% after
tumor implantation. However, all of the mice recovered after 7 days.
10 days after orthotopic implantation of CD18/HPAF.luc cells, the presence of the
tumors was established by whole-body bioluminescence imaging and mice were
randomized into three experimental groups (saline, Chol17-PCXG1/siScr, and Chol17-PCX
G1

/siNCOA3). Polyplexes were prepared at a polycation/siRNA w/w ratio of 2 and

administrated by tail vein injections with 40 µg siRNA/mouse, 3 times per week and 13
courses in total. None of the treatments caused any significant effect or lose on the body
weight, indicating the nontoxicity of the injected PCX/siNCOA3 polyplexes.
Mice were sacrificed on day 39 post-implantation. Treatments with both PCX/siScr
and PCX/siNCOA3 slowed down the progresses of primary pancreatic tumor (Figure 45
a-b). However, the combination of CXCR4 inhibition and NCOA3 silencing showed
significantly better effect on slowing down the growth of primary PC than PCX/siScr,
suggesting the superior activity of combination treatment. As shown in Figure 45c, the
NCOA3 gene silencing in primary PC tumors was confirmed by qRT-PCR. PCX/siNCOA3
induced 30% NCOA3 gene silencing compared with saline group, which had significantly
statistical difference (P<0.01).
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Figure 43. NCOA3 gene silencing by PCX/siNCOA3 polyplexes in CD18/HPAF.luc PC
cells. NCOA3 silencing was determined by Western blot (top) using polyplexes prepared
at w/w ratio of 2 and used at 200 nM siRNA. The percent of NCOA3 silencing (bottom)
was calculated from NCOA3 band intensity of PCX/siNCOA3 relative to the corresponding
PCX/siScr control. PEI polyplexes were prepared at w/w 1.5.
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Figure 44. Average body weight after orthotopic implantation of CD18/HPAF.luc cells and
during treatment with Chol17-PCXG1/siNCOA3 (n=6), Chol17-PCXG1/siScr (n=7), and
saline (n=7). The results were expressed as average of relative body weights ± SD values.
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Figure 45. Effect of systemic treatment with Chol17-PCXG1/siNCOA3 (w/w 2) on the
growth of primary pancreatic tumor. (a) Primary tumor weights were measured after
necropsy. (b) Photograph of resected primary PC tumors. (c) Silencing of NCOA3
expression in the primary PC tumors by RT-PCR (results shown as ratio of mean relative
NCOA3 expression compared with saline treated mice ± SD (n=3)). Statistical
comparisons by unpaired t-test (***p<0.001, **p<0.01, *p<0.05).
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4.4.10 Antimetastatic effect of PCX/siNCOA3 polyplexes
One of the significant reasons for low survival rate in PC is early metastasis. PC
metastasize to a broad range of organs, such as pericardium, stomach, spleen diaphragm,
small and large intestines, gallbladder, and ovaries [301, 302]. However, the most
common metastatic site is liver. As shown in Figure 46, the mice from saline group had
metastasis in a wide range of organs on day 39. All saline treated mice displayed
metastasis in the ovary and stomach, six out seven showed tumor spread to in small
intestine and diaphragm, five out seven had metastasis in liver, spleen and lymph node.
Furthermore, they also showed metastasis in kidney and large intestine. Treatment with
PCX/siScr, which inhibited CXCR4 in PC, reduced the metastasis in all of the organs
except spleen. Specifically, the incidence of stomach metastasis was much lower in the
PCX/siScr group compared with the saline group, which had statistically significant in
Fisher’s exact test (p=0.0047). Combination treatment with PCX/siNCOA3 greatly resulted
in much lower incidence of metastasis in all of the organs. Statistically significant
differences were observed in the incidences of metastases in liver, ovary and stomach
between PCX/siNCOA3 and saline groups. And PCX/siNCOA3 showed better effect on
preventing metastasis in liver, diaphragm, ovary, lymph node and stomach than PCX/siScr,
indicating that both CXCR4 inhibition and NCOA3 knock-down contributed to the overall
antimetastatic activity of the polyplexes for PC therapy.
4.4.11 Regulation of mucin expression and hypoxic environment by PCX/siNCOA3
polyplexes
Mucins are critical of PC progression, metastasis and chemoresistance. NCOA3
regulates mucin expression at both transcriptional and post-translational levels [85]. As
confirmed by the immunohistochemistry analysis in Figure 47a, NCOA3 silencing reduced
the expression of Muc4 significantly in PC primary tumors. Down-regulation of NCOA3
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also has shown to cause significant decrease in the expression of LOXL2, which
participates in fibroblast activation and hardening of desmoplasia [85]. Multiple
chemokines in PC microenvironment are enhanced by NCOA3 overexpression and
involves in the activation of pancreatic stellate cells, recruitment of immune cells as well
as maintenance of pro-inflammatory conditions. Pancreatic stellate cells secret large
amount of collagens and extracellular matrix proteins, which are crosslinked by LOXL2,
leading to the formation of desmoplasia, poor tumor perfusion and severe hypoxia in PC
microenvironment. As shown in Figure 47a, the H&E staining revealed the inner structure
of primary PC tumors. The less purple (pink) part corresponded to the tumor necrosis,
which was induced by the hypoxia in tumor microenvironment. Figure 47b revealed that
treatment with PCX/siNCOA3 significantly decreased the necrotic area in PC primary
tumors from about 17% to 2.5% in comparison with PCX/siScr and saline group.
4.4.12 Tumor perfusion enhanced by PCX/siNCOA3 polyplexes
Desmoplasia subsequently caused collapse of the blood vessels, poor tumor
perfusion, increased interstitial pressure, extreme hypoxia, and poor delivery of
therapeutics. If the tumor perfusion is enhanced, more chemotherapeutics can be
delivered into PC tissues and improve the chemosensitivity. It was reported that inhibition
of LOXL2 reduced extracellular matrix and desmoplasia [303, 304]. In order to investigate
whether tumor perfusion can be improved by PCX/siNCOA3 treatment, tumor perfusion
was evaluated by magnetic resonance imaging. As shown in Figure 48, PC tumor
perfusion was enhanced after NCOA3 silencing, which was due to its role in desmoplastic
reaction. After treatment with PCX/siNCOA3, the tumor perfusion increased from 44.3 to
62.5 mL/100 g/min. The enhanced tumor perfusion will facilitate drug delivery, regulate
PC microenvironment, ameliorate hypoxia condition, improve the chemosensitivity and
decrease the aggressiveness in PC.
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4.4.13 Conclusion
We have designed dual-function polyplexes to simultaneously deliver siNCOA3
and inhibit CXCR4 chemokine receptor to treat pancreatic cancer. Our study tested a
series of PCX formed polyplexes and screened formulations that can effectively knock
down NCOA3 expression at protein level. Cholesterol modification of PCX provided the
most optimized set of properties to achieve CXCR4 antagonism, siRNA delivery and
efficient gene silencing in PC. Our results demonstrates that combining the tumor
microenvironment regulation by NCOA3 silencing and antimetastatic effect of CXCR4
antagonism led to slow-down of pancreatic tumor progress, prevention of tumor
metastasis to distant organs, decrease of Muc4 expression in primary tumors and
enhancement of perfusion in PC microenvironment. Since desmoplasia and CXCR4
overexpression are characteristic features of both primary and metastatic PC tumors, the
developed PCX polyplexes are suitable for delivery to both primary and metastatic PC
sites [305]. Furthermore, regulation of tumor microenvironment led to enhanced tumor
perfusion, however, may also facilitate cancer cell metastasis out of primary site.
Therefore, combining tumor-microenvironment modulating strategies with simultaneous
antimetastatic ability of CXCR4-inhibiting polymers has the potential to minimize any side
effects. Future development of these dual-function systems will focus on optimization of
NCOA3 silencing in vivo to decrease the treatment courses and improve overall antitumor
effects with combination of chemodrugs.
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Figure 48. Primary tumor perfusion on day 39 determined from magnetic resonance
imaging.
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Chapter 5 – Overall Conclusions, Significance and Future Studies
Metastasis is the main cause of cancer mortality and morbidity, resulting in several
million deaths annually. Unfortunately, existing therapeutic approaches rarely reverse or
stop metastatic progression. For PC, less than 20% of patients are candidates for surgery
due to spread beyond the pancreas. Gemcitabine is the first-line treatment for metastatic
pancreatic cancer. However, the objective response rate is less than 10%. The emergence
of desmoplasia in PC is becoming a problem which presents substantial barriers to
perfusion, diffusion, and convection of antitumor therapeutics into the PC tissues. It results
in collapse of the blood vessels, increases interstitial pressure, extreme hypoxia, poor
tumor perfusion, and poor delivery of therapeutics. Thus, there is very urgent need to
develop therapies that focus on regulating tumor microenvironment, chemosensitizing
tumor to therapeutics and preventing metastasis.
Small interfering RNA (siRNA) has rapidly emerged as one of the most promising
new therapeutic agents for the treatment of many diseases. The capacity of siRNA to
selectively destroy any mRNA sequences offers the possibility to alter the behavior of
pathological cells. siRNA has shown great potential for therapeutic benefits even in
complex diseases like cancer [306]. PLK1 is a key mitotic regulator in mammalian cells,
which is an attractive target in cancer treatment [269, 270]. PLK1 expression is elevated
in multiple types of human cancers and it has a prognostic value for predicting
aggressiveness of cancer [271]. Inhibition of PLK1 by using gene silencing with siRNA
results in cell apoptosis and inhibition of tumor growth. NCOA3 is a master regulator of
musin expression in PC both at the transcriptional and post-translational levels [307]. The
NCOA3 expression is significantly elevated in primary PC tumors and in metastatic lung,
lymph and liver lesions. NCOA3 also upregulates the expression of chemokines to impact
tumor microenvironment. NCOA3 silencing by siRNA leads to downregulate the
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expression of mucins and diminish desmoplasia to enhance treatment. A major obstacle
that currently prevents the clinical use of siRNA therapy is a lack of reliable methods to
deliver siRNA to target cells. The short half-life of siRNA in blood circulation and the need
for intracellular cytoplasmic delivery represent major challenges for clinical translation
[308]. Therefore, the effective delivery system should be developed.
CXCR4 and its chemokine ligand SDF-1 play a crucial role in the crosstalk
between cancer cells and their microenvironment, and are involved in tumor progression,
angiogenesis, metastasis and survival. Many clinical studies show that CXCR4 expression
in various cancers (e.g. PC) is associated with more aggressive disease, more metastases,
and shorter overall patient survival. This dissertation addresses the need for such
therapies by exploiting the decisive role of CXCR4 chemokine receptor in the metastatic
spread of PC as a target for development of combination treatments based on dualfunction nanoparticles. There is growing evidence that inhibition of CXCR4 has the
potential to prevent metastasis and limit tumor growth. Metastasis is a systemic disease
and therefore, effective methods of systemic delivery of the treatments are necessary. By
developing nanoparticles capable of simultaneous CXCR4 inhibition and delivery of
antitumor therapeutic siRNA, we are able to prevent metastasis and improve overall
anticancer activity.
We have successfully synthesized CXCR4-inhibiting polycations (PCX) using
Michael polyaddition. The PCX could self-assemble into nanosized particles with nucleic
acids through electrostatic interaction and function as efficient transfection agent while
exhibiting effective CXCR4 antagonism. To enhance the CXCR4 antagonism, we reported
synthesis of novel monocyclam monomers and their polymerization to PCX. The CXCR4
inhibitory activity of the synthesized monocyclam monomers increased significantly
following incorporation into the polymers. Furthermore, the CXCR4 inhibitory activity of
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second generation of PCX was higher compared with the previously reported polymers
based on commercial CXCR4 antagonist AMD3100, confirming the importance of a proper
presentation of the ligands within synthetic polymers. To improve the physical properties
and safety of PCX, it was modified by PEGylation. Our results demonstrated that
modification of PCX with PEG decreased toxicity of the polymers, while preserving their
CXCR4 antagonism. Polyplexes prepared with PEG-PCX inhibited invasion of cancer cells
to an extent similar to the commercial CXCR4 antagonist Plerixafor. Negative effect of
PEG on transfection activity of PEG-PCX polyplexes could be overcome by using
polyplexes formulated with a mixture of PCX and PEG-PCX. Although efficient in DNA
delivery, the original PCX exhibited poor siRNA delivery activity. Therefore, we developed
PCX as siRNA delivery vectors to achieve combined antimetastatic and antitumor effect.
PCX was modified with cholesterol, which led to increased overall stability, cell uptake as
well as intracellular trafficking of siRNA polyplexes. After obtaining a series of dualfunction PCX polymers with the conceptually new approach to deliver therapeutic nucleic
acids and preventing cancer metastasis, NCOA3 siRNA was chosen to form nanoparticles
with PCX to address unresolved problems of chemoresistance and provide an immediate
therapeutic opportunity for the lethal PC. We tested a series of PCX formed polyplexes
and screened formulations that can effectively knock down NCOA3 expression at protein
level. Our results demonstrate that in the combination of the tumor microenvironment
regulation by NCOA3 silencing with antimetastatic effect of CXCR4 antagonism, slowdown of the pancreatic tumor progress, prevention of tumor metastasis to distant organs,
decrease of mucin expression in primary tumors and enhancement of perfusion in tumor
microenvironment were achieved.
Despite tremendous promise in anticancer therapies, siRNA is nearly certainly to
be used in combination with other treatments. Our study supports the use of
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PCX/siNCOA3 as a promising neoadjuvant or adjuvant treatment with conventional
chemotherapeutics such as gemcitabine. Our future studies will focus on improving the
polyplex formulations and on the anticancer and antimetastatic effect of these polyplexes
in combination with gemcitabine. We predict that increased tumor perfusion observed here,
together with chemosensitizing effect of NCOA3 knockdown and related mucin
downregulation will improve activity. Further, given the well-established fact that
gemcitabine treatment upregulates CXCR4 expression in pancreatic cancer, the use of
PCX in the siNCOA3 delivery is an ideal choice. However, the NCOA3 silencing of dualfunction systems will be optimized in vivo to decrease the treatment courses and improve
overall antitumor effects.
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